<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Med</journal-id><journal-id journal-id-type="iso-abbrev">Ann Med</journal-id><journal-title-group><journal-title>Annals of Medicine</journal-title></journal-title-group><issn pub-type="ppub">0785-3890</issn><issn pub-type="epub">1365-2060</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38165919</article-id><article-id pub-id-type="pmc">10769134</article-id>
<article-id pub-id-type="doi">10.1080/07853890.2023.2295398</article-id><article-id pub-id-type="publisher-id">2295398</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Infectious Diseases</subject></subj-group></article-categories><title-group><article-title>Brucellosis: epidemiology, pathogenesis, diagnosis and treatment&#x2013;a comprehensive review</article-title><alt-title alt-title-type="left-running-head">K. A. Qureshi et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3498-797X</contrib-id><name><surname>Qureshi</surname><given-names>Kamal A.</given-names></name><xref rid="AF0001" ref-type="aff">a</xref><xref rid="AF0002" ref-type="aff">b</xref><xref rid="AN0001" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Parvez</surname><given-names>Adil</given-names></name><xref rid="AF0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Fahmy</surname><given-names>Nada A.</given-names></name><xref rid="AF0004" ref-type="aff">d</xref><xref rid="AF0005" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Abdel Hady</surname><given-names>Bassant H.</given-names></name><xref rid="AF0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Shweta</given-names></name><xref rid="AF0006" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name><surname>Ganguly</surname><given-names>Anusmita</given-names></name><xref rid="AF0007" ref-type="aff">g</xref></contrib><contrib contrib-type="author"><name><surname>Atiya</surname><given-names>Akhtar</given-names></name><xref rid="AF0008" ref-type="aff">h</xref></contrib><contrib contrib-type="author"><name><surname>Elhassan</surname><given-names>Gamal O.</given-names></name><xref rid="AF0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Alfadly</surname><given-names>Saeed O.</given-names></name><xref rid="AF0009" ref-type="aff">i</xref></contrib><contrib contrib-type="author"><name><surname>Parkkila</surname><given-names>Seppo</given-names></name><xref rid="AF0002" ref-type="aff">b</xref><xref rid="AF0009" ref-type="aff">i</xref><xref rid="AF0010" ref-type="aff">j</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6938-7835</contrib-id><name><surname>Aspatwar</surname><given-names>Ashok</given-names></name><xref rid="AF0002" ref-type="aff">b</xref><xref rid="AF0009" ref-type="aff">i</xref><xref rid="AN0002" ref-type="corresp"/></contrib><aff id="AF0001"><label>a</label><institution>Department of Pharmaceutics, Unaizah College of Pharmacy, Qassim University</institution>, <city>Unaizah</city>, <country>Saudi Arabia</country></aff><aff id="AF0002"><label>b</label><institution>Faculty of Medicine and Health Technology, Tampere University</institution>, <city>Tampere</city>, <country>Finland</country></aff><aff id="AF0003"><label>c</label><institution>Department of Biotechnology, School of Chemical and Life Sciences, Jamia Hamdard University</institution>, <city>New Delhi</city>, <country>India</country></aff><aff id="AF0004"><label>d</label><institution>Center for Microbiology and Phage Therapy, Biomedical Sciences, Zewail City of Science and Technology</institution>, <city>Giza</city>, <country>Egypt</country></aff><aff id="AF0005"><label>e</label><institution>Faculty of Applied Health Science, Galala University</institution>, <city>Suez</city>, <country>Egypt</country></aff><aff id="AF0006"><label>f</label><institution>Department of General Medicine, All India Institute of Medical Sciences</institution>, <city>Bhopal</city>, <country>India</country></aff><aff id="AF0007"><label>g</label><institution>Department of Biotechnology, Pondicherry University</institution>, <city>Puducherry</city>, <country>India</country></aff><aff id="AF0008"><label>h</label><institution>Department of Pharmacognosy, College of Pharmacy, King Khalid University (KKU)</institution>, <city>Abha</city>, <country>Saudi Arabia</country></aff><aff id="AF0009"><label>i</label><institution>Department of Pharmacy Practice, Unaizah College of Pharmacy, Qassim University</institution>, <city>Unaizah</city>, <country>Saudi Arabia</country></aff><aff id="AF0010"><label>j</label><institution>Fimlab Ltd., Tampere University Hospital</institution>, <city>Tampere</city>, <country>Finland</country></aff></contrib-group><author-notes><corresp id="AN0001">CONTACT Kamal A. Qureshi <email xlink:href="mailto:ka.qurishe@qu.edu.sa">ka.qurishe@qu.edu.sa</email>, <email xlink:href="mailto:kamal.qureshi@tuni.fi">kamal.qureshi@tuni.fi</email></corresp><corresp id="AN0002">Ashok Aspatwar <email xlink:href="mailto:ashok.aspatwar@tuni.fi">ashok.aspatwar@tuni.fi</email>
<institution>Faculty of Medicine and Health Technology, Tampere University</institution>, <city>Tampere</city>
<postal-code>33520</postal-code>, <country>Finland</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>2</day><month>1</month><year>2024</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2023</year></pub-date><pub-date pub-type="pmc-release"><day>2</day><month>1</month><year>2024</year></pub-date><volume>55</volume><issue>2</issue><elocation-id>2295398</elocation-id><pub-history><event event-type="received"><date><day>19</day><month>10</month><year>2023</year></date></event><event event-type="revised"><date><day>10</day><month>12</month><year>2023</year></date></event><event event-type="accepted"><date><day>12</day><month>12</month><year>2023</year></date></event><event event-type="tagger"><event-desc>KnowledgeWorks Global Ltd.</event-desc><date><day>2</day><month>1</month><year>2024</year></date></event><event event-type="build-issue-online"><event-desc>published online in a building issue</event-desc><date><day>2</day><month>1</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#xA9; 2024 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IANN_55_2295398.pdf"/><abstract><title>Abstract</title><p><bold>Background:</bold> Brucellosis is a pervasive zoonotic disease caused by various <italic toggle="yes">Brucella</italic> species. It mainly affects livestock and wildlife and poses significant public health threats, especially in regions with suboptimal hygiene, food safety, and veterinary care standards. Human contractions occur by consuming contaminated animal products or interacting with infected animals. <bold>Objective:</bold> This study aims to provide an updated understanding of brucellosis, from its epidemiology and pathogenesis to diagnosis and treatment strategies. It emphasizes the importance of ongoing research, knowledge exchange, and interdisciplinary collaboration for effective disease control and prevention, highlighting its global health implications. <bold>Methods:</bold> Pathogenesis involves intricate interactions between bacteria and the host immune system, resulting in chronic infections characterized by diverse clinical manifestations. The diagnostic process is arduous owing to non-specific symptomatology and sampling challenges, necessitating a fusion of clinical and laboratory evaluations, including blood cultures, serological assays, and molecular methods. Management typically entails multiple antibiotics, although the rise in antibiotic-resistant <italic toggle="yes">Brucella</italic> strains poses a problem. Animal vaccination is a potential strategy to curb the spread of infection, particularly within livestock populations. <bold>Results:</bold> The study provides insights into the complex pathogenesis of brucellosis, the challenges in its diagnosis, and the management strategies involving antibiotic therapy and animal vaccination. It also highlights the emerging issue of antibiotic-resistant <italic toggle="yes">Brucella</italic> strains. <bold>Conclusions:</bold> In conclusion, brucellosis is a significant zoonotic disease with implications for public health. Efforts should be directed towards improved diagnostic methods, antibiotic stewardship to combat antibiotic resistance, and developing and implementing effective animal vaccination programs. Interdisciplinary collaboration and ongoing research are crucial for addressing the global health implications of brucellosis.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Brucellosis</kwd><kwd>zoonotic disease</kwd><kwd><italic toggle="yes">Brucella</italic></kwd><kwd>livestock and wildlife</kwd><kwd>public health threats</kwd><kwd>antibiotic-resistant strains</kwd></kwd-group><support-group><funding-group><award-group><funding-source>
<institution-wrap><institution>Deanship of Scientific Research at King Khalid University, Saudi Arabia</institution></institution-wrap>
</funding-source></award-group><award-group><funding-source>
<institution-wrap><institution>Large Research Groups Program</institution></institution-wrap>
</funding-source><award-id>RGP.2/14/1444</award-id></award-group><award-group><funding-source>
<institution-wrap><institution>Finnish Cultural Foundation</institution><institution-id institution-id-type="open-funder-registry">10.13039/501100003125</institution-id></institution-wrap>
</funding-source></award-group><award-group><funding-source>
<institution-wrap><institution>Tampere Tuberculosis Foundation</institution><institution-id institution-id-type="open-funder-registry">10.13039/501100006706</institution-id></institution-wrap>
</funding-source></award-group><award-group><funding-source>
<institution-wrap><institution>Academy of Finland</institution><institution-id institution-id-type="open-funder-registry">10.13039/501100002341</institution-id></institution-wrap>
</funding-source></award-group><award-group><funding-source>
<institution-wrap><institution>Jane and Aatos Erkko Foundation</institution><institution-id institution-id-type="open-funder-registry">10.13039/501100004012</institution-id></institution-wrap>
</funding-source></award-group><funding-statement>The authors extend their appreciation to the Deanship of Scientific Research at King Khalid University, Saudi Arabia, for funding this work through the Large Research Groups Program under grant number RGP.2/14/44 (Akhtar Atiya). In addition, Ashok Aspatwar acknowledges the support of the Finnish Cultural Foundation and the Tampere Tuberculosis Foundation, both affiliated with Tampere University, Finland. Furthermore, Seppo Parkkila extended his appreciation to the Academy of Finland and the Jane and Aatos Erkko Foundation, both associated with Tampere University, Finland, for their invaluable financial and technical assistance.</funding-statement></funding-group></support-group><counts><fig-count count="0"/><table-count count="5"/><page-count count="24"/><word-count count="16713"/></counts></article-meta></front>
  <body>
    <sec sec-type="intro" disp-level="1" id="S0001">
      <label>1.</label>
      <title>Introduction</title>
      <p>Brucellosis is a zoonotic disease that primarily affects both livestock and wildlife. This infectious condition has considerable public health implications and causes significant economic challenges, especially in regions with inadequate food safety measures, hygiene standards and veterinary care. Brucellosis transmission to humans occurs through ingesting contaminated animal products or direct contact with infected animals. The disease exhibits endemicity in regions such as the Middle East, Mediterranean, Central and South America [<xref rid="CIT0001" ref-type="bibr">1</xref>].</p>
      <p><italic toggle="yes">Brucella</italic> spp. exploit host immune defences to establish chronic infections, leading to a spectrum of clinical manifestations ranging from fever, fatigue and joint pain to more severe complications, such as endocarditis and neurological disorders [<xref rid="CIT0002" ref-type="bibr">2</xref>]. Diagnosis of brucellosis necessitates the use of clinical evaluations and laboratory examinations, including blood cultures, serological testing and molecular approaches. Nevertheless, diagnostic challenges arise due to the non-specific nature of the symptoms and difficulties in obtaining suitable samples for testing [<xref rid="CIT0003" ref-type="bibr">3</xref>].</p>
      <p>Treatment strategies typically involve a combination of multiple antibiotics; however, the emergence of antibiotic-resistant <italic toggle="yes">Brucella</italic> strains presents significant challenges [<xref rid="CIT0004" ref-type="bibr">4</xref>]. Vaccination of animals that are potential carriers of bacteria, especially within livestock populations, is promising for controlling the spread of brucellosis [<xref rid="CIT0005" ref-type="bibr">5</xref>].</p>
      <p>Despite concerted efforts to manage and mitigate the spread of brucellosis, it continues to pose a significant challenge to public health. This study provides a complete overview of brucellosis, specifically emphasising its epidemiology, pathophysiology, diagnosis and treatment methods. It also presents the latest research on <italic toggle="yes">Brucella</italic> species, their host range, and their transmission modes.</p>
      <p>Finally, the review emphasises the need for sustained research and interdisciplinary collaboration among public health officials, healthcare providers and veterinary experts to develop effective strategies to control and prevent brucellosis [<xref rid="CIT0006" ref-type="bibr">6</xref>]. This provides a comprehensive understanding of brucellosis and its impact on global health.</p>
    </sec>
    <sec disp-level="1" id="S0002">
      <label>2.</label>
      <title>Epidemiology of brucellosis</title>
      <sec disp-level="2" id="S0002-S2001">
        <label>2.1.</label>
        <title>Global prevalence</title>
        <p>Brucellosis is a zoonotic infection caused by various <italic toggle="yes">Brucella</italic> species, affecting both humans and animals, including cattle, dogs, sheep and goats [<xref rid="CIT0007" ref-type="bibr">7</xref>, <xref rid="CIT0008" ref-type="bibr">8</xref>]. Recent studies reveal a higher global incidence than previously estimated, with 1.6&#x2013;2.1 million new human cases annually [<xref rid="CIT0009" ref-type="bibr">9</xref>, <xref rid="CIT0010" ref-type="bibr">10</xref>]. Resource-limited regions, such as the Mediterranean, Middle East, Central Asia and certain parts of Africa, report elevated incidence rates [<xref rid="CIT0007" ref-type="bibr">7</xref>]. Iran, Kyrgyzstan, Tajikistan, Kazakhstan, Azerbaijan, Turkmenistan, Armenia and Uzbekistan are among the countries with the highest reported incidences of brucellosis [<xref rid="CIT0011" ref-type="bibr">11</xref>, <xref rid="CIT0012" ref-type="bibr">12</xref>].</p>
      </sec>
      <sec disp-level="2" id="S0002-S2002">
        <label>2.2.</label>
        <title>Regional Epidemiology</title>
        <sec disp-level="3" id="S0002-S2002-S3001">
          <label>2.2.1.</label>
          <title>Regional epidemiology&#x2013;California, United States of America</title>
          <p>In Latin America, Mexico and Peru have reported many cases [<xref rid="CIT0013" ref-type="bibr">13</xref>]. A study conducted by Fritz et&#xA0;al. on the epidemiology of brucellosis in California found that the disease is particularly prevalent among older Latino men, with a significant link to the consumption of unpasteurised Mexican-style soft cheese and <italic toggle="yes">B. melitensis</italic> was the most common species detected in cases. There were 492 cases reported in California from 1993 to 2017, underscoring the health risks of brucellosis. This study emphasises the importance of public health initiatives to inform the Latino community, especially the older population, about the risks associated with importing and consuming unpasteurised dairy products, particularly those from Mexico [<xref rid="CIT0014" ref-type="bibr">14</xref>].</p>
        </sec>
        <sec disp-level="3" id="S0002-S2002-S3002">
          <label>2.2.2.</label>
          <title>Regional epidemiology&#x2013;Europe</title>
          <p>In the 28 EU countries, the annual incidence rate for 2017&#x2013;2018 was 0.09 per 100,000 people [<xref rid="CIT0015" ref-type="bibr">15</xref>]. The European Food Safety Authority (EFSA) noted a decline in brucellosis cases from 735 in 2008 to 352 in 2011, highlighting successful intervention measures [<xref rid="CIT0013" ref-type="bibr">13</xref>].</p>
          <p>In Europe, <italic toggle="yes">Brucella canis</italic> has emerged as a cause of canine brucellosis, indicating a zoonotic threat to public health. The lack of comprehensive surveillance and awareness of <italic toggle="yes">B. canis</italic> among veterinarians and dog owners complicates disease management. The current diagnostic tools for detecting <italic toggle="yes">B. canis</italic> infection are insufficient in sensitivity and specificity, underscoring the need for better diagnostic methods. The lack of universal reagents and standards for serological tests adds to the challenge of accurately diagnosing this infection. To address these issues, this study emphasises the importance of developing awareness materials, profession-specific guidance and enhanced diagnostic techniques to curb the spread of <italic toggle="yes">B. canis</italic> and increase awareness among the public and professionals [<xref rid="CIT0016" ref-type="bibr">16</xref>].</p>
        </sec>
        <sec disp-level="3" id="S0002-S2002-S3003">
          <label>2.2.3.</label>
          <title>Regional epidemiology&#x2013;Bosnia and Herzegovina</title>
          <p>Between 2008 and 2018, 263 cases were studied in Bosnia and Herzegovina, decreasing from 102 in 2008 to 3 in 2018. The findings of this study regarding epidemiological characteristics align with the data from other global studies. Specifically, there was a notable male predominance; the most affected age group was between 25 and 49&#xA0;years, and most patients either hailed from rural settings or had previous exposure to animals [<xref rid="CIT0013" ref-type="bibr">13</xref>, <xref rid="CIT0015" ref-type="bibr">15</xref>, <xref rid="CIT0017" ref-type="bibr">17</xref>, <xref rid="CIT0018" ref-type="bibr">18</xref>].</p>
        </sec>
        <sec disp-level="3" id="S0002-S2002-S3004">
          <label>2.2.4.</label>
          <title>Regional epidemiology&#x2013;Turkey</title>
          <p>A study was conducted in Turkey to investigate the prevalence of brucellosis in children. The primary risk factor identified was occupational exposure, with 71.1% of the studied families engaging in animal breeding. Additionally, having a family member previously diagnosed with brucellosis accounted for 15.6% of the total risk. The study also emphasised that consuming raw milk and dairy products, such as cheese, is the primary transmission route in most instances. These findings are consistent with previous studies conducted in other regions of Turkey [<xref rid="CIT0019" ref-type="bibr">19</xref>].</p>
        </sec>
        <sec disp-level="3" id="S0002-S2002-S3005">
          <label>2.2.5.</label>
          <title>Regional epidemiology&#x2013;Iran</title>
          <p>Brucellosis is present in most parts of Iran, with 80,000 cases reported annually since 1989. It has been reported in Iran that healthcare workers are accidentally exposed to <italic toggle="yes">Brucella</italic> strains during routine animal vaccination programs [<xref rid="CIT0020" ref-type="bibr">20</xref>]. Brucellosis incidence in Iran varies by region and has decreased in recent years. Males aged 25&#x2013;29&#xA0;years are more commonly affected by the disease, with western provinces reporting higher prevalence. The seasonality of brucellosis cases is notable, with spring months seeing increased diagnoses. Occupational risks for healthcare workers, including accidental exposure during animal vaccination programs, highlight the need for targeted prevention strategies. <italic toggle="yes">Brucella melitensis</italic> biovar 1 remains the dominant causative agent in Iran, and risk factors include the consumption of unpasteurised dairy products and living in rural areas. Efforts to control and manage brucellosis in Iran require a multifaceted approach that addresses regional variations and occupational exposures [<xref rid="CIT0021" ref-type="bibr">21&#x2013;24</xref>].</p>
        </sec>
        <sec disp-level="3" id="S0002-S2002-S3006">
          <label>2.2.6.</label>
          <title>Regional epidemiology&#x2013;Jordan</title>
          <p>In Jordan, brucellosis is prevalent among young adults in rural areas and those working in livestock-related occupations, particularly during the spring and summer. Al-Amr et&#xA0;al. revealed variations in seropositivity rates, with occupational exposure being a significant risk factor. This research also highlights the substantial health burden of brucellosis in Jordan, exceeding that in North America and Western Europe, with 31.1% of febrile illnesses in Jordan attributed to the disease. These findings are crucial in informing and enhancing disease control and prevention strategies, offering valuable insights into the epidemiology of brucellosis in Jordan and contributing to reducing its impact [<xref rid="CIT0025" ref-type="bibr">25</xref>].</p>
        </sec>
        <sec disp-level="3" id="S0002-S2002-S3007">
          <label>2.2.7.</label>
          <title>Regional epidemiology&#x2013;India</title>
          <p>A study by Holt et&#xA0;al. [<xref rid="CIT0026" ref-type="bibr">26</xref>] revealed that brucellosis, a zoonotic disease caused by <italic toggle="yes">Brucella</italic> species, is endemic in rural areas of India, with a seroprevalence of 15.1% (95% CI: 15.9&#x2013;19.8%). This finding emphasises the disease&#x2019;s prevalence in regions where agriculture and livestock farming are common, facilitating disease transmission due to close human&#x2013;animal interaction. Seroprevalence, denoting the presence of <italic toggle="yes">Brucella</italic> antibodies in individuals&#x2019; blood, highlights substantial exposure within the rural population. Moreover, the study&#x2019;s 95% confidence interval underscores the statistical reliability of this seroprevalence estimate. In conclusion, Holt et&#xA0;al.&#x2019;s research underscores brucellosis as a significant health concern in rural India, necessitating effective control measures and increased community awareness to address this zoonotic disease&#x2019;s impact [<xref rid="CIT0026" ref-type="bibr">26</xref>].</p>
        </sec>
        <sec disp-level="3" id="S0002-S2002-S3008">
          <label>2.2.8.</label>
          <title>Regional epidemiology&#x2013;Punjab, Pakistan</title>
          <p>In Punjab, Pakistan, a study by Nawaz et&#xA0;al. on the epidemiology of brucellosis revealed a seroprevalence of 13.13%, with higher rates in males aged 25&#x2013;40. Risk factors were lack of education, involvement in farming, keeping animals at home, animal slaughter and consumption of raw milk. This study further emphasises the necessity of raising awareness regarding disease transmission and risk factors among individuals with direct animal exposure, particularly livestock farmers. Furthermore, it underscores the importance of avoiding unpasteurised dairy products to mitigate the spread of this often underestimated zoonotic disease, which has a high regional morbidity rate [<xref rid="CIT0027" ref-type="bibr">27</xref>].</p>
        </sec>
        <sec disp-level="3" id="S0002-S2002-S3009">
          <label>2.2.9.</label>
          <title>Regional epidemiology&#x2013;China</title>
          <p>A study in China examined the epidemiological features, morbidity and endemic nature of human brucellosis and observed a notable increase in the population [<xref rid="CIT0028" ref-type="bibr">28</xref>]. Four-year study revealed divergent trends in the incidence of brucellosis across China, with a nationwide average annual incidence of 3.0 per 100,000 people. While the rate substantially decreased in Xinjiang, it more than doubled in Inner Mongolia, contributing to the higher incidence rate in Northern China. Notably, males aged 45&#x2013;64 in this region are more than twice as likely to be affected by their female counterparts [<xref rid="CIT0029" ref-type="bibr">29</xref>].</p>
        </sec>
        <sec disp-level="3" id="S0002-S2002-S3010">
          <label>2.2.10.</label>
          <title>Regional epidemiology&#x2013;Mongolia</title>
          <p>A study found a declining incidence but increasing seroprevalence of human brucellosis in Inner Mongolia from 2012 to 2016, with genetic data pointing to both sporadic cases and cross-infections potentially exacerbated by long-term livestock trade [<xref rid="CIT0030" ref-type="bibr">30</xref>]. Notably, Mongolia ranks second globally in incidence, whereas Syria has the highest annual prevalence.</p>
        </sec>
        <sec disp-level="3" id="S0002-S2002-S3011">
          <label>2.2.11.</label>
          <title>Regional epidemiology&#x2013;sub-Saharan Africa</title>
          <p>Brucellosis is endemic to many regions of the world, including sub-Saharan Africa. According to the literature published between 2010 and 2019, the prevalence of brucellosis in livestock ranged from 0.2% to 43.8% in cattle, 0.0% to 20.0% in goats, and 0.0% to 13.8% in sheep. In humans, the prevalence of brucellosis in the sub-Saharan African region ranges from 0% to 55.8%, highlighting the significant presence of brucellosis infection in this area [<xref rid="CIT0031" ref-type="bibr">31</xref>].</p>
        </sec>
      </sec>
    </sec>
    <sec disp-level="1" id="S0003">
      <label>3.</label>
      <title>Transmission of brucellosis</title>
      <p>The prevention and control of brucellosis is of paramount significance, and a thorough understanding of its mode of transmission is indispensable in achieving this objective. Brucellosis can be transmitted to humans through several paths.</p>
      <sec disp-level="2" id="S0003-S2001">
        <label>3.1.</label>
        <title>Direct contact with infected animals</title>
        <p>Brucellosis is primarily transmitted through direct contact with infected animals or their bodily fluids, including vaginal discharges, aborted materials and semen. Those who work closely with livestock, such as farmers, veterinarians and livestock handlers, are at a heightened risk of contracting the disease due to their frequent interactions with animals [<xref rid="CIT0009" ref-type="bibr">9</xref>, <xref rid="CIT0010" ref-type="bibr">10</xref>, <xref rid="CIT0032" ref-type="bibr">32</xref>].</p>
      </sec>
      <sec disp-level="2" id="S0003-S2002">
        <label>3.2.</label>
        <title>Consumption of contaminated products</title>
        <p>Brucellosis can also be transmitted through the consumption of raw or unpasteurised dairy products from infected animals, including milk and cheese. The consumption of these contaminated food products can result in human infection, emphasising the importance of food safety practices to prevent the spread of the disease [<xref rid="CIT0007" ref-type="bibr">7</xref>].</p>
      </sec>
      <sec disp-level="2" id="S0003-S2003">
        <label>3.3.</label>
        <title>Inhalation of airborne agents</title>
        <p>In certain occupational settings, such as slaughterhouses and meat processing facilities, the airborne transmission of <italic toggle="yes">Brucella</italic> bacteria can become a concern. It is possible for workers in these environments to inhale airborne agents, which may result in infection. This highlights the necessity of implementing effective workplace safety measures and utilising appropriate protective equipment [<xref rid="CIT0009" ref-type="bibr">9</xref>, <xref rid="CIT0010" ref-type="bibr">10</xref>].</p>
      </sec>
      <sec disp-level="2" id="S0003-S2004">
        <label>3.4.</label>
        <title>Occupational hazard</title>
        <p>Human brucellosis poses a significant risk factor for occupational exposure, particularly for individuals in professions such as butchers, laboratory workers and hunters, who have direct contact with infected animals or their products. To mitigate this risk, it is essential to implement occupational health precautions [<xref rid="CIT0007" ref-type="bibr">7</xref>].</p>
        <p>Laboratory-acquired human brucellosis infections are not uncommon [<xref rid="CIT0013" ref-type="bibr">13</xref>]. For example, 12 out of 48 healthcare workers tested positive for <italic toggle="yes">Brucella</italic> spp. in a hospital facility in Ankara, resulting in an infection risk of 8% per employee per year [<xref rid="CIT0019" ref-type="bibr">19</xref>]. While person-to-person transmission is rare, it is crucial to recognise other potential sources of brucellosis transmission. These include blood transfusions and bone marrow transplants, underscoring the importance of antibody detection methods, especially in endemic areas [<xref rid="CIT0012" ref-type="bibr">12</xref>, <xref rid="CIT0013" ref-type="bibr">13</xref>, <xref rid="CIT0020" ref-type="bibr">20</xref>].</p>
        <p>Additionally, brucellosis can be transmitted through inhalation of aerosols, contact with contaminated skin, and colonisation of the udder by using contaminated milking equipment [<xref rid="CIT0012" ref-type="bibr">12</xref>, <xref rid="CIT0013" ref-type="bibr">13</xref>, <xref rid="CIT0020" ref-type="bibr">20</xref>]. It is worth noting that brucellosis is considered a potential type B bioweapon [<xref rid="CIT0033" ref-type="bibr">33</xref>]. Furthermore, the unhygienic processing of milk, milk products and meat has contributed to the spread of human brucellosis, highlighting its zoonotic nature [<xref rid="CIT0013" ref-type="bibr">13</xref>, <xref rid="CIT0033" ref-type="bibr">33</xref>]. In conclusion, occupational exposure is a significant concern in brucellosis transmission. Professionals in specific fields need to be vigilant and take appropriate precautions to reduce the risk of infection, and public health measures should address these potential transmission sources.</p>
      </sec>
      <sec disp-level="2" id="S0003-S2005">
        <label>3.5.</label>
        <title>Indirect transmission</title>
        <p>Indirect transmission can occur through contact with contaminated materials or environments. People encountering surfaces or objects contaminated with <italic toggle="yes">Brucella</italic> can become infected. Proper sanitation and hygiene practices are essential in reducing the risk of indirect transmission [<xref rid="CIT0009" ref-type="bibr">9</xref>, <xref rid="CIT0010" ref-type="bibr">10</xref>].</p>
      </sec>
      <sec disp-level="2" id="S0003-S2006">
        <label>3.6.</label>
        <title>Intrauterine transmission</title>
        <p>Brucellosis, although rarely transmitted, can be passed from an infected mother to her unborn child during pregnancy, underscoring the significance of prenatal care and monitoring for pregnant individuals with brucellosis [<xref rid="CIT0009" ref-type="bibr">9</xref>, <xref rid="CIT0010" ref-type="bibr">10</xref>, <xref rid="CIT0032" ref-type="bibr">32</xref>]. Therefore, a thorough understanding of the various modes of transmission is crucial to prevent its spread. Implementing effective preventive measures, such as vaccinating livestock and promoting public health education, is imperative in controlling this zoonotic disease.</p>
      </sec>
    </sec>
    <sec disp-level="1" id="S0004">
      <label>4.</label>
      <title>Trends and seasonal variations</title>
      <p>The seasonal trends showed the highest prevalence of brucellosis from March to June. Spring showed a marked distribution of brucellosis in areas where the disease is endemic [<xref rid="CIT0015" ref-type="bibr">15</xref>]. A study by Delam et&#xA0;al. conducted from 2015 to 2020 utilising the Cochran&#x2013;Armitage test, revealed that the average annual incidence of the disease was 8.94 per 100,000 individuals. The study also found a significant decrease in the incidence rates, dropping from 26.83 per 100,000 people in 2015 to 1.83 per 100,000 people in 2020. The Cochran&#x2013;Armitage test confirmed that this reduction in incidence was statistically significant [<xref rid="CIT0034" ref-type="bibr">34</xref>].</p>
    </sec>
    <sec disp-level="1" id="S0005">
      <label>5.</label>
      <title>Species and biovars</title>
      <p>The <italic toggle="yes">Brucella</italic> genus comprises six species, each categorised by its principal host: <italic toggle="yes">B. melitensis</italic> (sheep and goats), <italic toggle="yes">B. abortus</italic> (cattle), <italic toggle="yes">B. suis</italic> (pigs), <italic toggle="yes">B. ovis</italic> (sheep), <italic toggle="yes">B. canis</italic> (dogs) and <italic toggle="yes">B. neotomae</italic> (wood desert rats). <italic toggle="yes">B. melitensis</italic> is the most virulent bacterium in humans [<xref rid="CIT0010" ref-type="bibr">10</xref>, <xref rid="CIT0035" ref-type="bibr">35</xref>]. <italic toggle="yes">B. abortus</italic> is found worldwide in cattle-raising regions, except Japan, Canada and some European countries [<xref rid="CIT0012" ref-type="bibr">12</xref>]. In recent years, several new species have been successfully isolated, including <italic toggle="yes">B. inopinata</italic> (from humans), <italic toggle="yes">B. pinnipedialis</italic>, <italic toggle="yes">B. ceti</italic> (from aquatic animals) and <italic toggle="yes">B. microti</italic> (from the common vole), expanding the count to 10 species [<xref rid="CIT0036" ref-type="bibr">36</xref>].</p>
      <p>Studies have shown that each <italic toggle="yes">Brucella</italic> species comprises multiple biovars. <italic toggle="yes">B. abortus</italic> consists of eight different biovars (1&#x2013;7 and 9), <italic toggle="yes">B. melitensis</italic> has three biovars (1&#x2013;3) and <italic toggle="yes">B. suis</italic> has five biovars (1&#x2013;5). Other <italic toggle="yes">Brucella</italic> species have not yet been differentiated into biovars [<xref rid="CIT0037" ref-type="bibr">37</xref>, <xref rid="CIT0038" ref-type="bibr">38</xref>]. In a study by Liu et&#xA0;al., 107 human isolates of <italic toggle="yes">Brucella</italic>, identified explicitly as the <italic toggle="yes">B. melitensis</italic> species and predominantly as biovar 3, were subjected to an MLVA-16 assay to explore their genetic diversity. This assay classified these isolates into 75 unique MLVA-16 genotypes. Intriguingly, 54 of these genotypes represent unique, epidemiologically unrelated and sporadic cases of brucellosis. In contrast, the remaining 21 shared genotypes among two to four strains indicated cross-infections and multiple outbreak events. Moreover, substantial genotype overlap was observed with strains from Kazakhstan, Mongolia and Turkey, which are the key members of the Grassland Silk Road. The extensive trade of small ruminants, mainly sheep, in these countries may have contributed to the regional spread of <italic toggle="yes">Brucella</italic> spp. [<xref rid="CIT0030" ref-type="bibr">30</xref>].</p>
    </sec>
    <sec disp-level="1" id="S0006">
      <label>6.</label>
      <title>Diagnostic challenges and public health response</title>
      <p>Brucellosis poses numerous diagnostic challenges that significantly hinder public health initiatives. These difficulties are closely related to the extent of contact individuals have with infected animals or their products [<xref rid="CIT0009" ref-type="bibr">9</xref>, <xref rid="CIT0010" ref-type="bibr">10</xref>]. Here are some crucial aspects to take into account:<list list-type="alpha-lower"><list-item><p><italic toggle="yes">Misdiagnosis and underdiagnosis</italic>: One of the main obstacles in diagnosing brucellosis is the risk of misdiagnosis or underdiagnosis. The symptoms of the disease, such as fever, fatigue and joint pain, are non-specific and can be similar to those of various other illnesses. As a result, healthcare providers may either overlook the diagnosis or confuse it with other conditions, leading to delayed appropriate treatment.</p></list-item><list-item><p><italic toggle="yes">Resource-poor settings</italic>: Diagnostic inaccuracies, particularly misdiagnosis and underdiagnosis, are notably prevalent in regions with limited access to advanced diagnostic equipment and healthcare infrastructure. Consequently, the disease burden in such resource-poor settings may be considerably underestimated, resulting in inadequate public health responses.</p></list-item><list-item><p><italic toggle="yes">Overestimated case numbers</italic>: The paradoxical nature of diagnosing brucellosis is such that the difficulty in doing so can lead to an overestimation of case numbers in regions where healthcare systems rely on less specific diagnostic methods. This overestimation can in turn foster heightened risk perceptions and unwarranted panic among the general population.</p></list-item></list></p>
      <p>In response to these challenges, several crucial measures need to be implemented:<list list-type="alpha-lower"><list-item><p><italic toggle="yes">Improved diagnostic methods</italic>: The development of reliable diagnostic tests for brucellosis is imperative, as current methods are often inaccurate and slow. Research and development initiatives should focus on creating tests that can accurately differentiate brucellosis from other febrile illnesses and are suitable for use in resource-limited settings. These tests should also be easily accessible to improve early diagnosis and treatment of the disease.</p></list-item><list-item><p><italic toggle="yes">Enhanced surveillance</italic>: The implementation of comprehensive surveillance systems is crucial for the purpose of closely monitoring the occurrence and geographic proliferation of brucellosis. This entails identifying outbreaks at an early stage and gaining insight into the disease&#x2019;s epidemiological patterns within particular demographics.</p></list-item><list-item><p><italic toggle="yes">Increased awareness</italic>: Brucellosis, a zoonotic disease with significant public health implications, requires increased awareness and education among health professionals, particularly those working in endemic regions. Enhanced understanding of the clinical manifestations and diagnostic challenges associated with the disease is crucial for accurate and timely diagnoses, which is essential for effective public health responses. Improved diagnostics, strengthened surveillance and increased awareness among healthcare providers are vital components in mitigating the impact of brucellosis, especially in resource-poor settings where the burden is often high. These efforts are essential for controlling the spread of the disease and minimising its impact on affected populations.</p></list-item></list></p>
    </sec>
    <sec disp-level="1" id="S0007">
      <label>7.</label>
      <title>Virulence factors and pathogenesis</title>
      <p>Regarding virulence factors, <italic toggle="yes">Brucella</italic> lacks classical factors such as exotoxins, cytolysins and exoenzymes. Its pathogenesis is attributed to unique factors, such as lipopolysaccharide (LPS), type IV secretion system (T4SS) and the BvrR/BvrS system. These factors facilitate interactions with host cells, the formation of <italic toggle="yes">Brucella</italic>-containing vacuoles (BCVs), and interactions with the endoplasmic reticulum (ER) during bacterial multiplication [<xref rid="CIT0039" ref-type="bibr">39&#x2013;41</xref>].</p>
      <p>The pathogenesis of brucellosis is intricate and involves bacterial invasion of host cells, immune evasion and chronic infections. <italic toggle="yes">Brucella</italic> uniquely penetrates and persists within host cells, such as macrophages, and uses strategies to bypass host immune defences, leading to prolonged infection. Symptoms in humans include fatigue, fever, generalised discomfort, and more severe manifestations, such as arthritis, osteomyelitis, endocarditis and meningoencephalitis [<xref rid="CIT0039" ref-type="bibr">39&#x2013;41</xref>]. <italic toggle="yes">Brucella</italic> is an adept intracellular pathogen that can survive and replicate within the host cells, evading the immune system. They inhibit phagocytosis, reduce bactericidal activity, diminish endotoxic reactions and impede antigen presentation [<xref rid="CIT0039" ref-type="bibr">39&#x2013;41</xref>].</p>
      <p>The pathogenesis of <italic toggle="yes">Brucella</italic> extends to its survival and multiplication within phagocytic and non-phagocytic cells, its ability to manipulate host cell processes, disrupt phagocyte function, inhibit phagocytosis and prevent host cell apoptosis. It modulates the host immune response by targeting signalling pathways involved in innate immunity, such as the degradation of the TLR signalling adapter MAL [<xref rid="CIT0039" ref-type="bibr">39&#x2013;41</xref>]. <italic toggle="yes">Brucella</italic>&#x2019;s resilience in various environments, including water, soil, dairy products and meat, further contributes to its pathogenesis and transmission [<xref rid="CIT0039" ref-type="bibr">39&#x2013;41</xref>].</p>
    </sec>
    <sec disp-level="1" id="S0008">
      <label>8.</label>
      <title>Clinical manifestations</title>
      <p>The clinical manifestations of brucellosis vary significantly, making the diagnosis challenging. Symptoms range from flu-like illnesses to more severe complications involving multiple organs. The non-specific nature of symptoms and the difficulty in obtaining samples for laboratory testing contribute to challenges in diagnosing the disease. Haemorrhagic anaemia is an important clinical manifestation of brucellosis in children. <italic toggle="yes">Brucella</italic> infections can lead to microangiopathic haemolytic anaemia and severe thrombocytopenia in children. The ability of <italic toggle="yes">Brucella</italic> to change from a non-haemolytic to a haemolytic phenotype may influence its pathogenicity and contribute to the correlation between acute brucellosis and haemolytic anaemia in humans. The expression of haemolysin genes in <italic toggle="yes">Brucella</italic> may have accumulated mutations during growth, resulting in the repair of the default genes and the ability to express haemolysin, which can affect pathogenicity. However, a conclusive explanation for the development of haemolytic anaemia during <italic toggle="yes">Brucella</italic> infection is still missing. The presence of haemolysin genes and haemolytic anaemia in humans has been reported [<xref rid="CIT0042" ref-type="bibr">42</xref>].</p>
      <sec disp-level="2" id="S0008-S2001">
        <label>8.1.</label>
        <title>Symptoms and complications associated with brucellosis</title>
        <p>Brucellosis in humans is a multifaceted disease that affects various organs with a diverse range of symptoms ranging from mild to severe. This complexity often leads to misdiagnosis. If untreated, it may transition to the chronic phase, increasing the risk of disability [<xref rid="CIT0043" ref-type="bibr">43</xref>]. The incubation period ranged from five days to 6&#xA0;months [<xref rid="CIT0044" ref-type="bibr">44</xref>]. Upon ingestion, <italic toggle="yes">Brucella</italic> bacteria are carried by macrophages to lymphoid tissues, spread through the lymphatic system, and can potentially multiply in multiple organs, causing localised and systemic infections [<xref rid="CIT0045" ref-type="bibr">45</xref>].</p>
        <p>The symptoms can persist for months or years in chronic cases [<xref rid="CIT0045" ref-type="bibr">45</xref>], making a comprehensive medical and dietary history essential for accurate diagnosis, especially in non-endemic regions where infection can occur from consuming imported contaminated food [<xref rid="CIT0046" ref-type="bibr">46</xref>]. Brucellosis presents symptoms such as headaches, recurring fever, migratory joint pain, muscle pain, weakness, loss of appetite, fatigue, general discomfort, sweating, vomiting, diarrhoea, abdominal pain and even miscarriage [<xref rid="CIT0041" ref-type="bibr">41</xref>]. Complications such as sacroiliitis, osteomyelitis, spondylodiscitis, septic arthritis and epidural abscesses may arise [<xref rid="CIT0047" ref-type="bibr">47</xref>]. Rarely, brucellosis is linked to conditions such as hepatic abscesses, granulomas, spontaneous bacterial peritonitis, ventriculoperitoneal shunt infection and immune thrombocytopenic purpura [<xref rid="CIT0048" ref-type="bibr">48&#x2013;52</xref>]. Respiratory symptoms and neurological manifestations, including Guillain-Barre syndrome, can also occur [<xref rid="CIT0053" ref-type="bibr">53</xref>, <xref rid="CIT0054" ref-type="bibr">54</xref>]. Death is rare, with cases reporting a unique unpleasant odour in patients&#x2019; sweat [<xref rid="CIT0055" ref-type="bibr">55</xref>, <xref rid="CIT0056" ref-type="bibr">56</xref>].</p>
        <p>Physical examination findings may appear normal, but signs such as lymphadenopathy, splenomegaly and hepatomegaly may be present [<xref rid="CIT0045" ref-type="bibr">45</xref>]. Epididymoorchitis and endocarditis are uncommon complications, with the latter being the primary cause of death related to brucellosis [<xref rid="CIT0057" ref-type="bibr">57</xref>, <xref rid="CIT0058" ref-type="bibr">58</xref>]. Ocular and skin manifestations such as uveitis, keratoconjunctivitis, iridocyclitis, optic neuritis, cataracts, maculopapular eruptions, erythema nodosum, abscesses and panniculitis have also been reported [<xref rid="CIT0059" ref-type="bibr">59&#x2013;62</xref>].</p>
        <p>The CDC and the WHO do not precisely define chronic brucellosis. Generally, symptoms persist for over a year after the initial diagnosis [<xref rid="CIT0046" ref-type="bibr">46</xref>]. Patients with chronic brucellosis exhibit either a focal complication with objective evidence of infection or persistent symptoms without objective signs of infection, manifesting as general malaise and psychiatric complaints, such as depression and anxiety [<xref rid="CIT0004" ref-type="bibr">4</xref>, <xref rid="CIT0063" ref-type="bibr">63</xref>].</p>
      </sec>
      <sec disp-level="2" id="S0008-S2002">
        <label>8.2.</label>
        <title>Relapse after treatment</title>
        <p>The incidence of relapse after treatment ranges from 5% to 15%. Typically, relapses are observed within six months after treatment completion, although they can occur up to 12&#xA0;months later [<xref rid="CIT0064" ref-type="bibr">64</xref>]. The multivariate model identified several factors as independent predictors of relapse. These factors include a temperature of 38.3&#x2009;&#xB0;C or higher, experiencing symptoms for less than 10&#xA0;days before starting treatment, and testing positive for <italic toggle="yes">Brucella</italic> in blood cultures [<xref rid="CIT0065" ref-type="bibr">65</xref>]. Distinguishing between relapse and reinfection can pose challenges, particularly in regions where individuals are continuously exposed to infectious agents [<xref rid="CIT0064" ref-type="bibr">64</xref>]. Relapses can be attributed to various causes, such as an insufficient antibiotic treatment plan, a shorter duration of antibiotic therapy than required, nonadherence to the prescribed regimen, or localised areas of infection. Relapses rarely occur because of antibiotic resistance [<xref rid="CIT0066" ref-type="bibr">66</xref>].</p>
      </sec>
      <sec disp-level="2" id="S0008-S2003">
        <label>8.3.</label>
        <title>Laboratory diagnosis and its challenges</title>
        <p>Humans can act as sporadic hosts for <italic toggle="yes">Brucella</italic> infection, primarily due to a virulent strain, which is <italic toggle="yes">B. melitensis</italic>, <italic toggle="yes">B. abortus</italic>, <italic toggle="yes">B. suis</italic> and <italic toggle="yes">B. canis.</italic> Identifying human cases of brucellosis relies heavily on microbiological analysis because of the variability and lack of specificity of the symptoms associated with the disease [<xref rid="CIT0067" ref-type="bibr">67</xref>]. Diagnostic tools for brucellosis include <italic toggle="yes">blood culture</italic>, <italic toggle="yes">serological assays</italic> and <italic toggle="yes">molecular methods</italic>. Each method has advantages and limitations, such as sensitivity, specificity and time required for accurate results. The choice of diagnostic method depends on clinical presentation and available resources. There are three primary techniques used for microbiological identification of human brucellosis: blood cultures, serology assays and molecular assays. Here, we summarise recent advancements in evaluating diagnostic techniques, their clinical value, and their respective advantages and disadvantages [<xref rid="CIT0068" ref-type="bibr">68</xref>, <xref rid="CIT0069" ref-type="bibr">69</xref>].</p>
        <sec disp-level="3" id="S0008-S2003-S3001">
          <label>8.3.1.</label>
          <title>Blood cultures</title>
          <p>Peripheral blood cultures are crucial for confirming human brucellosis, especially during bacteraemia. However, their sensitivities were inconsistent, ranging from 10% to 90%. Patients with early-stage brucellosis often have low-level persistent bacteraemia detectable in multiple blood samples. However, as the infection advances, the bacterial concentration in the blood drops, creating an unpredictable bacteraemia pattern and increasing bacterial isolation from blood specimens [<xref rid="CIT0070" ref-type="bibr">70</xref>].</p>
          <p><italic toggle="yes">Brucella</italic> may intermittently re-enter the bloodstream, increasing the chances of clinical recurrence and spreading to other areas. Despite its generally low virulence in humans, <italic toggle="yes">Brucella</italic> spp. can be recovered from mildly symptomatic or even afebrile patients. This underscores the necessity of obtaining blood cultures from suspected brucellosis cases, even without fever [<xref rid="CIT0069" ref-type="bibr">69</xref>].</p>
          <p>Several factors affect the effectiveness of blood culture techniques for <italic toggle="yes">Brucella</italic> detection, including its long generation time and reduced CO<sub>2</sub> emissions. For enhanced recovery, it is suggested to incubate the inoculated medium for four weeks and perform blind subcultures of seemingly negative blood culture media. Despite its effectiveness, this method is costly, labour-intensive and significantly delays the diagnosis.</p>
          <p>Shorter incubation periods (3&#x2013;7&#xA0;days) have been explored, showing varying successes in detecting circulating <italic toggle="yes">Brucella</italic>. However, the risk of prematurely discarding vials containing viable <italic toggle="yes">Brucella</italic> cannot be ignored, highlighting the importance of carefully assessing the sensitivity and detection time of blood culture systems [<xref rid="CIT0071" ref-type="bibr">71</xref>]. Various blood culture techniques have been employed.<list list-type="alpha-lower"><list-item><p><italic toggle="yes">Manual monophasic approach.</italic> Patient blood samples were incubated in culture vials at 35&#x2009;&#xB0;C and checked for bacterial and fungal growth. However, <italic toggle="yes">Brucella</italic>&#x2019;s slow growth often went undetected, leading to premature vial disposal within 5&#x2013;7&#xA0;days. To improve <italic toggle="yes">Brucella</italic> detection, vials were kept longer, and blind subcultures were conducted when brucellosis was suspected.</p></list-item><list-item><p><italic toggle="yes">Manual biphasic approach</italic><list list-type="bullet"><list-item><p><italic toggle="yes">Casta&#xF1;eda flask:</italic> Ruiz-Casta&#xF1;eda proposed a biphasic flask to avoid repeated blind subcultures, save time and labour, and minimise the risk of laboratory-acquired brucellosis. Despite its non-specificity to <italic toggle="yes">Brucella</italic>, it remains popular in regions with limited resources owing to its affordability and practicality [<xref rid="CIT0072" ref-type="bibr">72</xref>]. Proper identification is essential for confirming the presence of <italic toggle="yes">Brucella</italic> spp.</p></list-item><list-item><p><italic toggle="yes">TUMS medium:</italic> A variant in the Casta&#xF1;eda flask medium, Tehran University of Medical Sciences (TUMS) medium, expedites <italic toggle="yes">Brucella</italic> identification. It uses a solid urea agar substrate to note the colour change of the pH indicator, indicating <italic toggle="yes">Brucella</italic>-positive urease activity.</p></list-item><list-item><p><italic toggle="yes">H&#xE9;moline medium:</italic> A study on H&#xE9;moline, a commercial biphasic blood culture medium, showed a five-day detection period for <italic toggle="yes">Brucella</italic>. However, in 23.5% of the cases, detection was delayed beyond seven days.</p></list-item></list></p></list-item><list-item><p><italic toggle="yes">Lysis-based blood cultures.</italic> In this method, white blood cells are lysed before seeding onto a solid medium. This is crucial, as <italic toggle="yes">Brucella</italic> does not circulate freely in the blood but is engulfed by specific white blood cells. This engulfment often leads to bacterial death, lowering culture sensitivity and prolonging the detection time. Lysing white blood cells releases live <italic toggle="yes">Brucella</italic>, which is then transferred to solid media, enhancing the likelihood and speed of detecting viable <italic toggle="yes">Brucella</italic> organisms in culture.</p></list-item><list-item><p><italic toggle="yes">Blood clot medium</italic>. The procedure involves collecting a blood sample, allowing coagulation, and separating the serum by centrifugation for serodiagnosis. The clot was shaken vigorously to break it apart, and the material was spread on solid agar media for cultivation. Despite its rational basis, this approach has limited published data and has shown inconsistent results, necessitating further research and evaluation to optimise this method for brucellosis detection [<xref rid="CIT0073" ref-type="bibr">73</xref>].</p></list-item><list-item><p><italic toggle="yes">Automated blood culture method</italic>. Recent advancements in CO<sub>2</sub> monitoring and liquid culture media have notably enhanced the diagnosis of <italic toggle="yes">Brucella</italic> bacteraemia. These modern bacteriological techniques boost the sensitivity of <italic toggle="yes">Brucella</italic> cultures, decrease the detection time, and make the diagnostic procedure more efficient. Automated systems employing these techniques can process numerous blood culture bottles, reduce media contamination, and ensure safe bacterial management.</p></list-item></list></p>
          <p>Despite the conventional practices of extended incubation and intermittent subculturing, modern blood culture techniques promise increased sensitivity and faster detection. If used early in the infection, these automated techniques can identify acute brucellar infections within a standard one-week incubation period, negating the need for sub-culturing presumed negative vials. However, some patients may require prolonged incubation and terminal subcultures, especially in long-duration or focused infection cases.</p>
          <p>Modern technologies provide quicker results than traditional culture methods, especially for slow-growing organisms, such as <italic toggle="yes">Mycobacterium tuberculosis</italic>.<list list-type="bullet"><list-item><p><italic toggle="yes">Radiometric detection (BACTEC 460TB system):</italic> This method uses a radiometric approach to detect CO<sub>2</sub> produced by the metabolism of the bacterium. The BACTEC 460TB system is widely used for rapidly detecting mycobacteria but has been largely replaced by non-radiometric systems because of concerns regarding radioactive waste disposal.</p></list-item><list-item><p><italic toggle="yes">Fluorescence and colorimetric methods (e.g. BACTEC MGIT 960 system):</italic> Instead of radiometric detection, these systems rely on fluorescent or colorimetric indicators that change in response to O<sub>2</sub> consumption or CO<sub>2</sub> production during bacterial growth.</p></list-item><list-item><p><italic toggle="yes">BacT/alert system:</italic> This continuous monitoring system detects CO<sub>2</sub> production using colorimetric sensors.</p></list-item><list-item><p><italic toggle="yes">Bactec 9000:</italic> Similar to the BACTEC 460TB system, this system uses fluorescence instead of radiometry.</p></list-item><list-item><p><italic toggle="yes">Infrared technology:</italic> Some newer systems use infrared technology to detect CO<sub>2</sub> production to indicate bacterial growth.</p></list-item></list></p>
          <p>All these technologies can reduce the time required for detection compared to traditional culture methods. The choice of method depends on laboratory requirements, available resources and specific applications. Comparative studies suggest that the automated Bactec system is more effective for recovering <italic toggle="yes">Brucella</italic> in blood cultures, outperforming the isolator microbial tube in terms of overall susceptibility and detection time. Nonetheless, further research is essential to comprehensively assess the performance of other available blood culture systems [<xref rid="CIT0074" ref-type="bibr">74</xref>]. In conclusion, the appropriate diagnosis of brucellosis depends on various patient- and method-related factors, necessitating a careful approach to blood culture techniques for optimal <italic toggle="yes">Brucella</italic> detection and identification. These factors are summarised in <xref rid="t0001" ref-type="table">Table 1</xref>.</p>
          <table-wrap position="float" id="t0001">
            <label>Table 1.</label>
            <caption>
              <p>Factors affecting brucellosis detection in blood culture.</p>
            </caption>
            <!--OASIS TABLE HERE-->
            <table frame="hsides" rules="groups">
              <colgroup>
                <col width="80pt"/>
                <col width="80pt"/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left">Characteristics</th>
                  <th align="center">Related factors</th>
                </tr>
              </thead>
              <tbody valign="top">
                <tr>
                  <td align="left">Microbiological</td>
                  <td align="left"><italic toggle="yes">Brucella</italic> spp. involved.</td>
                </tr>
                <tr>
                  <td align="left">Patient</td>
                  <td align="left">Age of the patient, systemic (involving multiple organs) or focal (localised to specific organs), differentiating between a first-time infection and a relapse of a previous infection, prior or ongoing antibiotic treatment.</td>
                </tr>
                <tr>
                  <td align="left">Culture technique and specimen</td>
                  <td align="left">Volume and number of specimens, rate of detection, susceptibility of culture, period of incubation, and periodicity of blind subcultures (subculturing of negative blood cultures at regular intervals can help identify slow-growing or low-level bacterial growth).</td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
          <sec disp-level="4" id="S0008-S2003-S3001-S4001">
            <label>8.3.1.1.</label>
            <title>Advantages</title>
            <p>Patients with acute brucellosis can detect the causative organism within the standard seven&#xA0;days incubation period, eliminating the need for subculture. In many laboratories, automated blood culture systems (BacT/Alert, BACTEC 9000 series, Vital, and ESP) for brucellosis have assumed the position of traditional blood culture systems. These methods appear to reduce the time (&#x223C;3&#xA0;days) required to identify these organisms in blood and other bodily fluids. Nucleic acid amplification assays, hybridisation tests and matrix-assisted laser desorption ionisation-time of flight mass spectrometry (MALDI-TOF) have advanced the identification and classification of <italic toggle="yes">Brucella</italic> species. These methods provide a rapid, accurate and safe means of identifying and classifying recovered <italic toggle="yes">Brucella</italic> isolates. Blood cultures are more helpful than serology during disease recurrence because the latter is already positive at relapse [<xref rid="CIT0075" ref-type="bibr">75</xref>].</p>
          </sec>
          <sec disp-level="4" id="S0008-S2003-S3001-S4002">
            <label>8.3.1.2.</label>
            <title>Disadvantages</title>
            <p>The sensitivity of blood cultures differs according to the laboratory protocol used to obtain the cultures and how actively they are collected. Fifteen to seventy percent of cases showed a positive culture rate. MALDI-TOF mass spectrometry technology offers several advantages, including relatively low cost per detected bacterium. However, it is worth noting that this technology is still expensive, which limits its widespread availability, particularly in countries where brucellosis is prevalent [<xref rid="CIT0075" ref-type="bibr">75</xref>].</p>
          </sec>
        </sec>
        <sec disp-level="3" id="S0008-S2003-S3002">
          <label>8.3.2.</label>
          <title>Serological assays</title>
          <p>In contrast to molecular and culture-based detection methods, serological diagnostics for brucellosis do not directly identify the presence of living bacteria or their DNA sequences in bodily fluids or tissues. Instead, the serological method relies on an indirect approach of examining the patient&#x2019;s immune response for the presence of antibodies that indicate prior exposure or contact with the <italic toggle="yes">Brucella</italic> pathogen. It measures the presence of specific antibodies such as IgM and IgG in patients&#x2019; serums. Detection of these antibodies provides evidence of previous or ongoing brucellosis infection. The clinical application of the available serodiagnostic tests for brucellosis in humans is outlined in <xref rid="t0002" ref-type="table">Table 2</xref>.</p>
          <table-wrap position="float" id="t0002">
            <label>Table 2.</label>
            <caption>
              <p>Serodiagnostic assays for the diagnosis of human brucellosis [<xref rid="CIT0073" ref-type="bibr">73</xref>, <xref rid="CIT0069" ref-type="bibr">69</xref>, <xref rid="CIT0071" ref-type="bibr">71</xref>, <xref rid="CIT0076" ref-type="bibr">76</xref>, <xref rid="CIT0077" ref-type="bibr">77</xref>].</p>
            </caption>
            <!--OASIS TABLE HERE-->
            <table frame="hsides" rules="groups">
              <colgroup>
                <col width="80pt"/>
                <col width="80pt"/>
                <col width="80pt"/>
                <col width="80pt"/>
                <col width="80pt"/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left">Diagnostic assay</th>
                  <th align="center">Principle</th>
                  <th align="center">Recommended use</th>
                  <th align="center">Merits</th>
                  <th align="center">Demerits</th>
                </tr>
              </thead>
              <tbody valign="top">
                <tr>
                  <td align="left">Buffered Acidified Plate Antigen Test (BAPAT)</td>
                  <td align="left">Detection of anti-<italic toggle="yes">Brucella</italic> antibodies in sheep serum samples</td>
                  <td align="left">Screening test for brucellosis diagnosis in sheep herds</td>
                  <td align="left">High sensitivity as a screening test for brucellosis</td>
                  <td align="left">Lower specificity compared to other tests due to non-specific agglutinins</td>
                </tr>
                <tr>
                  <td align="left">Rose Bengal Plate Test (RBPT)</td>
                  <td align="left">Plate agglutination test detects agglutinating and non-agglutinating antibodies</td>
                  <td align="left">Screening test for brucellosis diagnosis in sheep herds</td>
                  <td align="left">Quick, cheap and simple<break/>Higher specificity compared to BAPAT due to pH inhibition of non-specific agglutinins&#xA0;</td>
                  <td align="left">Lower sensitivity compared to BAPAT</td>
                </tr>
                <tr>
                  <td align="left">Milk Ring Test (MRT)</td>
                  <td align="left">Detection of anti-<italic toggle="yes">Brucella</italic> antibodies in sheep milk samples.</td>
                  <td align="left">Screening test for brucellosis diagnosis in sheep herds.</td>
                  <td align="left">Easy application and high-sensitivity</td>
                  <td align="left">Less sensitive in detecting antibodies in milk with low concentrations or fat clustering factors</td>
                </tr>
                <tr>
                  <td align="left">Standard Tube Agglutination Test (STAT)</td>
                  <td align="left">Total antibodies against S-lipopolysaccharide (S-LPS) on bacterial surfaces detected</td>
                  <td align="left">Safe, popular, especially in acute cases.</td>
                  <td align="left">Practical, efficient and cost-effective</td>
                  <td align="left">They have limitations in detecting <italic toggle="yes">B. canis</italic> infection, leading to false negatives due to blocking of antibodies, cross-reactivity and non-specific agglutination.</td>
                </tr>
                <tr>
                  <td align="left">2-Mercaptoethanol test</td>
                  <td align="left">Chemical inactivation of the IgM pentamer&#x2019;s agglutinating properties by 2-mercaptoethanol</td>
                  <td align="left">Monitoring the effectiveness of antimicrobic medications in patients who have already received a diagnosis; early identification of treatment failure</td>
                  <td align="left">Confirmatory test&#x2013;elimination of IgM confounder</td>
                  <td align="left">Toxicity of 2-mercaptoethanol</td>
                </tr>
                <tr>
                  <td align="left"><italic toggle="yes">Brucella</italic> Coombs Gel Test</td>
                  <td align="left">Expansion of STAT</td>
                  <td align="left">Sensitive to chronic infections and relapses.</td>
                  <td align="left">Quick and straightforward (2&#x2009;h)</td>
                  <td align="left">Labour-intensive and time-consuming</td>
                </tr>
                <tr>
                  <td align="left">Complement Fixation Test (CFT)</td>
                  <td align="left">IgG1 isotype antibody detection by complement fixation</td>
                  <td align="left">Useful for the serological diagnosis of zoonosis in obliteration operations</td>
                  <td align="left">Sensitive</td>
                  <td align="left">Due to its technical difficulty and issues with its standardisation, it is not frequently employed in human infection</td>
                </tr>
                <tr>
                  <td align="left">Immunocapture agglutination test (<italic toggle="yes">Brucella</italic> Capt test; Vircell, Granada, Spain)</td>
                  <td align="left">Detection of IgG, IgM and non-agglutinating antibodies to the three smooth O-polysaccharide-containing <italic toggle="yes">Brucella</italic> species in a single step</td>
                  <td align="left">Confirmatory test, patient monitoring after treatment</td>
                  <td align="left">Performance is equivalent to that of the Coombs test; however, it is quicker and simpler to complete</td>
                  <td align="left">Individuals can vary greatly, and individuals who have relapsed may have a one-dilution decrease in titer.</td>
                </tr>
                <tr>
                  <td align="left">Enzymatic linked immuno sorbent assay (ELISA)</td>
                  <td align="left">The standard method of sensitising plates is with cytosolic protein antigens</td>
                  <td align="left">Test of preference for complex, focused, and chronic patients. Neurobrucellosis and <italic toggle="yes">B. canis</italic> infection diagnosis</td>
                  <td align="left">Compassionate, specific, rapid (4&#x2013;6&#x2009;h), simple. Detects total and individual specific Igs (IgG, IgM and IgA) when other tests are negative</td>
                  <td align="left">Expensive and requires trained personnel</td>
                </tr>
                <tr>
                  <td align="left">Immunofluorescence assay (IFA)</td>
                  <td align="left">Antigens prepared from whole-cell preparations</td>
                  <td align="left">&#xA0;</td>
                  <td align="left">Quick, accuracy equivalent to ELISA</td>
                  <td align="left">Expensive equipment and manpower</td>
                </tr>
                <tr>
                  <td align="left">Time-resolved fluorescent resonance energy transfer (TR-FRET) assay</td>
                  <td align="left">Based on the transfer of energy between fluorophores-labelled antigens and antibodies (a donor and an acceptor). An anti-<italic toggle="yes">Brucella</italic> monoclonal antibody is labelled with a donor fluorophore and <italic toggle="yes">Brucella</italic> S-LPS</td>
                  <td align="left">Simple to perform, robust and has excellent serodetection ability</td>
                  <td align="left">Does not require washing and only a single 30-minute incubation time followed by fluorescence readout. They provide comparable performance to other diagnostic methods.</td>
                  <td align="left">&#xA0;</td>
                </tr>
                <tr>
                  <td align="left">Fluorescent polarisation immunoassay (FPA)</td>
                  <td align="left">A fluorescent dye (labelled to an antigen or antibody) can be excited by polarised light, and difference in the rotational velocities is measured</td>
                  <td align="left">Diagnosis of zoonosis in the dairy sector</td>
                  <td align="left">Widely used in animals. Rarely used in human infections. Fast and straightforward method and equipment.</td>
                  <td align="left">&#xA0;</td>
                </tr>
                <tr>
                  <td align="left">Quantum dot (QD) immunochromatographic test system</td>
                  <td align="left">Handheld QD immunochromatographic strip equipment</td>
                  <td align="left">Point-of-care test and preliminary screening.</td>
                  <td align="left">Rapid and simple. Specific, sensitive, reliable</td>
                  <td align="left">&#xA0;</td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
          <sec disp-level="4" id="S0008-S2003-S3002-S4001">
            <label>8.3.2.1.</label>
            <title>Advantages</title>
            <p>Despite these limitations, serological tests are crucial for diagnosing human brucellosis, particularly in endemic countries. Their cost-effectiveness and simplicity make them preferable to culture-based or nucleic acid amplification methods, particularly in resource-limited settings. In high-prevalence areas, serological testing is an accessible and practical diagnostic option, contributing to the timely diagnosis and management of brucellosis cases. The widespread availability and feasibility of serological tests bolster screening and surveillance efforts to ensure early detection and appropriate intervention [<xref rid="CIT0069" ref-type="bibr">69</xref>, <xref rid="CIT0071" ref-type="bibr">71</xref>, <xref rid="CIT0073" ref-type="bibr">73</xref>, <xref rid="CIT0076" ref-type="bibr">76</xref>].</p>
          </sec>
          <sec disp-level="4" id="S0008-S2003-S3002-S4002">
            <label>8.3.2.2.</label>
            <title>Disadvantages</title>
            <p>Various factors, such as early testing, blocking antibodies or the &#x2018;prozone&#x2019; phenomenon, can lead to non-detection of brucellosis. Additives such as EDTA, 2-mercaptoethanol or anti-human globulin may overcome these issues, but serum agglutination tests remain unsuitable for follow-up due to sustained high titers [<xref rid="CIT0069" ref-type="bibr">69</xref>, <xref rid="CIT0071" ref-type="bibr">71</xref>, <xref rid="CIT0073" ref-type="bibr">73</xref>, <xref rid="CIT0076" ref-type="bibr">76</xref>].</p>
            <p>Analysing serological tests for brucellosis is challenging due to patient history variations, previous illnesses and individual immune responses, making standardised test interpretation difficult. Antibody detection indicates <italic toggle="yes">Brucella</italic> exposure and is not necessarily an active or recent infection [<xref rid="CIT0069" ref-type="bibr">69</xref>, <xref rid="CIT0071" ref-type="bibr">71</xref>, <xref rid="CIT0073" ref-type="bibr">73</xref>, <xref rid="CIT0076" ref-type="bibr">76</xref>].</p>
            <p>Several diagnostic assays have become obsolete over the years. The intradermal skin test, which cannot distinguish exposure levels, complicates later serodiagnostic tests by inducing antibody production. The opsonocytophagic index poses infection risks to laboratory workers and offers inconsistent results. Despite their use in some regions, haemagglutination tests lack global acceptance owing to these shortcomings [<xref rid="CIT0068" ref-type="bibr">68</xref>].</p>
          </sec>
        </sec>
        <sec disp-level="3" id="S0008-S2003-S3003">
          <label>8.3.3.</label>
          <title>Molecular approaches and nucleic acid amplification tests (NAATs)</title>
          <p>The genomic approach is accurate and rapid for detecting brucellosis in humans and animals, providing successful results even in ambiguous or asymptomatic cases. However, a positive result does not always signify an active infection, as it may detect genetic material from inactive or treated bacteria. Although sensitive nucleic acid amplification and serological tests are adequate for identifying brucellosis, culture remains the gold standard for its widespread clinical and epidemiological use. Peripheral blood is optimal for the molecular interpretation of human brucellosis. Other specimens from various systems can aid in diagnosing focal brucellosis, where cultures may be negative. Genetic materials from formalin-fixed, paraffin-embedded tissues can also be evaluated using established procedures.</p>
          <p>Several gene targets have been used to diagnose <italic toggle="yes">Brucella</italic> infections. The 16S rRNA gene is a potential diagnostic target; however, there have been instances of cross-reactions that might lead to false-positive results. Thus, the IS711 insertion sequence is a potential target. However, its utility has been questioned because of sequence variations and absence in some <italic toggle="yes">Brucella</italic> strains, making it unreliable in certain contexts. Moreover, <italic toggle="yes">bcsp31</italic> is most frequently used for diagnosis as it encodes an immunogenic membrane protein. Its consistent presence and immune response make it the preferred choice for diagnostic testing [<xref rid="CIT0078" ref-type="bibr">78&#x2013;80</xref>]. <xref rid="t0003" ref-type="table">Table 3</xref> shows the amplification of various genes, including <italic toggle="yes">omp2</italic>, <italic toggle="yes">omp31</italic> and <italic toggle="yes">bcsp31</italic>, which have been targeted for molecular diagnosis; however, cross-reactions and variations in gene sequences may present challenges.</p>
          <table-wrap position="float" id="t0003">
            <label>Table 3.</label>
            <caption>
              <p>Gene targets and primers are commonly utilised for the molecular detection of <italic toggle="yes">Brucella</italic> infection.</p>
            </caption>
            <!--OASIS TABLE HERE-->
            <table frame="hsides" rules="groups">
              <colgroup>
                <col width="80pt"/>
                <col width="80pt"/>
                <col width="80pt"/>
                <col width="80pt"/>
                <col width="80pt"/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left">Gene target</th>
                  <th align="center">Primer name</th>
                  <th align="center">Primer sequence (5&#x2032;&#x2013;3&#x2032;)</th>
                  <th align="center">Product size (bp)</th>
                  <th align="center">References</th>
                </tr>
              </thead>
              <tbody valign="top">
                <tr>
                  <td rowspan="2" align="left">
<italic toggle="yes">omp2</italic>
</td>
                  <td align="left">JPF</td>
                  <td align="left">GCGCTCAGGCTGCCGACGCAA</td>
                  <td rowspan="2" align="char" char=".">193</td>
                  <td rowspan="2" align="left">[<xref rid="CIT0081" ref-type="bibr">81</xref>]</td>
                </tr>
                <tr>
                  <td align="left">JPR</td>
                  <td align="left">ACCAGCCATTGCGGTCGGTA</td>
                </tr>
                <tr>
                  <td rowspan="2" align="left">
<italic toggle="yes">omp31</italic>
</td>
                  <td align="left">F</td>
                  <td align="left">TGGTAAGGTCAAGTCTGCGTT</td>
                  <td rowspan="2" align="char" char=".">281</td>
                  <td rowspan="2" align="left">[<xref rid="CIT0082" ref-type="bibr">82</xref>]</td>
                </tr>
                <tr>
                  <td align="left">R</td>
                  <td align="left">CTTCTTCATTCCGTGTTCGTG</td>
                </tr>
                <tr>
                  <td rowspan="2" align="left">
<italic toggle="yes">omp28/bp26</italic>
</td>
                  <td align="left">26A</td>
                  <td align="left">GCCCCTGACATAACCCGCTT</td>
                  <td rowspan="2" align="char" char=".">1029</td>
                  <td rowspan="2" align="left">[<xref rid="CIT0083" ref-type="bibr">83</xref>]</td>
                </tr>
                <tr>
                  <td align="left">26B</td>
                  <td align="left">GAGCGTGACATTTGCCGATA</td>
                </tr>
                <tr>
                  <td rowspan="2" align="left">
<italic toggle="yes">16S rRNA</italic>
</td>
                  <td align="left">F4</td>
                  <td align="left">TCGAGCGCCCGCAAG GGG</td>
                  <td rowspan="2" align="char" char=".">905</td>
                  <td rowspan="2" align="left">[<xref rid="CIT0080" ref-type="bibr">80</xref>]</td>
                </tr>
                <tr>
                  <td align="left">R2</td>
                  <td align="left">AACCATAGTGTCTCCACTAA</td>
                </tr>
                <tr>
                  <td rowspan="2" align="left">
<italic toggle="yes">IS711</italic>
</td>
                  <td align="left">I1</td>
                  <td align="left">TCAATCCAACACGTTCC</td>
                  <td rowspan="2" align="char" char=".">52</td>
                  <td rowspan="2" align="left">[<xref rid="CIT0084" ref-type="bibr">84</xref>]</td>
                </tr>
                <tr>
                  <td align="left">I2</td>
                  <td align="left">TCCTTGTACAGCCTCC</td>
                </tr>
                <tr>
                  <td rowspan="2" align="left">
<italic toggle="yes">bcsp31</italic>
</td>
                  <td align="left">B4</td>
                  <td align="left">TGGCTCGGTTGCCAATATCAA</td>
                  <td rowspan="2" align="char" char=".">223</td>
                  <td rowspan="2" align="left">[<xref rid="CIT0085" ref-type="bibr">85</xref>]</td>
                </tr>
                <tr>
                  <td align="left">B5</td>
                  <td align="left">CGCGCTTGCCTTTCAGGTCTG</td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
          <p>Real-time PCR assays that are species-specific and traditional <italic toggle="yes">Brucella</italic> ladder PCR assays are crucial for identifying and classifying <italic toggle="yes">Brucella</italic> species. The MLVA-16 (multilocus variable number tandem repeat analysis) panel, which targets 16 loci, is a reliable tool for diagnosing human brucellosis. These PCR-based methods provide specific and sensitive detection of <italic toggle="yes">Brucella</italic> and play a crucial role in confirming the presence of the pathogen and determining the species involved. Various amplification methodologies have been employed, including real-time PCR, multiplex PCR, nested PCR, PCR-enzyme immunoassay (PCR-EIA) and loop-mediated isothermal amplification (LAMP). Nested PCR involves using two sets of primers in two successive runs to boost the specificity and sensitivity of detection. The PCR-EIA was coupled with an enzyme immunoassay using a microplate setup to improve detection sensitivity. LAMP offers advantages such as simplicity, rapid response time and cost-effectiveness in limited resource settings.</p>
          <p>Although genomic techniques are emerging, conventional methods, such as culture and serology assays, remain fundamental in diagnosing brucellosis and related infections by <italic toggle="yes">Brucella</italic> spp. Sending all <italic toggle="yes">Brucella</italic> strains to a reference laboratory for comprehensive species-level identification and biovar determination is essential for proper identification. This is vital for identifying the infection source, investigating outbreaks, tracking strains, differentiating isolates and assessing veterinary control strategies.</p>
          <p>Traditional approaches to species differentiation, while reliable, are time-consuming, labour-intensive and present infection risks to lab workers. Molecular methods have emerged as quick and accurate alternatives. A fluorescence <italic toggle="yes">in situ</italic> hybridisation (FISH) test targeting the 16S rRNA gene permits the rapid and specific detection of human-pathogenic <italic toggle="yes">Brucella</italic> species. However, the limited polymorphism within the <italic toggle="yes">Brucellaceae</italic> family&#x2019;s 16S rRNA gene makes it challenging to differentiate <italic toggle="yes">Brucella</italic> from closely related organisms, such as the <italic toggle="yes">Ochrobactrum</italic> genus.</p>
          <p>Novel nucleic acid amplification methods have been developed to differentiate <italic toggle="yes">between Brucella</italic> species. These tests demonstrate high sensitivity and specificity. However, caution should be exercised when interpreting the NAAT results, as a positive test does not always indicate an ongoing infection. Instead, it could indicate a small number of bacteria present, DNA from non-viable organisms, or the presence of the pathogen in individuals who have already recovered from the infection [<xref rid="CIT0086" ref-type="bibr">86</xref>]. Initially employed on peripheral blood with satisfactory results, serum samples are now considered the preferred choice for molecular detection of human brucellosis because of their higher effectiveness in yielding accurate diagnoses [<xref rid="CIT0087" ref-type="bibr">87</xref>]. Furthermore, it is possible to use formalin-fixed paraffin-embedded (FFPE) tissue obtained from surgical biopsy samples for analysis if validated DNA extraction methods are employed [<xref rid="CIT0088" ref-type="bibr">88</xref>].</p>
          <p>Terrestrial <italic toggle="yes">Brucella</italic> species, including the strains used in vaccines, can be recognised and distinguished using the AMOS PCR test. Other PCR-based NAAT assays have been developed to identify specific <italic toggle="yes">Brucella</italic> and marine species rapidly. The Bruce Ladder multiplex PCR assay has high reproducibility and is species-specific. Additionally, five terrestrial <italic toggle="yes">Brucella</italic> species can be simultaneously detected using multiplex real-time PCR techniques based on single nucleotide polymorphisms (SNPs) [<xref rid="CIT0089" ref-type="bibr">89</xref>].</p>
          <sec disp-level="4" id="S0008-S2003-S3003-S4001">
            <label>8.3.3.1.</label>
            <title>Advantages</title>
            <p>Compared with bacteriological isolation, molecular methods offer several advantages regarding safety, sensitivity and speed. These methods enable rapid detection and differentiation of various bacterial species, particularly those with slow growth rates.</p>
          </sec>
          <sec disp-level="4" id="S0008-S2003-S3003-S4002">
            <label>8.3.3.2.</label>
            <title>Disadvantages</title>
            <p>Comparative studies and standardised commercial molecular methods for brucellosis detection are limited, and the availability of next-generation sequencing technologies in low-income countries is insufficient. According to the OIE Terrestrial Manual (OIE 2016), no test can positively identify a bacterium such as <italic toggle="yes">Brucella</italic>. Integrating multiple techniques, including culture and serology, is necessary for the definitive diagnosis of <italic toggle="yes">Brucella</italic> infection [<xref rid="CIT0074" ref-type="bibr">74</xref>].</p>
          </sec>
        </sec>
        <sec disp-level="3" id="S0008-S2003-S3004">
          <label>8.3.4.</label>
          <title>Important aspects regarding animal diagnosis</title>
          <p>A definitive diagnosis of <italic toggle="yes">Brucella</italic> infection can be established through the isolation of the bacteria from tissue samples obtained during autopsy, milk or abortion. The most practical method for diagnosing <italic toggle="yes">Brucella</italic> infection is serology, which can be used to screen cattle using the Rose Bengal Test (RBT) and to confirm infection in specific animals using the enzyme-linked immunosorbent assay (ELISA) or Complement Fixation Test (CFT). For surveillance, milk samples can be screened using the milk ring test or ELISA. However, no serological test can confirm infection in specific animals such as sheep, goats and pigs. Serological testing should be applied on a herd or flock basis, and the skin test is useful for screening on a herd or flock level, particularly when immunisation is not used. For the diagnosis of <italic toggle="yes">B. canis</italic> infection, a &#x2018;rough-specific&#x2019; antigen is required [<xref rid="CIT0090" ref-type="bibr">90</xref>].</p>
        </sec>
      </sec>
    </sec>
    <sec disp-level="1" id="S0009">
      <label>9.</label>
      <title>Current treatment methods for brucellosis</title>
      <p>Doxycycline and rifampin are commonly used antibiotics for treating brucellosis. They form the basis for treating all types of human brucellosis. Following suitable antibiotic therapy, full recovery is expected in acute, uncomplicated brucellosis. Adults and children over eight usually take doxycycline, the preferred antibiotic due to its dosing frequency and fewer gastrointestinal side effects, orally for six weeks. To minimise the risk of relapse, aminoglycosides are often added during the initial 2&#x2013;3&#xA0;weeks of therapy [<xref rid="CIT0004" ref-type="bibr">4</xref>, <xref rid="CIT0035" ref-type="bibr">35</xref>, <xref rid="CIT0041" ref-type="bibr">41</xref>, <xref rid="CIT0091" ref-type="bibr">91</xref>]. Although gentamicin shows promise, further research is needed to establish the optimal dosage and duration. Rifampicin is another effective alternative. A six-week oral administration of both doxycycline and rifampicin showed similar efficacy in treating uncomplicated brucellosis. Fluoroquinolones are considered secondary alternatives because of their high efficacy (<xref rid="t0004" ref-type="table">Table 4</xref>).</p>
      <table-wrap position="float" id="t0004">
        <label>Table 4.</label>
        <caption>
          <p>Recommendations for treating different cases of human brucellosis [<xref rid="CIT0004" ref-type="bibr">4</xref>, <xref rid="CIT0035" ref-type="bibr">35</xref>, <xref rid="CIT0041" ref-type="bibr">41</xref>, <xref rid="CIT0091" ref-type="bibr">91</xref>].</p>
        </caption>
        <!--OASIS TABLE HERE-->
        <table frame="hsides" rules="groups">
          <colgroup>
            <col width="80pt"/>
            <col width="80pt"/>
            <col width="80pt"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left">Case</th>
              <th colspan="2" align="center">Treatment</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td rowspan="3" align="left">Uncomplicated brucellosis: adults and children &#x2265;8&#xA0;years</td>
              <td align="left">First line of treatment</td>
              <td align="left">Doxycycline 500&#x2009;mg every six hours orally for 6&#xA0;weeks or 2.2&#x2009;mg/kg IV every 12&#x2009;h</td>
            </tr>
            <tr>
              <td align="left">Principal alternative therapy</td>
              <td align="char" char=".">Doxycycline (200&#x2009;mg/day orally)&#xA0;+&#xA0;rifampicin (600&#x2013;900&#x2009;mg/day orally), with both drugs administered for 6&#xA0;weeks. This regimen has generally been found to be of similar efficacy to doxycycline&#xA0;+&#xA0;streptomycin for patients with uncomplicated brucellosis</td>
            </tr>
            <tr>
              <td align="left">Secondary alternative therapy</td>
              <td align="left">Fluoroquinolones, trimethoprim/sulfamethoxazole (TMP/SMZ, co-trimoxazole)</td>
            </tr>
            <tr>
              <td align="left">Children &lt;8&#xA0;years</td>
              <td colspan="2" align="char" char=".">Aminoglycosides, co-trimoxazole and rifampicin. TMP/SMZ (8/40&#x2009;mg/kg/day twice daily orally) administered for 6&#xA0;weeks&#xA0;+&#xA0;streptomycin (30&#x2009;mg/kg/day once daily intramuscularly) administered for 3&#xA0;weeks or gentamicin (5&#x2009;mg/kg/day once daily intravenously or intramuscularly) administered for 7&#x2013;10&#xA0;days. Alternatives include TMP/SMZ&#xA0;+&#xA0;rifampicin (15&#x2009;mg/kg/day orally), each administered for 6&#xA0;weeks, or rifampicin&#xA0;+&#xA0;an aminoglycoside</td>
            </tr>
            <tr>
              <td rowspan="3" align="left">Complicated cases of brucellosis</td>
              <td align="left">Spondylitis</td>
              <td align="left">May require prolonged therapy, such as the continuation of doxycycline for 8&#xA0;weeks or more</td>
            </tr>
            <tr>
              <td align="left">Neurobrucellosis</td>
              <td align="left">Since tetracyclines and aminoglycosides do not penetrate the blood/brain barrier well, rifampicin or co-trimoxazole be added to the standard regimen of doxycycline&#xA0;+&#xA0;streptomycin for a minimum of 6&#x2013;8&#xA0;weeks</td>
            </tr>
            <tr>
              <td align="left"><italic toggle="yes">Brucella</italic> endocarditis</td>
              <td align="left">Doxycycline&#xA0;+&#xA0;aminoglycoside rapidly kills the bacteria, as does rifampicin or co-trimoxazole. Prolonged therapy is recommended for at least 8&#xA0;weeks</td>
            </tr>
            <tr>
              <td align="left">Pregnancy</td>
              <td colspan="2" align="left">Co-trimoxazole has been used in individual cases with reported success. Another alternative is rifampicin therapy for at least 45&#xA0;days</td>
            </tr>
            <tr>
              <td align="left">Post-exposure prophylaxis</td>
              <td colspan="2" align="left">Tetanus toxoid (when indicated) with doxycycline for 6&#xA0;weeks</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>While the WHO-recommended brucellosis treatment has evolved, the optimal approach remains unclear. This review suggests that a combination of doxycycline and aminoglycosides is common for uncomplicated brucellosis. Short-term treatment is discouraged because of the high failure and relapse rates. For complicated cases of spondylitis, neurobrucellosis or endocarditis, a prolonged triple therapy regimen involving streptomycin, gentamicin, doxycycline and rifampicin is more effective.</p>
      <p>In resource-limited areas, various combinations of oral drugs such as tetracycline/rifampicin, doxycycline/ofloxacin or ciprofloxacin/rifampicin can be used. Rifampicin should be used cautiously and never alone to avoid multidrug-resistant tuberculosis. In children, co-trimoxazole combined with gentamicin or rifampicin is recommended, and quinolones should be used cautiously as a monotherapy.</p>
      <p>For dogs with <italic toggle="yes">B. suis</italic> infection, a combination of rifampicin and doxycycline was administered. Euthanasia should be considered in severe cases to prevent zoonotic exposure. In <italic toggle="yes">B. canis</italic>-infected dogs, dual therapy is recommended despite the high relapse rates, particularly in males.</p>
      <p>In production animals, brucellosis treatment is typically avoided, and the affected animals are usually culled. This varied information underscores the complexity of brucellosis treatment and different approaches, depending on the species affected [<xref rid="CIT0004" ref-type="bibr">4</xref>, <xref rid="CIT0035" ref-type="bibr">35</xref>, <xref rid="CIT0041" ref-type="bibr">41</xref>, <xref rid="CIT0091" ref-type="bibr">91</xref>].</p>
      <p>Antibiotic choices for brucellosis should consider factors such as patient details, drug availability and local resistance patterns. Close monitoring and follow-up are vital for successful treatment and prevention of relapse [<xref rid="CIT0091" ref-type="bibr">91</xref>]. Despite this, treatment failure and relapse rates in mild brucellosis cases are common (5&#x2013;15%), highlighting the need for continuous monitoring and repeated serological testing for one year.</p>
      <p>The emergence of multidrug-resistant <italic toggle="yes">Brucella</italic> strains in endemic areas worldwide has been linked to improper antimicrobial use. The use of antibiotics in livestock contributes to this issue, posing a public health risk and limiting the availability of treatments. Regular antimicrobial susceptibility testing is essential for effective brucellosis management. Techniques such as microdilution, E-tests, Kirby Bauer and real-time PCR can help ascertain the minimum inhibitory concentrations (MICs) of drugs and assess the <italic toggle="yes">Brucella</italic> resistance profiles [<xref rid="CIT0035" ref-type="bibr">35</xref>].</p>
    </sec>
    <sec disp-level="1" id="S0010">
      <label>10.</label>
      <title>Antimicrobial resistance in <italic toggle="yes">Brucella</italic></title>
      <p>Challenges in managing the disease include the emergence of antibiotic-resistant strains and the need for continued treatment to avoid recurrence. The chronic nature of brucellosis, combined with the capacity of <italic toggle="yes">Brucella</italic> to reside within host cells and sequester at difficult-to-reach sites, can contribute to treatment relapse. The relapse rate in uncomplicated cases is estimated to be 5&#x2013;15%. The cause of these relapses is unclear because of the emergence of antimicrobial resistance (AMR) or the inability to eradicate germs at the infection sites. However, studies on <italic toggle="yes">Brucella</italic> MICs in endemic regions have generally shown that bacteria remain susceptible to doxycycline and rifampicin, which are commonly used antibiotics for brucellosis treatment [<xref rid="CIT0065" ref-type="bibr">65</xref>, <xref rid="CIT0070" ref-type="bibr">70</xref>, <xref rid="CIT0092" ref-type="bibr">92</xref>].</p>
      <p>Several studies describing potential resistance to rifampin in brucellosis have been reported, for instance, from various countries throughout the globe. Rifampicin, co-trimoxazole (trimethoprim-sulfamethoxazole), ampicillin-sulbactam and colistin intermediate resistance phenotypes have also been reported (<xref rid="t0005" ref-type="table">Table 5</xref>).</p>
      <table-wrap position="float" id="t0005">
        <label>Table 5.</label>
        <caption>
          <p>Global antibiotic resistance pattern data.</p>
        </caption>
        <!--OASIS TABLE HERE-->
        <table frame="hsides" rules="groups">
          <colgroup>
            <col width="80pt"/>
            <col width="80pt"/>
            <col width="80pt"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left">Country</th>
              <th align="center">Resistance pattern</th>
              <th align="center">References</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left">Norway</td>
              <td align="left">Resistant to rifampicin</td>
              <td align="center">[<xref rid="CIT0093" ref-type="bibr">93</xref>]</td>
            </tr>
            <tr>
              <td align="left">Iran</td>
              <td align="left">Resistant to cotrimoxazole</td>
              <td align="center">[<xref rid="CIT0094" ref-type="bibr">94</xref>]</td>
            </tr>
            <tr>
              <td align="left">Kazakhstan</td>
              <td align="left">48% resistance to rifampicin</td>
              <td align="center">[<xref rid="CIT0095" ref-type="bibr">95</xref>]</td>
            </tr>
            <tr>
              <td align="left">China</td>
              <td align="left">Resistance to cotrimoxazole (7.0%) and rifampin (1.0%)</td>
              <td align="center">[<xref rid="CIT0096" ref-type="bibr">96</xref>]</td>
            </tr>
            <tr>
              <td align="left">Peru</td>
              <td align="left">No resistance</td>
              <td align="center">[<xref rid="CIT0097" ref-type="bibr">97</xref>]</td>
            </tr>
            <tr>
              <td align="left">UK</td>
              <td align="left">No resistance</td>
              <td align="center">[<xref rid="CIT0098" ref-type="bibr">98</xref>]</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>The application of whole-genome sequencing (WGS) has enabled a more thorough identification of genes linked to virulence and resistance in <italic toggle="yes">Brucella</italic> strains. Even among strains recovered from various hosts, there was no discernible variation in AMR distribution and virulence genes between resistant and sensitive <italic toggle="yes">B. abortus</italic> and <italic toggle="yes">B. melitensis</italic> strains. Therefore, additional research on the antibiotic susceptibility of <italic toggle="yes">Brucella</italic> isolates is required. Although many microbes have benefited from research on resistance and virulence mechanisms at the genome level, they have limited value for <italic toggle="yes">Brucella</italic>. Future research should examine virulence mechanisms and resistance at proteomic and transcriptomic levels in <italic toggle="yes">Brucella</italic>.</p>
    </sec>
    <sec disp-level="1" id="S0011">
      <label>11.</label>
      <title>&#x3B2;-Carbonic anhydrases (CAs) as potential targets</title>
      <p><italic toggle="yes">Brucella</italic> spp. are known to develop resistance to several clinically used drugs. Therefore, there is an urgent need to identify novel treatment strategies targeting unique bacterial pathways. <italic toggle="yes">Brucella</italic> genome sequencing has revealed potential drug targets, and metalloenzymes have emerged as promising candidates for novel treatments [<xref rid="CIT0099" ref-type="bibr">99</xref>]. One such metalloprotein, histidine dehydrogenase (HDH), is vital for the intracellular growth of bacteria.</p>
      <p>Further genomic studies identified two CAs (BR1829 and BRA0788 in <italic toggle="yes">B. suis</italic>) in <italic toggle="yes">Brucella</italic>. These enzymes, which are part of the &#x3B2;-class CA family and contain zinc as a metal ion, resemble &#x3B2;-CAs found in other pathogens [<xref rid="CIT0100" ref-type="bibr">100</xref>, <xref rid="CIT0101" ref-type="bibr">101</xref>]. It has been demonstrated that the &#x3B2;-CAs of pathogenic microbes can be inhibited both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> and, therefore, can be targeted using small molecular inhibitors. In living organisms, there are eight distinct classes of CAs: &#x3B1;, &#x3B2;, &#x3B3;, &#x3B4;, &#x3B6;, &#x3B7;, &#x3B8; and &#x3B9; [<xref rid="CIT0102" ref-type="bibr">102</xref>]. Although humans only have &#x3B1;-CAs, pathogenic microbes can express multiple classes of CAs, including &#x3B1;, &#x3B2; and &#x3B3;, which are present in both prokaryotic and eukaryotic organisms. Notably, most CAs are zinc-dependent and facilitate the conversion of carbon dioxide into bicarbonate and protons [<xref rid="CIT0103" ref-type="bibr">103</xref>, <xref rid="CIT0104" ref-type="bibr">104</xref>].</p>
      <p>&#x3B2;-CAs in <italic toggle="yes">Brucella</italic> play a role in several vital biosynthetic processes, some of which are critical for intracellular growth and virulence. These &#x3B2;-CAs are emerging as potential drug targets, offering a new avenue for developing antibacterial agents that do not share resistance patterns with existing antibiotics. Their significance is further underscored by their essential roles in the growth and virulence of various intracellular pathogens. This makes &#x3B2;-CAs a promising target for <italic toggle="yes">Brucella</italic> treatment without adverse side effects.</p>
      <p>Recent studies have identified multiple inhibitors of &#x3B2;-CAs in pathogens, such as <italic toggle="yes">Neisseria</italic> spp., <italic toggle="yes">H. pylori</italic>, <italic toggle="yes">B. suis</italic>, <italic toggle="yes">M. tuberculosis</italic>, <italic toggle="yes">S. pneumoniae</italic> and pathogenic parasites, which effectively hamper their growth <italic toggle="yes">in vitro</italic> [<xref rid="CIT0100" ref-type="bibr">100</xref>, <xref rid="CIT0105" ref-type="bibr">105&#x2013;110</xref>] and <italic toggle="yes">in vivo</italic> [<xref rid="CIT0110" ref-type="bibr">110</xref>, <xref rid="CIT0111" ref-type="bibr">111</xref>]. Detailed studies on <italic toggle="yes">Brucella</italic> &#x3B2;-CAs have revealed their susceptibility to inhibition by these compounds, from classical aromatic and heteroaromatic sulfonamides to carbohydrate-based entities. Specifically, &#x3B2;-CA1 in <italic toggle="yes">Brucella</italic> is sensitive to sulfamide, sulfamic acid, phenyl boronic/arsonic acid, and, to a lesser extent, diethyldithiocarbamate. &#x3B2;-CA2 shows pronounced inhibition by several anions [<xref rid="CIT0112" ref-type="bibr">112</xref>].</p>
      <p>Compounds such as acetazolamide, ethoxzolamide, topiramate and sulpiride have shown strong inhibitory effects against <italic toggle="yes">Brucella</italic> &#x3B2;-CAs <italic toggle="yes">in vitro</italic>. Specific sulfonamide-based carbonic anhydrase inhibitors (CAIs) have been demonstrated to stifle <italic toggle="yes">Brucella</italic> growth in cultures [<xref rid="CIT0113" ref-type="bibr">113</xref>]. Evidence suggests that targeting <italic toggle="yes">Brucella</italic> &#x3B2;-CAs using CAIs may represent a promising strategy for combating brucellosis [<xref rid="CIT0112" ref-type="bibr">112</xref>].</p>
    </sec>
    <sec disp-level="1" id="S0012">
      <label>12.</label>
      <title>Vaccination as a strategy for controlling the spread of brucellosis</title>
      <p>Vaccination is a prospective approach for controlling the spread of brucellosis, particularly in livestock. Various vaccines have been developed for animals, but their efficacies vary. However, no human vaccine is currently available.</p>
      <p>Currently, there are no officially approved vaccines for brucellosis in humans. The absence of accessible vaccines hampers efforts to manage the disease in humans [<xref rid="CIT0022" ref-type="bibr">22</xref>]. Consequently, controlling animal brucellosis is the most efficient approach to preventing human infection [<xref rid="CIT0114" ref-type="bibr">114</xref>]. Since the early 1900s, investigations and scientific inquiries into creating vaccines for brucellosis have commenced. The development of brucellosis vaccines involves the development of inactivated, live-attenuated and rough-attenuated vaccines. Initially, inactivated vaccines were formulated as a preventive measure against the disease. However, they were later replaced with more immunologically potent live attenuated vaccines to control brucellosis [<xref rid="CIT0115" ref-type="bibr">115</xref>]. However, current vaccines have certain drawbacks. For instance, some of these vaccines can potentially induce human infections and result in abortions in pregnant cattle.</p>
      <p>Despite these limitations, they remain crucial for preventing and managing brucellosis and are used globally [<xref rid="CIT0005" ref-type="bibr">5</xref>]. With advancements in molecular techniques, new vaccines based on genetic engineering have been developed. These innovative vaccines have replaced conventional vaccines to prevent and control brucellosis more effectively [<xref rid="CIT0116" ref-type="bibr">116</xref>]. The following are the various types of brucellosis vaccines and their efficacies.</p>
      <sec disp-level="2" id="S0012-S2001">
        <label>12.1.</label>
        <title>Live attenuated vaccines</title>
        <p>Immunising animals effectively manages brucellosis, whereas human vaccines are not available. Live-attenuated vaccines, considered optimal for controlling animal brucellosis, have drawbacks, such as antibiotic resistance potential, diagnostic interference and residual virulence [<xref rid="CIT0117" ref-type="bibr">117</xref>]. Widely used vaccines, such as <italic toggle="yes">B. abortus</italic> S19 and <italic toggle="yes">B. melitensis</italic> Rev1, exhibit these issues, complicating the differentiation between vaccinated and infected animals [<xref rid="CIT0118" ref-type="bibr">118</xref>, <xref rid="CIT0119" ref-type="bibr">119</xref>]. The <italic toggle="yes">Brucella</italic> suis S2 vaccine exhibits a favourable immune response and cross-species protection [<xref rid="CIT0120" ref-type="bibr">120</xref>] but has a limited range of host species [<xref rid="CIT0121" ref-type="bibr">121</xref>].</p>
        <p>Recent advances have focused on engineered live attenuated vaccines with deleted virulence genes that offer enhanced safety and immune responses [<xref rid="CIT0122" ref-type="bibr">122</xref>]. For example, the <italic toggle="yes">B. melitensis</italic> 16M hfq mutant strain [<xref rid="CIT0123" ref-type="bibr">123</xref>] and a mutant of the <italic toggle="yes">B. melitensis</italic> TcfSR promoter demonstrated significant protection and no interference with serodiagnostic tests [<xref rid="CIT0124" ref-type="bibr">124</xref>]. Other potential vaccines, such as the M5-90&#x394;wboA mutant [<xref rid="CIT0118" ref-type="bibr">118</xref>] and 6M&#x394;wzt, have demonstrated reduced pathogenicity and improved defence mechanisms, although they exhibit sensitivity to polymyxin B [<xref rid="CIT0125" ref-type="bibr">125</xref>].</p>
        <p>The <italic toggle="yes">2308DNodVDNodW</italic> rough vaccine from the virulent <italic toggle="yes">B. abortus</italic> 2308 strain offers a significant immune response similar to the <italic toggle="yes">B. ovis abcBA</italic> (<italic toggle="yes">BoabcBA</italic>) vaccine [<xref rid="CIT0126" ref-type="bibr">126</xref>] against the <italic toggle="yes">B. melitensis</italic> strain 16M [<xref rid="CIT0127" ref-type="bibr">127</xref>]. Both ensure effective immunity and minimise diagnostic issues. Furthermore, the VTRS2 vaccine from <italic toggle="yes">B. suis</italic>, despite its sensitivity to polymyxin B [<xref rid="CIT0128" ref-type="bibr">128</xref>] and detergents, and the rough mutant strain of <italic toggle="yes">B. neotomae</italic> show promising results in immune response and protection, showing the potential for further vaccine development in managing brucellosis [<xref rid="CIT0129" ref-type="bibr">129</xref>].</p>
      </sec>
      <sec disp-level="2" id="S0012-S2002">
        <label>12.2.</label>
        <title>Subunit vaccines</title>
        <p>Creating effective vaccines for brucellosis poses a significant challenge because of highly virulent strains and specific tissue preferences. Subunit vaccines show potential in terms of safety, non-infectious and non-viable. However, their ability to mimic the replication of natural infections is limited [<xref rid="CIT0130" ref-type="bibr">130</xref>]. Although subunit vaccines offer the benefit of being safe, they require multiple booster shots and the use of various antigens, adjuvants and delivery mechanisms to generate robust immunity and safeguard against brucellosis in cattle. However, this approach may not be economically feasible because of associated costs [<xref rid="CIT0131" ref-type="bibr">131</xref>].</p>
        <p>Additionally, it is crucial to recognise that the immune reactions observed in mice cannot precisely represent the immune reactions triggered in the hosts following vaccination. Therefore, further comprehensive research is required to discover recombinant vaccines incorporating multiple <italic toggle="yes">Brucella</italic> antigens. Unfortunately, despite numerous efforts, no effective subunit vaccine has been successfully developed for brucellosis [<xref rid="CIT0132" ref-type="bibr">132</xref>]. Furthermore, multiple studies have demonstrated that subunit vaccines can generate protection and immune reactions comparable to those of attenuated vaccines [<xref rid="CIT0133" ref-type="bibr">133&#x2013;135</xref>]. However, it is essential to note that contradictory findings have been reported in other studies in which such equivalence was not observed [<xref rid="CIT0136" ref-type="bibr">136</xref>].</p>
      </sec>
      <sec disp-level="2" id="S0012-S2003">
        <label>12.3.</label>
        <title>Vaccines based on nanoparticles</title>
        <p>In animal model experiments, nanoparticle-based oral vaccines incorporating the <italic toggle="yes">Brucella</italic> vaccine triggered antibody responses, including IgM, mucosal IgA and IgG. These vaccines have demonstrated notable advantages in animal studies, such as a more pronounced Th1&#x2013;Th17 immune response [<xref rid="CIT0137" ref-type="bibr">137</xref>]. However, due to the potential risk of disease transmission, nanoparticle-based vaccines cannot immunise humans against brucellosis [<xref rid="CIT0138" ref-type="bibr">138</xref>]. The main drawbacks of these vaccines include toxicity, limitations in antigen loading and production, and suboptimal ability to stimulate the immune system [<xref rid="CIT0139" ref-type="bibr">139</xref>]. The MAN-NP-HS vaccine candidate employs nanoparticle technology with mannosylation to target mannose receptors, thereby improving antigen uptake. This approach stimulates the production of mucosal IgA antibodies and Th1&#x2013;Th2 cytokines, including IFN-&#x3B3;, which promotes cellular immunity. Compared to Rev1, MAN-NP-HS provides better protection by inducing more specific IgA responses [<xref rid="CIT0140" ref-type="bibr">140</xref>]. A promising vaccine candidate combines LPS and OPS antigens with PLGA nanoparticles. This approach aims to offer robust protection to both humans and animals by stimulating the production of IgM and IgG antibodies. Although adding these antigens without any combination is insufficient for inducing immune responses, their combination with nanoparticles increases antibody production [<xref rid="CIT0141" ref-type="bibr">141</xref>].</p>
      </sec>
      <sec disp-level="2" id="S0012-S2004">
        <label>12.4.</label>
        <title>DNA vaccines</title>
        <p>DNA-based <italic toggle="yes">Brucella</italic> vaccines have demonstrated both safety and efficacy in combating brucellosis. These vaccines elicit robust cellular immune responses because of their ability to express antigens and incorporate CpG motifs. Additionally, DNA-based vaccines offer the advantage of simple storage conditions. They contain crucial gene sequences that play vital roles in the intracellular survival of <italic toggle="yes">Brucella</italic> spp. [<xref rid="CIT0142" ref-type="bibr">142</xref>]. Extensive research has yielded compelling evidence for boosting immune responses and the effectiveness of diverse virulence genes in animal experiments. DNA vaccines have the potential to overcome the drawbacks associated with other brucellosis vaccines, as the vaccination of animals with various types of DNA vaccines has demonstrated complete immunisation to virulent strains [<xref rid="CIT0143" ref-type="bibr">143</xref>]. DNA-based vaccines for brucellosis activate the immune system and promote the activation of TCD4 and TCD8 helper cells. These vaccines also lead to elevated levels of protective cytokines such as IFN-&#x3B3;, TNF-&#x3B1; and IL-12, contributing to the immune response and defence against the disease [<xref rid="CIT0144" ref-type="bibr">144</xref>].</p>
        <p>Nevertheless, DNA-based vaccines do not confer substantial protection compared with live-attenuated vaccines. Research indicates no notable alterations in IL-4, IL-10 and IFN-&#x3B3; expression, indicating an immune response to DNA-based vaccines [<xref rid="CIT0140" ref-type="bibr">140</xref>]. The lack of significant protection offered by DNA-based vaccines could be attributed to their inability to effectively express specific antigens, such as the GroEL-Hsp antigen in the PcDNA3-DNA vaccine. Additionally, the need to repeatedly boost doses is associated with a diminished long-term immune response, which can be enhanced by incorporating an adjuvant into the vaccine formulation [<xref rid="CIT0145" ref-type="bibr">145</xref>]. Although DNA-based vaccines express protective antigens, there may be limitations in the amount of antigen expression achieved. Ongoing efforts are being made to address this issue by developing strategies to prolong the expression of these genes and to prevent gene silencing over an extended period.</p>
      </sec>
      <sec disp-level="2" id="S0012-S2005">
        <label>12.5.</label>
        <title>Vector vaccines</title>
        <p>Live vector-based vaccines using <italic toggle="yes">Brucella</italic> as a delivery system have emerged as an effective method for delivering diverse antigens, whether heterologous or homologous. These genetically modified vaccines are formulated to trigger an antigen-specific T-cell immune response by replicating within host cells and producing multiple copies of the <italic toggle="yes">Brucella</italic> antigen [<xref rid="CIT0146" ref-type="bibr">146</xref>]. Different viral and bacterial vectors, including <italic toggle="yes">Salmonella</italic>, <italic toggle="yes">Escherichia coli</italic>, <italic toggle="yes">Salmonella</italic> and Influenza viruses, can be used to express <italic toggle="yes">Brucella</italic> proteins. <italic toggle="yes">Salmonella</italic> offers advantages such as its inherent adjuvant effect, potential for single-dose vaccination, ability to present more than one antigen, and ability to penetrate natural barriers. However, it is essential to note that multiple <italic toggle="yes">Salmonella</italic> infections can lead to exacerbated disease outcomes in affected animals, potentially resulting in miscarriages and reduced productivity [<xref rid="CIT0147" ref-type="bibr">147</xref>].</p>
        <p>To address the absence of pre-existing immunity to the H5N1 influenza virus in humans, researchers have developed influenza viral vectors (IVVs) [<xref rid="CIT0148" ref-type="bibr">148</xref>]. Lactic acid bacteria-based mucosal vaccines have demonstrated protective responses against various challenges. Nonetheless, these vaccines have the drawback of potentially disseminating genetically modified organisms with markers for drug resistance in both the host microbiota and the surrounding environment [<xref rid="CIT0149" ref-type="bibr">149</xref>]. However, adenovirus-based vaccines have certain drawbacks, including substantial periods of temporary transgene expression, pre-existing immunity and high immunogenicity [<xref rid="CIT0150" ref-type="bibr">150</xref>]. Several studies have assessed the potential of recombinant viral vector vaccines in formulating a potent human vaccine to combat human brucellosis infections. One study specifically examined an IVV of the H5N1 subtype that expressed <italic toggle="yes">Brucella</italic> Omp16, L7/L12, Omp19 and Cu-Zn SOD immunodominant proteins. The vaccine demonstrated significant protective effects when administered via intranasal and sublingual routes, comparable to the <italic toggle="yes">B. melitensis</italic> Rev1 vaccine [<xref rid="CIT0151" ref-type="bibr">151</xref>].</p>
        <p>Other studies have demonstrated that recombinant influenza A viruses of subtypes H5N1 and H1N1 can stimulate Th1 CD4+ and CD8+ T-cell immune responses, leading to effective protection against challenges [<xref rid="CIT0152" ref-type="bibr">152</xref>]. Probiotics, such as <italic toggle="yes">L. casei</italic>, have been explored as vectors for strong immune responses and provide a high level of protection, similar to the IRIBA Strain Vac Calf vaccine. Releasing cytokines such as IFN-&#x3B3;, IL-2 and IL-4 plays a crucial role in mediating cell-mediated immune responses. Mucosal vaccination using <italic toggle="yes">L. casei</italic> or <italic toggle="yes">L. lactis</italic> vector vaccines represents a potential vaccine delivery approach, with the advantage of reduced risk of eliciting immunological tolerance compared to persistent strains [<xref rid="CIT0153" ref-type="bibr">153</xref>].</p>
      </sec>
      <sec disp-level="2" id="S0012-S2006">
        <label>12.6.</label>
        <title>Recombinant peptides as a brucellosis vaccine</title>
        <p>The use of recombinant peptides as brucellosis vaccines is a promising approach in the field of brucellosis prevention and control. Traditional vaccines like the Rev-1 vaccine have limitations, including the risk of abortion in pregnant animals and interference with diagnostic tests. In contrast, recombinant peptides offer safer and more targeted alternatives [<xref rid="CIT0154" ref-type="bibr">154</xref>].</p>
        <p>Research has demonstrated that recombinant peptides, such as rBtuB-Hia-FlgK, can stimulate specific immune responses, particularly Th1 and Th2 responses, which are crucial for combating <italic toggle="yes">Brucella</italic> infection. These peptides can promote the proliferation of CD4+ and CD8+ T cells and the production of key cytokines, including IFN-&#x3B3;, TNF-&#x3B1; and IL-2, which play central roles in immune defence against <italic toggle="yes">Brucella</italic> [<xref rid="CIT0155" ref-type="bibr">155</xref>].</p>
        <p>One significant advantage of recombinant peptides is their ability to trigger an immune response similar to attenuated vaccines but without associated risks. This makes them a safer option for preventing brucellosis in livestock, such as goats, and potentially, in humans. Additionally, recombinant peptides can target specific <italic toggle="yes">Brucella</italic> species, enhancing vaccine specificity [<xref rid="CIT0155" ref-type="bibr">155</xref>]. In conclusion, the development and use of recombinant peptides as brucellosis vaccines hold promise for overcoming the limitations of traditional vaccines, providing a safer and more effective means of preventing this zoonotic disease. Further research and development in this area could potentially lead to improved strategies for brucellosis control, benefiting both animal and human health.</p>
      </sec>
    </sec>
    <sec disp-level="1" id="S0013">
      <label>13.</label>
      <title>Continued research and collaboration</title>
      <p>Continued research and collaboration are essential for devising effective strategies to control and prevent brucellosis. The coordinated efforts of public health officials, healthcare providers and veterinary experts are vital to enhance diagnosis, treatment and prevention. They conduct thorough surveillance, monitoring and public awareness campaigns, emphasising the One Health approach, vaccination programs and biosecurity measures for livestock. During outbreaks, timely control measures such as animal quarantine and movement restrictions are crucial.</p>
      <p>Healthcare providers play a significant role in diagnosing and treating infections early, implementing targeted screening and preventive measures, and educating patients about associated risks and prevention [<xref rid="CIT0156" ref-type="bibr">156</xref>]. Veterinary experts focus on surveillance, early detection and implementation of animal disease control strategies. They also contribute to wildlife management efforts to minimise the brucellosis spillover between wildlife and livestock. Their active involvement in research, collaboration and the one-health approach plays a substantial role in brucellosis control and prevention [<xref rid="CIT0157" ref-type="bibr">157</xref>].</p>
      <p>Recommendations for controlling and preventing brucellosis include enhanced food safety regulations, hygiene practices and surveillance systems. Improved awareness and education for healthcare providers and the public are also imperative [<xref rid="CIT0158" ref-type="bibr">158</xref>]. Assessing the current disease burden involves timely detection and obtaining precise data regarding potential carriers. Effective monitoring and control at the national level require collaboration between different governmental ministries and agencies [<xref rid="CIT0159" ref-type="bibr">159</xref>].</p>
      <p>The societal and economic impacts of zoonoses can be assessed using parameters such as disability-adjusted life years (DALY) for a comparative evaluation of the disease burden and for facilitating informed decision-making regarding brucellosis management programs [<xref rid="CIT0160" ref-type="bibr">160</xref>, <xref rid="CIT0161" ref-type="bibr">161</xref>]. Historical instances of quarantine due to brucellosis, such as the exposure of British soldiers to <italic toggle="yes">Brucella</italic>-contaminated milk, highlight the importance of addressing the occurrence and transmission to eradicate the etiology through quarantine and elimination of infected animals [<xref rid="CIT0162" ref-type="bibr">162</xref>].</p>
      <p>Measures to reduce the risk of brucellosis transmission through milk and dairy products include comprehensive thermal cooking before consumption and enhancing the safety standards of dairy supply chains. Workers exposed to <italic toggle="yes">Brucella</italic>, such as veterinarians, laboratory workers and those handling infected animals, must be equipped with appropriate protective equipment and training [<xref rid="CIT0163" ref-type="bibr">163</xref>].</p>
      <p>Although no approved human vaccine targeting <italic toggle="yes">Brucella</italic> exists, the management of human brucellosis has relied on controlling animal brucellosis through vaccination. Despite some drawbacks, ongoing research on developing novel vaccines using innovative approaches, such as vector-based, recombinant and subunit vaccines, shows promise. Continued efforts in these areas could potentially aid in developing a human <italic toggle="yes">Brucella</italic> vaccine, further strengthening the fight against brucellosis.</p>
    </sec>
    <sec disp-level="1" id="S0014">
      <label>14.</label>
      <title>Control and prevention of the spread of brucellosis</title>
      <p>Controlling and preventing brucellosis involve enhancing food safety, hygiene and surveillance and increasing public and healthcare provider awareness. Despite efforts by the International Task Force for Disease Eradication in 1993, eradication has been hampered by inadequate facilities and resources. CDC follows the Dahlem Workshop guidelines for eradicating infectious diseases, focusing on thorough disease assessment and management [<xref rid="CIT0164" ref-type="bibr">164</xref>].</p>
      <p>Timely and accurate data on symptomatic or asymptomatic animal carriers are vital for assessing disease burden. Governmental collaboration aids in effective monitoring and control of outbreaks. Delays in disease reporting exacerbate this problem, increasing societal and economic impacts measured using the DALY parameter [<xref rid="CIT0165" ref-type="bibr">165</xref>, <xref rid="CIT0166" ref-type="bibr">166</xref>].</p>
      <p>Historical instances, such as the British services&#x2019; brucellosis quarantine in 1906, highlight the significance of a quick response in reducing the spread of the disease [<xref rid="CIT0167" ref-type="bibr">167</xref>, <xref rid="CIT0168" ref-type="bibr">168</xref>]. Addressing both occurrence and transmission is of paramount importance. Despite the human role in disease spread among wildlife, international agreements, such as the Biological Weapons Convention of 1972, have helped in managing bioterrorism-related outbreaks [<xref rid="CIT0169" ref-type="bibr">169</xref>].</p>
      <p>Disease transmission mainly occurs through consuming raw or undercooked meat and unpasteurised dairy products, necessitating comprehensive preventive measures throughout the dairy and meat supply chain. Despite the resilience of <italic toggle="yes">Brucella</italic> species to various food-processing conditions, ensuring that all products undergo thorough cooking before consumption is vital [<xref rid="CIT0006" ref-type="bibr">6</xref>, <xref rid="CIT0170" ref-type="bibr">170</xref>].</p>
      <p>The WHO classifies <italic toggle="yes">Brucella</italic> in risk group 3, highlighting the significant risk for individuals such as veterinarians, laboratory workers and butchers, who frequently handle these bacteria and underscore the need for proper protective equipment and training [<xref rid="CIT0003" ref-type="bibr">3</xref>, <xref rid="CIT0006" ref-type="bibr">6</xref>].</p>
      <p>Currently, there is no FDA-approved human vaccine for <italic toggle="yes">Brucella</italic>, although China uses two live-attenuated vaccines targeting <italic toggle="yes">Brucella melitensis</italic> and <italic toggle="yes">Brucella suis</italic> strains, with limited international approval [<xref rid="CIT0006" ref-type="bibr">6</xref>, <xref rid="CIT0171" ref-type="bibr">171</xref>]. Control of human brucellosis predominantly relies on animal vaccination [<xref rid="CIT0114" ref-type="bibr">114</xref>, <xref rid="CIT0172" ref-type="bibr">172</xref>]. Despite its effectiveness, concerns over vaccination include potential abortion in animals, virulence towards humans, and the emergence of antibiotic-resistant strains. Ongoing research exploring novel vaccines using advanced methods holds promise for more effective and globally accepted <italic toggle="yes">Brucella</italic> vaccines. These vaccines use cutting-edge approaches such as reverse vaccinology, novel additives, structural vaccinology and generalised modules for membrane antigens (GMMA) [<xref rid="CIT0173" ref-type="bibr">173</xref>]. These approaches can potentially shed light on developing a human <italic toggle="yes">Brucella</italic> vaccine.</p>
    </sec>
    <sec sec-type="conclusions" disp-level="1" id="S0015">
      <label>15.</label>
      <title>Conclusions</title>
      <p>In conclusion, understanding the biological aspects of a disease is pivotal for its effective management, including tailored therapies and early detection. While ongoing research on disease mechanisms informs vaccine development, the extensive time required underscores the importance of continued drug discovery. Rapid growth in multi-omics and bioinformatics has significantly aided patient profiling and potential drug targeting, bolstering novel drugs and vaccine development [<xref rid="CIT0172" ref-type="bibr">172</xref>, <xref rid="CIT0174" ref-type="bibr">174</xref>].</p>
      <p>The cross-sector collaboration marks a significant step towards a comprehensive control program, necessitating community-wide active participation and endorsement. A multidisciplinary approach allows for transparent data exchange and implementation of an empirical surveillance model for accurate brucellosis tracking [<xref rid="CIT0175" ref-type="bibr">175</xref>]. Addressing the gap between socioeconomic challenges and research priorities involves prioritising funding for infrastructure and human resources. International collaboration is vital, as seen in the World Bank&#x2019;s recent $82 million grant to India for zoonosis and endemic disease prevention [<xref rid="CIT0176" ref-type="bibr">176</xref>]. This collective effort is essential for effectively managing and controlling zoonoses globally.</p>
    </sec>
  </body>
  <back>
    <sec disp-level="1" id="S0016">
      <title>Author contributions</title>
      <p>Conceptualisation, K.A.Q.; data curation, K.A.Q., A.P., N.A.F., B.H.A.H., S.K., A.G., A.A., G.O.E., S.O.A., S.P. and AS.A.; validation, K.A.Q., A.P., N.A.F., B.H.A.H., S.K.A.G., A.A., G.O.E., S.O.A., S.P. and AS.A.; writing&#x2013;original draft preparation, K.A.Q., A.P., N.A.F., B.H.A.H., S.K., A.G., A.A., G.O.E., S.O.A., S.P. and AS.A.; writing&#x2013;review and editing, K.A.Q., A.P., N.A.F., B.H.A.H., S.K., A.G., A.A., G.O.E., S.O.A., S.P. and AS.A.; supervision, K.A.Q. and AS.A.; funding acquisition, A.A. All the authors have read and agreed to the published version of the manuscript.</p>
    </sec>
    <sec disp-level="1" id="S0017">
      <title>Ethics statement</title>
      <p>Not applicable.</p>
    </sec>
    <sec disp-level="1" id="S0018">
      <title>Consent form</title>
      <p>Not applicable.</p>
    </sec>
    <sec sec-type="COI-statement" disp-level="1" id="S0019">
      <title>Disclosure statement</title>
      <p>No potential conflict of interest was reported by the author(s).</p>
    </sec>
    <sec sec-type="data-availability" disp-level="1" id="S0020">
      <title>Data availability statement</title>
      <p>Data sharing is not applicable to this article as no new data were created in this study.</p>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="CIT0001">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pappas</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Papadimitriou</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Akritidis</surname>
<given-names>N</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>The new global map of human brucellosis</article-title>. <source>Lancet Infect Dis</source>. <year>2006</year>;<volume>6</volume>(<issue>2</issue>):<fpage>1</fpage>&#x2013;<lpage>24</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1473-3099(06)70382-6</pub-id>.<pub-id pub-id-type="pmid">16377523</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0002">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Atluri</surname>
<given-names>VL</given-names></string-name>, <string-name><surname>Xavier</surname>
<given-names>MN</given-names></string-name>, <string-name><surname>De Jong</surname>
<given-names>MF</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Interactions of the human pathogenic <italic toggle="yes">Brucella</italic> species with their hosts</article-title>. <source>Annu Rev Microbiol</source>. <year>2011</year>;<volume>65</volume>(<issue>1</issue>):<fpage>523</fpage>&#x2013;<lpage>541</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev-micro-090110-102905</pub-id>.<pub-id pub-id-type="pmid">21939378</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0003">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Franco</surname>
<given-names>MP</given-names></string-name>, <string-name><surname>Mulder</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Gilman</surname>
<given-names>RH</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Human brucellosis</article-title>. <source>Lancet Infect Dis</source>. <year>2007</year>;<volume>7</volume>(<issue>12</issue>):<fpage>775</fpage>&#x2013;<lpage>786</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1473-3099(07)70286-4</pub-id>.<pub-id pub-id-type="pmid">18045560</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0004">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ariza</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Bosilkovski</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Cascio</surname>
<given-names>A</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations</article-title>. <source>PLoS Med</source>. <year>2007</year>;<volume>4</volume>(<issue>12</issue>):<fpage>e317</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pmed.0040317</pub-id>.<pub-id pub-id-type="pmid">18162038</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0005">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schurig</surname>
<given-names>GG</given-names></string-name>, <string-name><surname>Sriranganathan</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Corbel</surname>
<given-names>MJ.</given-names></string-name></person-group>
<article-title>Brucellosis vaccines: past, present and future</article-title>. <source>Vet Microbiol</source>. <year>2002</year>;<volume>90</volume>(<issue>1&#x2013;4</issue>):<fpage>479</fpage>&#x2013;<lpage>496</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0378-1135(02)00255-9</pub-id>.<pub-id pub-id-type="pmid">12414166</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0006">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goonaratna</surname>
<given-names>C.</given-names></string-name></person-group>
<article-title>Brucellosis in humans and animals</article-title>. <source>Ceylon Med J</source>. <year>2009</year>;<volume>52</volume>(<issue>2</issue>):<fpage>66</fpage>. doi: <pub-id pub-id-type="doi">10.4038/cmj.v52i2.1028</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0007">
        <label>7</label>
        <mixed-citation publication-type="webpage"><person-group person-group-type="author"><string-name><surname>Bennett</surname>
<given-names>NJ.</given-names></string-name></person-group>
<italic toggle="yes">Brucellosis</italic>. Medscape; <year>2023</year>. Available from: <ext-link xlink:href="https://emedicine.medscape.com/article/213430-overview?form=fpf" ext-link-type="uri">https://emedicine.medscape.com/article/213430-overview?form=fpf</ext-link></mixed-citation>
      </ref>
      <ref id="CIT0008">
        <label>8</label>
        <mixed-citation publication-type="webpage">Brucellosis; <year>2023</year> [cited 2023 Dec 8]. Available from: <ext-link xlink:href="https://www.who.int/news-room/fact-sheets/detail/brucellosis" ext-link-type="uri">https://www.who.int/news-room/fact-sheets/detail/brucellosis</ext-link></mixed-citation>
      </ref>
      <ref id="CIT0009">
        <label>9</label>
        <mixed-citation publication-type="webpage">Centers for Disease Control and Prevention. Estimates human Brucella infections could be four times higher than previously thought. Food Safety; <year>2023</year>. Available from: <ext-link xlink:href="https://www.food-safety.com/articles/8817-cdc-estimates-human-brucella-infections-could-be-four-times-higher-than-previously-thought" ext-link-type="uri">https://www.food-safety.com/articles/8817-cdc-estimates-human-brucella-infections-could-be-four-times-higher-than-previously-thought</ext-link>.</mixed-citation>
      </ref>
      <ref id="CIT0010">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Laine</surname>
<given-names>CG</given-names></string-name>, <string-name><surname>Johnson</surname>
<given-names>VE</given-names></string-name>, <string-name><surname>Scott</surname>
<given-names>HM</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Global estimate of human brucellosis incidence</article-title>. <source>Emerg Infect Dis</source>. <year>2023</year>;<volume>29</volume>(<issue>9</issue>):<fpage>1789</fpage>&#x2013;<lpage>1797</lpage>. doi: <pub-id pub-id-type="doi">10.3201/eid2909.230052</pub-id>.<pub-id pub-id-type="pmid">37610167</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0011">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khurana</surname>
<given-names>SK</given-names></string-name>, <string-name><surname>Sehrawat</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Tiwari</surname>
<given-names>R</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Bovine brucellosis&#x2013;a comprehensive review</article-title>. <source>Vet Q</source>. <year>2021</year>;<volume>41</volume>(<issue>1</issue>):<fpage>61</fpage>&#x2013;<lpage>88</lpage>. doi: <pub-id pub-id-type="doi">10.1080/01652176.2020.1868616</pub-id>.<pub-id pub-id-type="pmid">33353489</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0012">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pal</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Gizaw</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Fekadu</surname>
<given-names>G</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Public health and economic importance of bovine brucellosis: an overview</article-title>. <source>Am J Epid Inf Dis</source>. <year>2017</year>;<volume>5</volume>(<issue>2</issue>):<fpage>27</fpage>&#x2013;<lpage>34</lpage>. doi: <pub-id pub-id-type="doi">10.12691/ajeid-5-2-2</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0013">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bano</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Ahmad Lone</surname>
<given-names>S.</given-names></string-name></person-group>
<article-title>Brucellosis: an economically important infection</article-title>. <source>J Med Microb Diagn</source>. <year>2015</year>;<volume>4</volume>(<issue>4</issue>):<fpage>208</fpage>. doi: <pub-id pub-id-type="doi">10.4172/2161-0703.1000208</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0014">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fritz</surname>
<given-names>CL</given-names></string-name>, <string-name><surname>Nguyen</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Vugia</surname>
<given-names>DJ.</given-names></string-name></person-group>
<article-title>Epidemiology of brucellosis in California, 1993&#x2013;2017: a continuing foodborne disease risk for older Latinos</article-title>. <source>Clin Infect Dis</source>. <year>2021</year>;<volume>73</volume>(<issue>11</issue>):<fpage>2023</fpage>&#x2013;<lpage>2030</lpage>. doi: <pub-id pub-id-type="doi">10.1093/cid/ciab551</pub-id>.<pub-id pub-id-type="pmid">34134141</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0015">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Uzunovi&#x107;</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Skomorac</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ba&#x161;i&#x107;</surname>
<given-names>F</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Human brucellosis as an epidemic zoonosis in Zenica-Doboj canton (Bosnia and Herzegovina) during 2008&#x2013;2018</article-title>. <source>Open Infect Dis J</source>. <year>2020</year>;<volume>12</volume>(<issue>1</issue>):<fpage>1</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.2174/1874279302012010001</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0016">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Djokic</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Freddi</surname>
<given-names>L</given-names></string-name>, <string-name><surname>de Massis</surname>
<given-names>F</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>The emergence of <italic toggle="yes">Brucella canis</italic> as a public health threat in Europe: what we know and what we need to learn</article-title>. <source>Emerg Microb Infect</source>. <year>2023</year>;<volume>12</volume>(<issue>2</issue>):<fpage>2249126</fpage>. doi: <pub-id pub-id-type="doi">10.1080/22221751.2023.2249126</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0017">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ali</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Nawaz</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Akhtar</surname>
<given-names>A</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Epidemiological investigation of human brucellosis in Pakistan</article-title>. <source>Jundishapur J Microbiol</source>. <year>2018</year>;<volume>11</volume>(<issue>7</issue>):<fpage>e61764</fpage>. doi: <pub-id pub-id-type="doi">10.5812/jjm.61764</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0018">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kalin</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Karahan</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Acik</surname>
<given-names>MN</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Mastitisli inek s&#xFC;tlerinde &#xF6;nemli patojenlerin direkt tespiti i&#xE7;in bir multipleks PCR y&#xF6;nteminin geli&#x15F;tirilmesi</article-title>. <source>Kafkas Univ Vet Fak Derg</source>. <year>2017</year>;<volume>23</volume>(<issue>6</issue>):<fpage>925</fpage>&#x2013;<lpage>931</lpage>. doi: <pub-id pub-id-type="doi">10.9775/kvfd.2017.17995</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0019">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yumuk</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>O&#x2019;Callaghan</surname>
<given-names>D.</given-names></string-name></person-group>
<article-title>Brucellosis in Turkey&#x2014;an overview</article-title>. <source>Int J Infect Dis</source>. <year>2012</year>;<volume>16</volume>(<issue>4</issue>):<fpage>e228</fpage>&#x2013;<lpage>e235</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijid.2011.12.011</pub-id>.<pub-id pub-id-type="pmid">22333223</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0020">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alavi</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Motlagh</surname>
<given-names>ME.</given-names></string-name></person-group>
<article-title>A review of epidemiology, diagnosis and management of brucellosis for general physicians working in the Iranian Health Network</article-title>. <source>Jundishapur J Microbiol</source>. <year>2012</year>;<volume>5</volume>(<issue>2</issue>):<fpage>384</fpage>&#x2013;<lpage>387</lpage>. doi: <pub-id pub-id-type="doi">10.5812/jjm.3248</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0021">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bagheri</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Tapak</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Karami</surname>
<given-names>M</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Epidemiological features of human brucellosis in Iran (2011&#x2013;2018) and prediction of brucellosis with data-mining models</article-title>. <source>J Res Health Sci</source>. <year>2019</year>;<volume>19</volume>(<issue>4</issue>):<fpage>e00462</fpage>. <ext-link xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183567/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183567/</ext-link><pub-id pub-id-type="pmid">32291361</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0022">
        <label>22</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Etemadi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Moniri</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Saffari</surname>
<given-names>M</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Epidemiological, molecular characterization and risk factors of human brucellosis in Iran</article-title>. <source>Asian Pac J Trop Med</source>. <year>2020</year>;<volume>13</volume>(<issue>4</issue>):<fpage>169</fpage>. doi: <pub-id pub-id-type="doi">10.4103/1995-7645.280224</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0023">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nematollahi</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ayubi</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Karami</surname>
<given-names>M</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Epidemiological characteristics of human brucellosis in Hamadan province during 2009&#x2013;2015: results from the national notifiable diseases surveillance system</article-title>. <source>Int J Infect Dis</source>. <year>2017</year>;<volume>61</volume>:<fpage>56</fpage>&#x2013;<lpage>61</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijid.2017.06.002</pub-id>.<pub-id pub-id-type="pmid">28602765</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0024">
        <label>24</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Norouzinezhad</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Erfani</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Norouzinejad</surname>
<given-names>A</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Epidemiological characteristics and trend in the incidence of human brucellosis in Iran from 2009 to 2017</article-title>. <source>J Res Health Sci</source>. <year>2021</year>;<volume>21</volume>(<issue>4</issue>):<fpage>e00535</fpage>. doi: <pub-id pub-id-type="doi">10.34172/jrhs.2021.70</pub-id>.<pub-id pub-id-type="pmid">36511231</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0025">
        <label>25</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Al-Amr</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Abasi</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Khasawneh</surname>
<given-names>R</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Epidemiology of human brucellosis in military hospitals in Jordan: a five-year study</article-title>. <source>J Infect Dev Ctries</source>. <year>2022</year>;<volume>16</volume>(<issue>12</issue>):<fpage>1870</fpage>&#x2013;<lpage>1876</lpage>. doi: <pub-id pub-id-type="doi">10.3855/jidc.16861</pub-id>.<pub-id pub-id-type="pmid">36753655</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0026">
        <label>26</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Holt</surname>
<given-names>HR</given-names></string-name>, <string-name><surname>Bedi</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Kaur</surname>
<given-names>P</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Epidemiology of brucellosis in cattle and dairy farmers of rural Ludhiana, Punjab</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2021</year>;<volume>15</volume>(<issue>3</issue>):<fpage>e0009102</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pntd.0009102</pub-id>.<pub-id pub-id-type="pmid">33735243</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0027">
        <label>27</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nawaz</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Shafique</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Zahoor</surname>
<given-names>MA</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Sero-epidemiology and risk factor analysis of human brucellosis in Punjab, Pakistan: a cross sectional study</article-title>. <source>Trop Biomed</source>. <year>2021</year>;<volume>38</volume>(<issue>3</issue>):<fpage>413</fpage>&#x2013;<lpage>419</lpage>. doi: <pub-id pub-id-type="doi">10.47665/tb.38.3.084</pub-id>.<pub-id pub-id-type="pmid">34608115</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0028">
        <label>28</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shi</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Gao</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Pappas</surname>
<given-names>G</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Clinical features of 2041 human brucellosis cases in China</article-title>. <source>PLOS One</source>. <year>2018</year>;<volume>13</volume>(<issue>11</issue>):<fpage>e0205500</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0205500</pub-id>.<pub-id pub-id-type="pmid">30476930</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0029">
        <label>29</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tao</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>Y</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Epidemiological characteristics of human brucellosis&#x2014;China</article-title>. <source>China CDC Wkly</source>. <year>2021</year>;<volume>3</volume>(<issue>6</issue>):<fpage>114</fpage>&#x2013;<lpage>119</lpage>. doi: <pub-id pub-id-type="doi">10.46234/ccdcw2021.030</pub-id>.<pub-id pub-id-type="pmid">34595016</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0030">
        <label>30</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>
<given-names>Z G</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ta</surname>
<given-names>N</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Seroprevalence of human brucellosis and molecular characteristics of <italic toggle="yes">Brucella</italic> strains in Inner Mongolia autonomous region of China, from 2012 to 2016</article-title>. <source>Emerg Microbes Infect</source>. <year>2020</year>;<volume>9</volume>(<issue>1</issue>):<fpage>263</fpage>&#x2013;<lpage>274</lpage>. doi: <pub-id pub-id-type="doi">10.1080/22221751.2020.1720528</pub-id>.<pub-id pub-id-type="pmid">31997725</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0031">
        <label>31</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Djangwani</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ooko Abong&#x2019;</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Gicuku Njue</surname>
<given-names>L</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Brucellosis: prevalence with reference to East African community countries&#x2013;a rapid review</article-title>. <source>Vet Med Sci</source>. <year>2021</year>;<volume>7</volume>(<issue>3</issue>):<fpage>851</fpage>&#x2013;<lpage>867</lpage>. doi: <pub-id pub-id-type="doi">10.1002/vms3.425</pub-id>.<pub-id pub-id-type="pmid">33421354</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0032">
        <label>32</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vigeant</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Mendelson</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Miller</surname>
<given-names>MA.</given-names></string-name></person-group>
<article-title>Human to human transmission of <italic toggle="yes">Brucella melitensis</italic></article-title>. <source>Can J Infect Dis</source>. <year>1995</year>;<volume>6</volume>(<issue>3</issue>):<fpage>153</fpage>&#x2013;<lpage>155</lpage>. <ext-link xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327908/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327908/</ext-link> doi: <pub-id pub-id-type="doi">10.1155/1995/909404</pub-id>.<pub-id pub-id-type="pmid">22514390</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0033">
        <label>33</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shakir</surname>
<given-names>R.</given-names></string-name></person-group>
<article-title>Brucellosis</article-title>. <source>J Neurol Sci</source>. <year>2021</year>;<volume>420</volume>:<fpage>117280</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jns.2020.117280</pub-id>.<pub-id pub-id-type="pmid">33358192</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0034">
        <label>34</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Delam</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Keshtkaran</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Rezaei</surname>
<given-names>B</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Changing patterns in epidemiology of brucellosis in the South of Iran (2015&#x2013;2020): based on Cochran&#x2013;Armitage trend test</article-title>. <source>Ann Glob Health</source>. <year>2022</year>;<volume>88</volume>(<issue>1</issue>):<fpage>11</fpage>. doi: <pub-id pub-id-type="doi">10.5334/aogh.3474</pub-id>.<pub-id pub-id-type="pmid">35223430</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0035">
        <label>35</label>
        <mixed-citation publication-type="webpage">Centers for Disease Control and Prevention. Treatment. Brucellosis. CDC; <year>2012</year>. Available from: <ext-link xlink:href="https://www.cdc.gov/brucellosis/treatment/index.html" ext-link-type="uri">https://www.cdc.gov/brucellosis/treatment/index.html</ext-link></mixed-citation>
      </ref>
      <ref id="CIT0036">
        <label>36</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>De Figueiredo</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Ficht</surname>
<given-names>TA</given-names></string-name>, <string-name><surname>Rice-Ficht</surname>
<given-names>A</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Pathogenesis and immunobiology of brucellosis: review of <italic toggle="yes">Brucella</italic>&#x2013;host interactions</article-title>. <source>Am J Pathol</source>. <year>2015</year>;<volume>185</volume>(<issue>6</issue>):<fpage>1505</fpage>&#x2013;<lpage>1517</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ajpath.2015.03.003</pub-id>.<pub-id pub-id-type="pmid">25892682</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0037">
        <label>37</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Barbuddhe</surname>
<given-names>SB</given-names></string-name>, <string-name><surname>Vergis</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Rawool</surname>
<given-names>DB.</given-names></string-name></person-group> Immunodetection of bacteria causing brucellosis. In: Gurtler V, Patrauchan M, editors. Methods in microbiology. Vol. 47. Academic Press; <year>2020</year>. p. 75&#x2013;115. doi: <pub-id pub-id-type="doi">10.1016/bs.mim.2019.11.003</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0038">
        <label>38</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Matle</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Ledwaba</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Madiba</surname>
<given-names>K</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Characterisation of <italic toggle="yes">Brucella</italic> species and biovars in South Africa between 2008 and 2018 using laboratory diagnostic data</article-title>. <source>Vet Med Sci</source>. <year>2021</year>;<volume>7</volume>(<issue>4</issue>):<fpage>1245</fpage>&#x2013;<lpage>1253</lpage>. doi: <pub-id pub-id-type="doi">10.1002/vms3.483</pub-id>.<pub-id pub-id-type="pmid">33974356</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0039">
        <label>39</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Byndloss</surname>
<given-names>MX</given-names></string-name>, <string-name><surname>Tsolis</surname>
<given-names>RM.</given-names></string-name></person-group>
<article-title><italic toggle="yes">Brucella</italic> spp. virulence factors and immunity</article-title>. <source>Annu Rev Anim Biosci</source>. <year>2016</year>;<volume>4</volume>(<issue>1</issue>):<fpage>111</fpage>&#x2013;<lpage>127</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev-animal-021815-111326</pub-id>.<pub-id pub-id-type="pmid">26734887</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0040">
        <label>40</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Elrashedy</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Gaafar</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mousa</surname>
<given-names>W</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Immune response and recent advances in diagnosis and control of brucellosis</article-title>. <source>Ger J Vet Res</source>. <year>2022</year>;<volume>2</volume>(<issue>1</issue>):<fpage>10</fpage>&#x2013;<lpage>24</lpage>. doi: <pub-id pub-id-type="doi">10.51585/gjvr.2022.1.0033</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0041">
        <label>41</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>G&#x142;owacka</surname>
<given-names>P</given-names></string-name>, <string-name><surname>&#x17B;akowska</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Naylor</surname>
<given-names>K</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title><italic toggle="yes">Brucella</italic>&#x2013;virulence factors, pathogenesis and treatment</article-title>. <source>Pol J Microbiol</source>. <year>2018</year>;<volume>67</volume>(<issue>2</issue>):<fpage>151</fpage>&#x2013;<lpage>161</lpage>. doi: <pub-id pub-id-type="doi">10.21307/pjm-2018-029</pub-id>.<pub-id pub-id-type="pmid">30015453</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0042">
        <label>42</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wareth</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Melzer</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Neubauer</surname>
<given-names>H.</given-names></string-name></person-group>
<article-title>In <italic toggle="yes">Brucella</italic>: selective pressure may turn some genes on instead of default off position</article-title>. <source>Med Hypotheses</source>. <year>2017</year>;<volume>103</volume>:<fpage>29</fpage>&#x2013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mehy.2017.04.006</pub-id>.<pub-id pub-id-type="pmid">28571803</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0043">
        <label>43</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ulu Kilic</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Metan</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Alp</surname>
<given-names>E.</given-names></string-name></person-group>
<article-title>Clinical presentations and diagnosis of brucellosis</article-title>. <source>Recent Pat Antiinfect Drug Discov</source>. <year>2013</year>;<volume>8</volume>(<issue>1</issue>):<fpage>34</fpage>&#x2013;<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.2174/1574891X11308010007</pub-id>.<pub-id pub-id-type="pmid">22873352</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0044">
        <label>44</label>
        <mixed-citation publication-type="book">Centers for Disease Control and Prevention (CDC). Brucellosis reference guide: exposures, testing, and prevention. Atlanta (GA): The Center for Food Security and Public Health; <year>2018</year>. p. 1&#x2013;40.</mixed-citation>
      </ref>
      <ref id="CIT0045">
        <label>45</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Young</surname>
<given-names>EJ.</given-names></string-name></person-group>
<article-title>An overview of human brucellosis</article-title>. <source>Clin Infect Dis</source>. <year>1995</year>;<volume>21</volume>(<issue>2</issue>):<fpage>283</fpage>&#x2013;<lpage>289; quiz 290</lpage>. doi: <pub-id pub-id-type="doi">10.1093/clinids/21.2.283</pub-id>.<pub-id pub-id-type="pmid">8562733</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0046">
        <label>46</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rubach</surname>
<given-names>MP</given-names></string-name>, <string-name><surname>Halliday</surname>
<given-names>JEB</given-names></string-name>, <string-name><surname>Cleaveland</surname>
<given-names>S</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Brucellosis in low-income and middle-income countries</article-title>. <source>Curr Opin Infect Dis</source>. <year>2013</year>;<volume>26</volume>(<issue>5</issue>):<fpage>404</fpage>&#x2013;<lpage>412</lpage>. doi: <pub-id pub-id-type="doi">10.1097/QCO.0b013e3283638104</pub-id>.<pub-id pub-id-type="pmid">23963260</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0047">
        <label>47</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Heavey</surname>
<given-names>E.</given-names></string-name></person-group>
<article-title>Brucellosis: a global concern</article-title>. <source>Nursing</source>. <year>2019</year>;<volume>49</volume>(<issue>5</issue>):<fpage>14</fpage>&#x2013;<lpage>16</lpage>. doi: <pub-id pub-id-type="doi">10.1097/01.NURSE.0000554623.05347.a0</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0048">
        <label>48</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>&#xC7;avu&#x15F;</surname>
<given-names>B</given-names></string-name>, <string-name><surname>&#xC7;ayda&#x15F;&#x131;</surname>
<given-names>&#xD6;</given-names></string-name>, <string-name><surname>Aktan</surname>
<given-names>A</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Brucellosis as the cause of non-viral bacterial hepatitis: a case report</article-title>. <source>Open Access Maced J Med Sci</source>. <year>2018</year>;<volume>6</volume>(<issue>7</issue>):<fpage>1260</fpage>&#x2013;<lpage>1262</lpage>. doi: <pub-id pub-id-type="doi">10.3889/oamjms.2018.198</pub-id>.<pub-id pub-id-type="pmid">30087732</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0049">
        <label>49</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>G&#xFC;&#xE7;l&#xFC;</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Yakar</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Habeo&#x11F;lu</surname>
<given-names>MA.</given-names></string-name></person-group>
<article-title>Spontaneous bacterial peritonitis and chylothorax related to <italic toggle="yes">Brucella</italic> infection in a cirrhotic patient</article-title>. <source>Electron J Gen Med</source>. <year>2007</year>;<volume>4</volume>(<issue>4</issue>):<fpage>201</fpage>&#x2013;<lpage>204</lpage>. doi: <pub-id pub-id-type="doi">10.29333/ejgm/82530</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0050">
        <label>50</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Makaritsis</surname>
<given-names>KP</given-names></string-name>, <string-name><surname>Liaskos</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Papadamou</surname>
<given-names>G</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Spontaneous bacterial peritonitis: an unusual manifestation of brucellosis in a previous healthy male patient</article-title>. <source>BMJ Case Rep</source>. <year>2015</year>;<volume>2015</volume>(<issue>1</issue>):<fpage>bcr2015209387</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bcr-2015-209387</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0051">
        <label>51</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qiu</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>S.</given-names></string-name></person-group>
<article-title>Immune thrombocytopenic purpura and its rare association with a <italic toggle="yes">Brucella</italic> infection: a case report</article-title>. <source>Cureus</source>. <year>2022</year>;<volume>14</volume>(<issue>10</issue>):<fpage>e30049</fpage>. doi: <pub-id pub-id-type="doi">10.7759/cureus.30049</pub-id>.<pub-id pub-id-type="pmid">36381884</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0052">
        <label>52</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yamashita</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Takahashi</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Kaneko</surname>
<given-names>H</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Thrombotic thrombocytopenic purpura with an autoantibody to ADAMTS13 complicating Sj&#xF6;gren&#x2019;s syndrome: two cases and a literature review</article-title>. <source>Mod Rheumatol</source>. <year>2013</year>;<volume>23</volume>(<issue>2</issue>):<fpage>365</fpage>&#x2013;<lpage>373</lpage>. doi: <pub-id pub-id-type="doi">10.3109/s10165-012-0644-7</pub-id>.<pub-id pub-id-type="pmid">22526830</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0053">
        <label>53</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lambourne</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Brooks</surname>
<given-names>T.</given-names></string-name></person-group>
<article-title><italic toggle="yes">Brucella</italic> and <italic toggle="yes">Coxiella</italic>; if you don&#x2019;t look, you don&#x2019;t find</article-title>. <source>Clin Med</source>. <year>2015</year>;<volume>15</volume>(<issue>2</issue>):<fpage>212</fpage>. doi: <pub-id pub-id-type="doi">10.7861/clinmedicine.15-2-212</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0054">
        <label>54</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>W</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>A case of brucellosis-induced Guillain&#x2013;Barre syndrome</article-title>. <source>BMC Infect Dis</source>. <year>2022</year>;<volume>22</volume>(<issue>1</issue>):<fpage>72</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12879-021-07025-3</pub-id>.<pub-id pub-id-type="pmid">35057735</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0055">
        <label>55</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Essrani</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Shnitser</surname>
<given-names>A.</given-names></string-name></person-group>
<article-title><italic toggle="yes">Brucella melitensis</italic>-induced transaminitis</article-title>. <source>Cureus</source>. <year>2021</year>;<volume>13</volume>(<issue>3</issue>):<fpage>e13656</fpage>. doi: <pub-id pub-id-type="doi">10.7759/cureus.13656</pub-id>.<pub-id pub-id-type="pmid">33824807</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0056">
        <label>56</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Young</surname>
<given-names>EJ.</given-names></string-name></person-group> Clinical manifestations of human brucellosis. In: Young EJ and Corbel MJ, editors. Brucellosis: clinical and laboratory aspects. CRC Press; <year>2020</year>. p. 97&#x2013;126. doi: <pub-id pub-id-type="doi">10.1201/9781003068518-10</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0057">
        <label>57</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kaya</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Kocyigit</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Kaya</surname>
<given-names>C</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Brucellar testicular abscess presenting as a testicular mass: can color Doppler sonography be used in differentiation?</article-title>
<source>Turk J Emerg Med</source>. <year>2015</year>;<volume>15</volume>(<issue>1</issue>):<fpage>43</fpage>&#x2013;<lpage>46</lpage>. doi: <pub-id pub-id-type="doi">10.5505/1304.7361.2014.82698</pub-id>.<pub-id pub-id-type="pmid">27331193</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0058">
        <label>58</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Raju</surname>
<given-names>IT</given-names></string-name>, <string-name><surname>Solanki</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Patnaik</surname>
<given-names>AN</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title><italic toggle="yes">Brucella endocarditis</italic>&#x2014;a series of five case reports</article-title>. <source>Indian Heart J</source>. <year>2013</year>;<volume>65</volume>(<issue>1</issue>):<fpage>72</fpage>&#x2013;<lpage>77</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ihj.2012.12.017</pub-id>.<pub-id pub-id-type="pmid">23438616</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0059">
        <label>59</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bazzazi</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Yavarikia</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Keramat</surname>
<given-names>F.</given-names></string-name></person-group>
<article-title>Ocular involvement of brucellosis</article-title>. <source>Middle East Afr J Ophthalmol</source>. <year>2013</year>;<volume>20</volume>(<issue>1</issue>):<fpage>95</fpage>&#x2013;<lpage>97</lpage>. doi: <pub-id pub-id-type="doi">10.4103/0974-9233.106407</pub-id>.<pub-id pub-id-type="pmid">23580863</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0060">
        <label>60</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Karaali</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Baysal</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Poturoglu</surname>
<given-names>S</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Cutaneous manifestations in brucellosis</article-title>. <source>Indian J Dermatol</source>. <year>2011</year>;<volume>56</volume>(<issue>3</issue>):<fpage>339</fpage>&#x2013;<lpage>340</lpage>. doi: <pub-id pub-id-type="doi">10.4103/0019-5154.82505</pub-id>.<pub-id pub-id-type="pmid">21772606</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0061">
        <label>61</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Korkmaz</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Doyuk Kartal</surname>
<given-names>E.</given-names></string-name></person-group>
<article-title>Skin manifestations associated with brucellosis</article-title>. <source>EMJ Dermatol</source>. <year>2016</year>;<volume>4</volume>:<fpage>119</fpage>&#x2013;<lpage>125</lpage>. doi: <pub-id pub-id-type="doi">10.33590/emjdermatol/10312753</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0062">
        <label>62</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Lu</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>C</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>A man with recurrent fever, arthritis, and rashes&#x2014;brucellosis? A case report</article-title>. <source>BMC Infect Dis</source>. <year>2020</year>;<volume>20</volume>(<issue>1</issue>):<fpage>18</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12879-019-4746-0</pub-id>.<pub-id pub-id-type="pmid">31910802</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0063">
        <label>63</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Spink</surname>
<given-names>WW.</given-names></string-name></person-group>
<article-title>What is chronic brucellosis?</article-title>
<source>Ann Intern Med</source>. <year>1951</year>;<volume>35</volume>(<issue>2</issue>):<fpage>358</fpage>&#x2013;<lpage>374</lpage>. doi: <pub-id pub-id-type="doi">10.7326/0003-4819-35-2-358</pub-id>.<pub-id pub-id-type="pmid">14857606</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0064">
        <label>64</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ariza</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Corredoira</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Pallares</surname>
<given-names>R</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Characteristics of and risk factors for relapse of brucellosis in humans</article-title>. <source>Clin Infect Dis</source>. <year>1995</year>;<volume>20</volume>(<issue>5</issue>):<fpage>1241</fpage>&#x2013;<lpage>1249</lpage>. doi: <pub-id pub-id-type="doi">10.1093/clinids/20.5.1241</pub-id>.<pub-id pub-id-type="pmid">7620005</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0065">
        <label>65</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Solera</surname>
<given-names>J.</given-names></string-name></person-group>
<article-title>Update on brucellosis: therapeutic challenges</article-title>. <source>Int J Antimicrob Agents</source>. <year>2010</year>;<volume>36</volume>(<issue>Suppl. 1</issue>):<fpage>S18</fpage>&#x2013;<lpage>S20</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2010.06.015</pub-id>.<pub-id pub-id-type="pmid">20692127</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0066">
        <label>66</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Akkoc</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Tekerek</surname>
<given-names>S.</given-names></string-name></person-group>
<article-title>Osteoarticular involvement in childhood brucellosis: evaluation of clinical, laboratory and radiologic features of 185 cases</article-title>. <source>Pediatr Infect Dis J</source>. <year>2023</year>;<volume>42</volume>(<issue>5</issue>):<fpage>381</fpage>&#x2013;<lpage>388</lpage>. doi: <pub-id pub-id-type="doi">10.1097/INF.0000000000003844</pub-id>.<pub-id pub-id-type="pmid">36795549</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0067">
        <label>67</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Whatmore</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Koylass</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Muchowski</surname>
<given-names>J</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Extended multilocus sequence analysis to describe the global population structure of the genus <italic toggle="yes">Brucella</italic>: phylogeography and relationship to biovars</article-title>. <source>Front Microbiol</source>. <year>2016</year>;<volume>7</volume>:<fpage>2049</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2016.02049</pub-id>.<pub-id pub-id-type="pmid">28066370</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0068">
        <label>68</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pappas</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Akritidis</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Bosilkovski</surname>
<given-names>M</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Medical progress brucellosis</article-title>. <source>N Engl J Med</source>. <year>2005</year>;<volume>352</volume>(<issue>22</issue>):<fpage>2325</fpage>&#x2013;<lpage>2336</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMra050570</pub-id>.<pub-id pub-id-type="pmid">15930423</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0069">
        <label>69</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yagupsky</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Morat</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Colmenero</surname>
<given-names>JD.</given-names></string-name></person-group>
<article-title>Laboratory diagnosis of human brucellosis</article-title>. <source>Clin Microbiol Rev</source>. <year>2020</year>;<volume>33</volume>(<issue>1</issue>):<fpage>e00073-19</fpage>. doi: <pub-id pub-id-type="doi">10.1128/CMR.00073-19</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0070">
        <label>70</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pappas</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Papadimitriou</surname>
<given-names>P.</given-names></string-name></person-group>
<article-title>Challenges in <italic toggle="yes">Brucella bacteraemia</italic></article-title>. <source>Int J Antimicrob Agents</source>. <year>2007</year>;<volume>30</volume>(<issue>Suppl. 1</issue>):<fpage>29</fpage>&#x2013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2007.06.011</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0071">
        <label>71</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Olitzky</surname>
<given-names>AL.</given-names></string-name></person-group>
<article-title>Laboratory techniques in brucellosis</article-title>. <source>Harefuah</source>. <year>1976</year>;<volume>91</volume>(<issue>11</issue>):<fpage>408</fpage>&#x2013;<lpage>409</lpage>.<pub-id pub-id-type="pmid">1017740</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0072">
        <label>72</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Castaneda</surname>
<given-names>MR.</given-names></string-name></person-group>
<article-title>A practical method for routine blood cultures in brucellosis</article-title>. <source>Proc Soc Exp Biol Med</source>. <year>1947</year>;<volume>64</volume>(<issue>1</issue>):<fpage>114</fpage>&#x2013;<lpage>115</lpage>. doi: <pub-id pub-id-type="doi">10.3181/00379727-64-15717</pub-id>.<pub-id pub-id-type="pmid">20285481</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0073">
        <label>73</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Al-Attas</surname>
<given-names>RA</given-names></string-name>, <string-name><surname>Al-Khalifa</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Al-Qurashi</surname>
<given-names>AR</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Evaluation of PCR, culture and serology for the diagnosis of acute human brucellosis</article-title>. <source>Ann Saudi Med</source>. <year>2000</year>;<volume>20</volume>(<issue>3&#x2013;4</issue>):<fpage>224</fpage>&#x2013;<lpage>228</lpage>. doi: <pub-id pub-id-type="doi">10.5144/0256-4947.2000.224</pub-id>.<pub-id pub-id-type="pmid">17322662</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0074">
        <label>74</label>
        <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>OIE-WOAH. Terrestrial code online access - WOAH - World organisation for animal health. 2023. <ext-link xlink:href="https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/" ext-link-type="uri">https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/</ext-link>.</collab></person-group>
</mixed-citation>
      </ref>
      <ref id="CIT0075">
        <label>75</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wareth</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Pletz</surname>
<given-names>MW</given-names></string-name>, <string-name><surname>Neubauer</surname>
<given-names>H</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Proteomics of <italic toggle="yes">Brucella</italic>: technologies and their applications for basic research and medical microbiology</article-title>. <source>Microorganisms</source>. <year>2020</year>;<volume>8</volume>(<issue>5</issue>):<fpage>766</fpage>. doi: <pub-id pub-id-type="doi">10.3390/microorganisms8050766</pub-id>.<pub-id pub-id-type="pmid">32443785</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0076">
        <label>76</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Di Bonaventura</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Angeletti</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ianni</surname>
<given-names>A</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Microbiological laboratory diagnosis of human brucellosis: an overview</article-title>. <source>Pathogens</source>. <year>2021</year>;<volume>10</volume>(<issue>12</issue>):<fpage>1623</fpage>. doi: <pub-id pub-id-type="doi">10.3390/pathogens10121623</pub-id>.<pub-id pub-id-type="pmid">34959578</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0077">
        <label>77</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>El-Diasty</surname>
<given-names>M</given-names></string-name>, <string-name><surname>El-Said</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Abdelkhalek</surname>
<given-names>A.</given-names></string-name></person-group>
<article-title>Seroprevalence and molecular diagnosis of sheep brucellosis in Dakahlia Governorate, Egypt</article-title>. <source>Ger J Vet Res</source>. <year>2021</year>;<volume>1</volume>(<issue>1</issue>):<fpage>34</fpage>&#x2013;<lpage>39</lpage>. doi: <pub-id pub-id-type="doi">10.51585/gjvr.2021.0006</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0078">
        <label>78</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baddour</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Alkhalifa</surname>
<given-names>DH.</given-names></string-name></person-group>
<article-title>Evaluation of three polymerase chain reaction techniques for detection of <italic toggle="yes">Brucella</italic> DNA in peripheral human blood</article-title>. <source>Can J Microbiol</source>. <year>2008</year>;<volume>54</volume>(<issue>5</issue>):<fpage>352</fpage>&#x2013;<lpage>357</lpage>. doi: <pub-id pub-id-type="doi">10.1139/W08-017</pub-id>.<pub-id pub-id-type="pmid">18449219</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0079">
        <label>79</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bounaadja</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Albert</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Ch&#xE9;nais</surname>
<given-names>B</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Real-time PCR for identification of <italic toggle="yes">Brucella</italic> spp.: a comparative study of IS711, bcsp31 and per target genes</article-title>. <source>Vet Microbiol</source>. <year>2009</year>;<volume>137</volume>(<issue>1&#x2013;2</issue>):<fpage>156</fpage>&#x2013;<lpage>164</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vetmic.2008.12.023</pub-id>.<pub-id pub-id-type="pmid">19200666</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0080">
        <label>80</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Romero</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Gamazo</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Pardo</surname>
<given-names>M</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Specific detection of <italic toggle="yes">Brucella</italic> DNA by PCR</article-title>. <source>J Clin Microbiol</source>. <year>1995</year>;<volume>33</volume>(<issue>3</issue>):<fpage>615</fpage>&#x2013;<lpage>617</lpage>. doi: <pub-id pub-id-type="doi">10.1128/jcm.33.3.615-617.1995</pub-id>.<pub-id pub-id-type="pmid">7538508</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0081">
        <label>81</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leal-Klevezas</surname>
<given-names>DS</given-names></string-name>, <string-name><surname>Martinez-Vazquez</surname>
<given-names>IO</given-names></string-name>, <string-name><surname>Lopez-Merino</surname>
<given-names>A</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Single-step PCR for detection of <italic toggle="yes">Brucella</italic> spp. from blood and milk of infected animals</article-title>. <source>J Clin Microbiol</source>. <year>1995</year>;<volume>33</volume>(<issue>12</issue>):<fpage>3087</fpage>&#x2013;<lpage>3090</lpage>. doi: <pub-id pub-id-type="doi">10.1128/jcm.33.12.3087-3090.1995</pub-id>.<pub-id pub-id-type="pmid">8586678</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0082">
        <label>82</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kattar</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Zalloua</surname>
<given-names>PA</given-names></string-name>, <string-name><surname>Araj</surname>
<given-names>GF</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Development and evaluation of real-time polymerase chain reaction assays on whole blood and paraffin-embedded tissues for rapid diagnosis of human brucellosis</article-title>. <source>Diagn Microbiol Infect Dis</source>. <year>2007</year>;<volume>59</volume>(<issue>1</issue>):<fpage>23</fpage>&#x2013;<lpage>32</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2007.04.002</pub-id>.<pub-id pub-id-type="pmid">17532591</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0083">
        <label>83</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mitka</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Anetakis</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Souliou</surname>
<given-names>E</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Evaluation of different PCR assays for early detection of acute and relapsing brucellosis in humans in comparison with conventional methods</article-title>. <source>J Clin Microbiol</source>. <year>2007</year>;<volume>45</volume>(<issue>4</issue>):<fpage>1211</fpage>&#x2013;<lpage>1218</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JCM.00010-06</pub-id>.<pub-id pub-id-type="pmid">17267626</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0084">
        <label>84</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Al Nakkas</surname>
<given-names>AF</given-names></string-name>, <string-name><surname>Wright</surname>
<given-names>SG</given-names></string-name>, <string-name><surname>Mustafa</surname>
<given-names>AS</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Single-tube, nested PCR for the diagnosis of human brucellosis in Kuwait</article-title>. <source>Ann Trop Med Parasitol</source>. <year>2002</year>;<volume>96</volume>(<issue>4</issue>):<fpage>397</fpage>&#x2013;<lpage>403</lpage>. doi: <pub-id pub-id-type="doi">10.1179/000349802125001203</pub-id>.<pub-id pub-id-type="pmid">12171621</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0085">
        <label>85</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baily</surname>
<given-names>GG</given-names></string-name>, <string-name><surname>Krahn</surname>
<given-names>JB</given-names></string-name>, <string-name><surname>Drasar</surname>
<given-names>BS</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Detection of <italic toggle="yes">Brucella melitensis</italic> and <italic toggle="yes">Brucella abortus</italic> by DNA amplification</article-title>. <source>J Trop Med Hyg</source>. <year>1992</year>;<volume>95</volume>(<issue>4</issue>):<fpage>271</fpage>&#x2013;<lpage>275</lpage>.<pub-id pub-id-type="pmid">1495123</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0086">
        <label>86</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Navarro</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Escribano</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Fern&#xE1;ndez</surname>
<given-names>J</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Comparison of three different PCR methods for detection of <italic toggle="yes">Brucella</italic> spp. in human blood samples</article-title>. <source>FEMS Immunol Med Microbiol</source>. <year>2002</year>;<volume>34</volume>(<issue>2</issue>):<fpage>147</fpage>&#x2013;<lpage>151</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1574-695x.2002.tb00616.x</pub-id>.<pub-id pub-id-type="pmid">12381466</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0087">
        <label>87</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zerva</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Bourantas</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Mitka</surname>
<given-names>S</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Serum is the preferred clinical specimen for diagnosis of human brucellosis by PCR</article-title>. <source>J Clin Microbiol</source>. <year>2001</year>;<volume>39</volume>(<issue>4</issue>):<fpage>1661</fpage>&#x2013;<lpage>1664</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JCM.39.4.1661-1664.2001</pub-id>.<pub-id pub-id-type="pmid">11283112</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0088">
        <label>88</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>J</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Real-time PCR assays for diagnosing brucellar spondylitis using formalin-fixed paraffin-embedded tissues</article-title>. <source>Medicine</source>. <year>2018</year>;<volume>97</volume>(<issue>9</issue>):<fpage>e0062</fpage>. doi: <pub-id pub-id-type="doi">10.1097/MD.0000000000010062</pub-id>.<pub-id pub-id-type="pmid">29489665</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0089">
        <label>89</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gopaul</surname>
<given-names>KK</given-names></string-name>, <string-name><surname>Sells</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>R</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Development and assessment of multiplex high resolution melting assay as a tool for rapid single-tube identification of five <italic toggle="yes">Brucella</italic> species</article-title>. <source>BMC Res Notes</source>. <year>2014</year>;<volume>7</volume>(<issue>1</issue>):<fpage>903</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1756-0500-7-903</pub-id>.<pub-id pub-id-type="pmid">25495428</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0090">
        <label>90</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rajni Joshi</surname>
<given-names>NS.</given-names></string-name></person-group>
<article-title>Clinical, serological and molecular diagnosis of brucellosis in domestic animals</article-title>. <source>Int J Curr Microbiol Appl Sci</source>. <year>2021</year>;<volume>10</volume>(<issue>4</issue>):<fpage>368</fpage>&#x2013;<lpage>385</lpage>. doi: <pub-id pub-id-type="doi">10.20546/ijcmas.2021.1004.040</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0091">
        <label>91</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bosilkovski</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Keramat</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Arapovi&#x107;</surname>
<given-names>J.</given-names></string-name></person-group>
<article-title>The current therapeutical strategies in human brucellosis</article-title>. <source>Infection</source>. <year>2021</year>;<volume>49</volume>(<issue>5</issue>):<fpage>823</fpage>&#x2013;<lpage>832</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s15010-021-01586-w</pub-id>.<pub-id pub-id-type="pmid">33650077</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0092">
        <label>92</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Patra</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kalwaje Eshwara</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Pai</surname>
<given-names>AR</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Evaluation of clinical, diagnostic features and therapeutic outcome of neurobrucellosis: a case series and review of literature</article-title>. <source>Int J Neurosci</source>. <year>2022</year>;<volume>132</volume>(<issue>11</issue>):<fpage>1080</fpage>&#x2013;<lpage>1090</lpage>. doi: <pub-id pub-id-type="doi">10.1080/00207454.2020.1860969</pub-id>.<pub-id pub-id-type="pmid">33287603</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0093">
        <label>93</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Johansen</surname>
<given-names>TB</given-names></string-name>, <string-name><surname>Scheffer</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Jensen</surname>
<given-names>VK</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Whole-genome sequencing and antimicrobial resistance in <italic toggle="yes">Brucella melitensis</italic> from a Norwegian perspective</article-title>. <source>Sci Rep</source>. <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>8538</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-018-26906-3</pub-id>.<pub-id pub-id-type="pmid">29867163</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0094">
        <label>94</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reza Irajian</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Masjedian Jazi</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Mirnejad</surname>
<given-names>R</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Species-specific PCR for the diagnosis and determination of antibiotic susceptibilities of <italic toggle="yes">Brucella</italic> strains isolated from Tehran, Iran</article-title>. <source>Iran J Pathol</source>. <year>2016</year>;<volume>11</volume>(<issue>3</issue>):<fpage>238</fpage>&#x2013;<lpage>247</lpage>.<pub-id pub-id-type="pmid">27799972</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0095">
        <label>95</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shevtsov</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Syzdykov</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kuznetsov</surname>
<given-names>A</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Antimicrobial susceptibility of <italic toggle="yes">Brucella melitensis</italic> in Kazakhstan</article-title>. <source>Antimicrob Resist Infect Control</source>. <year>2017</year>;<volume>6</volume>(<issue>1</issue>):<fpage>130</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13756-017-0293-x</pub-id>.<pub-id pub-id-type="pmid">29299304</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0096">
        <label>96</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Doimari</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Singh</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Kumari</surname>
<given-names>R</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>In vitro antimicrobial susceptibility of <italic toggle="yes">Brucella</italic> species isolated from human and animals in India</article-title>. <source>J Antibiot Res</source>. <year>2019</year>;<volume>3</volume>:<fpage>1</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation>
      </ref>
      <ref id="CIT0097">
        <label>97</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maves</surname>
<given-names>RC</given-names></string-name>, <string-name><surname>Castillo</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Guillen</surname>
<given-names>A</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Antimicrobial susceptibility of <italic toggle="yes">Brucella melitensis</italic> isolates in Peru</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2011</year>;<volume>55</volume>(<issue>3</issue>):<fpage>1279</fpage>&#x2013;<lpage>1281</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.00979-10</pub-id>.<pub-id pub-id-type="pmid">21199926</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0098">
        <label>98</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cooke</surname>
<given-names>RPD</given-names></string-name>, <string-name><surname>Perrett</surname>
<given-names>L.</given-names></string-name></person-group>
<article-title>Antimicrobial susceptibility data for <italic toggle="yes">Brucella melitensis</italic> isolates cultured from UK patients</article-title>. <source>J Infect</source>. <year>2014</year>;<volume>68</volume>(<issue>4</issue>):<fpage>401</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jinf.2014.01.002</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0099">
        <label>99</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Carbonic anhydrases: novel therapeutic applications for inhibitors and activators</article-title>. <source>Nat Rev Drug Discov</source>. <year>2008</year>;<volume>7</volume>(<issue>2</issue>):<fpage>168</fpage>&#x2013;<lpage>181</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrd2467</pub-id>.<pub-id pub-id-type="pmid">18167490</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0100">
        <label>100</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aspatwar</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Kairys</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Rala</surname>
<given-names>S</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title><italic toggle="yes">Mycobacterium tuberculosis</italic> &#x3B2;-carbonic anhydrases: novel targets for developing antituberculosis drugs</article-title>. <source>Int J Mol Sci</source>. <year>2019</year>;<volume>20</volume>(<issue>20</issue>):<fpage>5153</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms20205153</pub-id>.<pub-id pub-id-type="pmid">31627429</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0101">
        <label>101</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>K&#xF6;hler</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ouahrani-Bettache</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Winum</surname>
<given-names>JY.</given-names></string-name></person-group>
<article-title><italic toggle="yes">Brucella suis</italic> carbonic anhydrases and their inhibitors: towards alternative antibiotics?</article-title>
<source>J Enzym Inhib Med Chem</source>. <year>2017</year>;<volume>32</volume>(<issue>1</issue>):<fpage>683</fpage>&#x2013;<lpage>687</lpage>. doi: <pub-id pub-id-type="doi">10.1080/14756366.2017.1295451</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0102">
        <label>102</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aspatwar</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Tolvanen</surname>
<given-names>MEE</given-names></string-name>, <string-name><surname>Barker</surname>
<given-names>H</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Carbonic anhydrases in metazoan model organisms: molecules, mechanisms, and physiology</article-title>. <source>Physiol Rev</source>. <year>2022</year>;<volume>102</volume>(<issue>3</issue>):<fpage>1327</fpage>&#x2013;<lpage>1383</lpage>. doi: <pub-id pub-id-type="doi">10.1152/physrev.00018.2021</pub-id>.<pub-id pub-id-type="pmid">35166161</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0103">
        <label>103</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aspatwar</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Parvathaneni</surname>
<given-names>NK</given-names></string-name>, <string-name><surname>Barker</surname>
<given-names>H</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Design, synthesis, in vitro inhibition and toxicological evaluation of human carbonic anhydrases I, II and IX inhibitors in 5-nitroimidazole series</article-title>. <source>J Enzyme Inhib Med Chem</source>. <year>2020</year>;<volume>35</volume>(<issue>1</issue>):<fpage>109</fpage>&#x2013;<lpage>117</lpage>. doi: <pub-id pub-id-type="doi">10.1080/14756366.2019.1685510</pub-id>.<pub-id pub-id-type="pmid">31687859</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0104">
        <label>104</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aspatwar</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT</given-names></string-name>, <string-name><surname>Waheed</surname>
<given-names>A</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Mitochondrial carbonic anhydrase VA and VB: properties and roles in health and disease</article-title>. <source>J Physiol</source>. <year>2023</year>;<volume>601</volume>(<issue>2</issue>):<fpage>257</fpage>&#x2013;<lpage>274</lpage>. doi: <pub-id pub-id-type="doi">10.1113/JP283579</pub-id>.<pub-id pub-id-type="pmid">36464834</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0105">
        <label>105</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abdoli</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Bonardi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Paoletti</surname>
<given-names>N</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Inhibition studies on human and mycobacterial carbonic anhydrases with N-((4-sulfamoylphenyl)carbamothioyl) amides</article-title>. <source>Molecules</source>. <year>2023</year>;<volume>28</volume>(<issue>10</issue>):<fpage>4020</fpage>. doi: <pub-id pub-id-type="doi">10.3390/molecules28104020</pub-id>.<pub-id pub-id-type="pmid">37241761</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0106">
        <label>106</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aspatwar</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Barker</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Aisala</surname>
<given-names>H</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Cloning, purification, kinetic and anion inhibition studies of a recombinant &#x3B2;-carbonic anhydrase from the Atlantic salmon parasite platyhelminth <italic toggle="yes">Gyrodactylus salaris</italic></article-title>. <source>J Enzyme Inhib Med Chem</source>. <year>2022</year>;<volume>37</volume>(<issue>1</issue>):<fpage>1577</fpage>&#x2013;<lpage>1586</lpage>. doi: <pub-id pub-id-type="doi">10.1080/14756366.2022.2080818</pub-id>.<pub-id pub-id-type="pmid">35637617</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0107">
        <label>107</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aspatwar</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Bonardi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Aisala</surname>
<given-names>H</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Sulphonamide inhibition studies of the &#x3B2;-carbonic anhydrase GsaCA&#x3B2; present in the salmon platyhelminth parasite <italic toggle="yes">Gyrodactylus salaris</italic></article-title>. <source>J Enzyme Inhib Med Chem</source>. <year>2023</year>;<volume>38</volume>(<issue>1</issue>):<fpage>2167988</fpage>. doi: <pub-id pub-id-type="doi">10.1080/14756366.2023.2167988</pub-id>.<pub-id pub-id-type="pmid">36647786</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0108">
        <label>108</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aspatwar</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hammaren</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Parikka</surname>
<given-names>M</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>In vitro inhibition of <italic toggle="yes">Mycobacterium tuberculosis</italic> &#x3B2;-carbonic anhydrase 3 with mono- and dithiocarbamates and evaluation of their toxicity using zebrafish developing embryos</article-title>. <source>J Enzyme Inhib Med Chem</source>. <year>2020</year>;<volume>35</volume>(<issue>1</issue>):<fpage>65</fpage>&#x2013;<lpage>71</lpage>. doi: <pub-id pub-id-type="doi">10.1080/14756366.2019.1683007</pub-id>.<pub-id pub-id-type="pmid">31663386</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0109">
        <label>109</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aspatwar</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Winum</surname>
<given-names>JY</given-names></string-name>, <string-name><surname>Carta</surname>
<given-names>F</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitors as novel drugs against mycobacterial &#x3B2;-carbonic anhydrases: an update on in vitro and in vivo studies</article-title>. <source>Molecules</source>. <year>2018</year>;<volume>23</volume>(<issue>11</issue>):<fpage>2911</fpage>. doi: <pub-id pub-id-type="doi">10.3390/molecules23112911</pub-id>.<pub-id pub-id-type="pmid">30413024</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0110">
        <label>110</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Bacterial carbonic anhydrases as drug targets: toward novel antibiotics?</article-title>
<source>Front Pharmacol</source>. <year>2011</year>;<volume>2</volume>:<fpage>34</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2011.00034</pub-id>.<pub-id pub-id-type="pmid">21779249</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0111">
        <label>111</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aspatwar</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hammar&#xE9;n</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Koskinen</surname>
<given-names>S</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>&#x3B2;-CA-specific inhibitor dithiocarbamate Fc14&#x2013;584B: a novel antimycobacterial agent with potential to treat drug-resistant tuberculosis</article-title>. <source>J Enzyme Inhib Med Chem</source>. <year>2017</year>;<volume>32</volume>(<issue>1</issue>):<fpage>832</fpage>&#x2013;<lpage>840</lpage>. doi: <pub-id pub-id-type="doi">10.1080/14756366.2017.1332056</pub-id>.<pub-id pub-id-type="pmid">28629306</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0112">
        <label>112</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maresca</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Scozzafava</surname>
<given-names>A</given-names></string-name>, <string-name><surname>K&#xF6;hler</surname>
<given-names>S</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Inhibition of beta-carbonic anhydrases from the bacterial pathogen <italic toggle="yes">Brucella suis</italic> with inorganic anions</article-title>. <source>J Inorg Biochem</source>. <year>2012</year>;<volume>110</volume>:<fpage>36</fpage>&#x2013;<lpage>39</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jinorgbio.2012.02.009</pub-id>.<pub-id pub-id-type="pmid">22459172</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0113">
        <label>113</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Nishimori</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Scozzafava</surname>
<given-names>A</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Inhibition studies of a &#x3B2;-carbonic anhydrase from <italic toggle="yes">Brucella suis</italic> with a series of water soluble glycosyl sulfanilamides</article-title>. <source>Bioorg Med Chem Lett</source>. <year>2010</year>;<volume>20</volume>(<issue>7</issue>):<fpage>2178</fpage>&#x2013;<lpage>2182</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bmcl.2010.02.042</pub-id>.<pub-id pub-id-type="pmid">20211561</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0114">
        <label>114</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Heidary</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Dashtbin</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ghanavati</surname>
<given-names>R</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Evaluation of brucellosis vaccines: a comprehensive review</article-title>. <source>Front Vet Sci</source>. <year>2022</year>;<volume>9</volume>:<fpage>925773</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fvets.2022.925773</pub-id>.<pub-id pub-id-type="pmid">35923818</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0115">
        <label>115</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Montaraz</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Winter</surname>
<given-names>AJ.</given-names></string-name></person-group>
<article-title>Comparison of living and nonliving vaccines for <italic toggle="yes">Brucella abortus</italic> in BALB/c mice</article-title>. <source>Infect Immun</source>. <year>1986</year>;<volume>53</volume>(<issue>2</issue>):<fpage>245</fpage>&#x2013;<lpage>251</lpage>. doi: <pub-id pub-id-type="doi">10.1128/iai.53.2.245-251.1986</pub-id>.<pub-id pub-id-type="pmid">3089933</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0116">
        <label>116</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Skyberg</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Cao</surname>
<given-names>L</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Progress in <italic toggle="yes">Brucella</italic> vaccine development</article-title>. <source>Front Biol</source>. <year>2013</year>;<volume>8</volume>(<issue>1</issue>):<fpage>60</fpage>&#x2013;<lpage>77</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11515-012-1196-0</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0117">
        <label>117</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mansoori</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Pourmand</surname>
<given-names>MR.</given-names></string-name></person-group>
<article-title>Vaccines and vaccine candidates against brucellosis</article-title>. <source>Infect Epidemiol Microbiol</source>. <year>2016</year>;<volume>2</volume>(<issue>4</issue>):<fpage>32</fpage>&#x2013;<lpage>36</lpage>. doi: <pub-id pub-id-type="doi">10.18869/modares.iem.2.4.32</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0118">
        <label>118</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>
<given-names>ZQ</given-names></string-name>, <string-name><surname>Shi</surname>
<given-names>JX</given-names></string-name>, <string-name><surname>Fu</surname>
<given-names>WD</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>A <italic toggle="yes">Brucella melitensis</italic> M5-90 wboA deletion strain is attenuated and enhances vaccine efficacy</article-title>. <source>Mol Immunol</source>. <year>2015a</year>;<volume>66</volume>(<issue>2</issue>):<fpage>276</fpage>&#x2013;<lpage>283</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.molimm.2015.04.004</pub-id>.<pub-id pub-id-type="pmid">25899866</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0119">
        <label>119</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Truong</surname>
<given-names>QL</given-names></string-name>, <string-name><surname>Cho</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>K</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Booster vaccination with safe, modified, live-attenuated mutants of <italic toggle="yes">Brucella abortus</italic> strain RB51 vaccine confers protective immunity against virulent strains of <italic toggle="yes">B. abortus</italic> and <italic toggle="yes">Brucella canis</italic> in BALB/c mice</article-title>. <source>Microbiology</source>. <year>2015</year>;<volume>161</volume>(<issue>11</issue>):<fpage>2137</fpage>&#x2013;<lpage>2148</lpage>. doi: <pub-id pub-id-type="doi">10.1099/mic.0.000170</pub-id>.<pub-id pub-id-type="pmid">26341622</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0120">
        <label>120</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Feng</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>G</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title><italic toggle="yes">Brucella suis</italic> strain 2 vaccine is safe and protective against heterologous <italic toggle="yes">Brucella</italic> spp. infections</article-title>. <source>Vaccine</source>. <year>2016</year>;<volume>34</volume>(<issue>3</issue>):<fpage>395</fpage>&#x2013;<lpage>400</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.09.116</pub-id>.<pub-id pub-id-type="pmid">26626213</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0121">
        <label>121</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Verger</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Grayon</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Zundel</surname>
<given-names>E</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Comparison of the efficacy of <italic toggle="yes">Brucella suis</italic> strain 2 and <italic toggle="yes">Brucella melitensis</italic> rev. 1 live vaccines against a <italic toggle="yes">Brucella melitensis</italic> experimental infection in pregnant ewes</article-title>. <source>Vaccine</source>. <year>1995</year>;<volume>13</volume>(<issue>2</issue>):<fpage>191</fpage>&#x2013;<lpage>196</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0264-410X(95)93135-V</pub-id>.<pub-id pub-id-type="pmid">7625115</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0122">
        <label>122</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gheibi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Khanahmad</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Kashfi</surname>
<given-names>K</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Development of new generation of vaccines for <italic toggle="yes">Brucella abortus</italic></article-title>. <source>Heliyon</source>. <year>2018</year>;<volume>4</volume>(<issue>12</issue>):<fpage>e01079</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.heliyon.2018.e01079</pub-id>.<pub-id pub-id-type="pmid">30603712</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0123">
        <label>123</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>C</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title><italic toggle="yes">Brucella melitensis</italic> 16M&#x394;hfq attenuation confers protection against wild-type challenge in BALB/c mice</article-title>. <source>Microbiol Immunol</source>. <year>2013</year>;<volume>57</volume>(<issue>7</issue>):<fpage>502</fpage>&#x2013;<lpage>510</lpage>. doi: <pub-id pub-id-type="doi">10.1111/1348-0421.12065</pub-id>.<pub-id pub-id-type="pmid">23647412</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0124">
        <label>124</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>K</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title><italic toggle="yes">Brucella melitensis</italic> 16M&#x394;TcfSR as a potential live vaccine allows for the differentiation between natural and vaccinated infection</article-title>. <source>Exp Ther Med</source>. <year>2015b</year>;<volume>10</volume>(<issue>3</issue>):<fpage>1182</fpage>&#x2013;<lpage>1188</lpage>. doi: <pub-id pub-id-type="doi">10.3892/etm.2015.2619</pub-id>.<pub-id pub-id-type="pmid">26622461</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0125">
        <label>125</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Niu</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Ui Wang</surname>
<given-names>XLe</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Evaluation of a <italic toggle="yes">Brucella melitensis</italic> mutant deficient in O-polysaccharide export system ATP-binding protein as a rough vaccine candidate</article-title>. <source>Microbes Infect</source>. <year>2014</year>;<volume>16</volume>(<issue>8</issue>):<fpage>633</fpage>&#x2013;<lpage>639</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.micinf.2014.06.013</pub-id>.<pub-id pub-id-type="pmid">25043564</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0126">
        <label>126</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Costa</surname>
<given-names>LF</given-names></string-name>, <string-name><surname>Cabello</surname>
<given-names>AL</given-names></string-name>, <string-name><surname>Batista</surname>
<given-names>DFA</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>The candidate vaccine strain <italic toggle="yes">Brucella ovis</italic> &#x394;abcBA is protective against <italic toggle="yes">Brucella melitensis</italic> infection in mice</article-title>. <source>Microbiol Immunol</source>. <year>2020</year>;<volume>64</volume>(<issue>11</issue>):<fpage>730</fpage>&#x2013;<lpage>736</lpage>. doi: <pub-id pub-id-type="doi">10.1111/1348-0421.12850</pub-id>.<pub-id pub-id-type="pmid">32965738</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0127">
        <label>127</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bao</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Tian</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>P</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Characterization of <italic toggle="yes">Brucella abortus</italic> mutant strain &#x394;22915, a potential vaccine candidate</article-title>. <source>Vet Res</source>. <year>2017</year>;<volume>48</volume>(<issue>1</issue>):<fpage>17</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13567-017-0422-9</pub-id>.<pub-id pub-id-type="pmid">28376905</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0128">
        <label>128</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Czibener</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Del Giudice</surname>
<given-names>MG</given-names></string-name>, <string-name><surname>Spera</surname>
<given-names>JM</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Delta-pgm, a new live-attenuated vaccine against <italic toggle="yes">Brucella suis</italic></article-title>. <source>Vaccine</source>. <year>2016</year>;<volume>34</volume>(<issue>13</issue>):<fpage>1524</fpage>&#x2013;<lpage>1530</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.02.025</pub-id>.<pub-id pub-id-type="pmid">26899373</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0129">
        <label>129</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jain-Gupta</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Waldrop</surname>
<given-names>SG</given-names></string-name>, <string-name><surname>Tenpenny</surname>
<given-names>NM</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Rough <italic toggle="yes">Brucella neotomae</italic> provides protection against <italic toggle="yes">Brucella suis</italic> challenge in mice</article-title>. <source>Vet Microbiol</source>. <year>2019</year>;<volume>239</volume>:<fpage>108447</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vetmic.2019.108447</pub-id>.<pub-id pub-id-type="pmid">31767087</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0130">
        <label>130</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ficht</surname>
<given-names>TA</given-names></string-name>, <string-name><surname>Kahl-McDonagh</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Arenas-Gamboa</surname>
<given-names>AM</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Brucellosis: the case for live, attenuated vaccines</article-title>. <source>Vaccine</source>. <year>2009</year>;<volume>27</volume>(<issue>Suppl. 4</issue>):<fpage>D40</fpage>&#x2013;<lpage>D43</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2009.08.058</pub-id>.<pub-id pub-id-type="pmid">19837284</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0131">
        <label>131</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Perkins</surname>
<given-names>SD</given-names></string-name>, <string-name><surname>Smither</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Atkins</surname>
<given-names>HS.</given-names></string-name></person-group>
<article-title>Towards a <italic toggle="yes">Brucella</italic> vaccine for humans</article-title>. <source>FEMS Microbiol Rev</source>. <year>2010</year>;<volume>34</volume>(<issue>3</issue>):<fpage>379</fpage>&#x2013;<lpage>394</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1574-6976.2010.00211.x</pub-id>.<pub-id pub-id-type="pmid">20180858</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0132">
        <label>132</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zimmermann</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Curtis</surname>
<given-names>N.</given-names></string-name></person-group>
<article-title>Factors that influence the immune response to vaccination</article-title>. <source>Clin Microbiol Rev</source>. <year>2019</year>;<volume>32</volume>(<issue>2</issue>):<fpage>e00084</fpage>. doi: <pub-id pub-id-type="doi">10.1128/CMR.00084-18</pub-id>.<pub-id pub-id-type="pmid">30867162</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0133">
        <label>133</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abdollahi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Mansouri</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Amani</surname>
<given-names>J</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>A recombinant chimera protein as a novel <italic toggle="yes">Brucella</italic> subunit vaccine: protective efficacy and induced immune response in BALB/c mice</article-title>. <source>Jundishapur J Microbiol</source>. <year>2018</year>;<volume>11</volume>(<issue>1</issue>):<fpage>1</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.5812/jjm.12776</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0134">
        <label>134</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ghasemi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Jeddi-Tehrani</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mautner</surname>
<given-names>J</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Immunization of mice with a novel recombinant molecular chaperon confers protection against <italic toggle="yes">Brucella melitensis</italic> infection</article-title>. <source>Vaccine</source>. <year>2014</year>;<volume>32</volume>(<issue>49</issue>):<fpage>6659</fpage>&#x2013;<lpage>6666</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.09.013</pub-id>.<pub-id pub-id-type="pmid">25240754</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0135">
        <label>135</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sadeghi</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Fasihi-Ramandi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Bouzari</surname>
<given-names>S.</given-names></string-name></person-group>
<article-title>Evaluation of immunogenicity of novel multi-epitope subunit vaccines in combination with poly I: c against <italic toggle="yes">Brucella melitensis</italic> and <italic toggle="yes">Brucella abortus</italic> infection</article-title>. <source>Int Immunopharmacol</source>. <year>2019</year>;<volume>75</volume>:<fpage>105829</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.intimp.2019.105829</pub-id>.<pub-id pub-id-type="pmid">31437796</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0136">
        <label>136</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Delpino</surname>
<given-names>MV</given-names></string-name>, <string-name><surname>Estein</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Fossati</surname>
<given-names>CA</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Vaccination with <italic toggle="yes">Brucella</italic> recombinant DnaK and SurA proteins induces protection against <italic toggle="yes">Brucella abortus</italic> infection in BALB/c mice</article-title>. <source>Vaccine</source>. <year>2007</year>;<volume>25</volume>(<issue>37&#x2013;38</issue>):<fpage>6721</fpage>&#x2013;<lpage>6729</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2007.07.002</pub-id>.<pub-id pub-id-type="pmid">17686554</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0137">
        <label>137</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abkar</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Fasihi-Ramandi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kooshki</surname>
<given-names>H</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Oral immunization of mice with Omp31-loaded N-trimethyl chitosan nanoparticles induces high protection against <italic toggle="yes">Brucella melitensis</italic> infection</article-title>. <source>Int J Nanomedicine</source>. <year>2017</year>;<volume>12</volume>:<fpage>8769</fpage>&#x2013;<lpage>8778</lpage>. doi: <pub-id pub-id-type="doi">10.2147/IJN.S149774</pub-id>.<pub-id pub-id-type="pmid">29263667</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0138">
        <label>138</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maleki</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Salouti</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Shafiee Ardestani</surname>
<given-names>M</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Preparation of a nanovaccine against <italic toggle="yes">Brucella melitensis</italic> M16 based on PLGA nanoparticles and oligopolysaccharide antigen</article-title>. <source>Artif Cells Nanomed Biotechnol</source>. <year>2019</year>;<volume>47</volume>(<issue>1</issue>):<fpage>4248</fpage>&#x2013;<lpage>4256</lpage>. doi: <pub-id pub-id-type="doi">10.1080/21691401.2019.1687490</pub-id>.<pub-id pub-id-type="pmid">31718300</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0139">
        <label>139</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Al-Halifa</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Gauthier</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Arpin</surname>
<given-names>D</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Nanoparticle-based vaccines against respiratory viruses</article-title>. <source>Front Immunol</source>. <year>2019</year>;<volume>10</volume>:<fpage>22</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2019.00022</pub-id>.<pub-id pub-id-type="pmid">30733717</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0140">
        <label>140</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leclerq</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Harms</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Rosinha</surname>
<given-names>GMS</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Induction of a Th1-type of immune response but not protective immunity by intramuscular DNA immunisation with <italic toggle="yes">Brucella abortus</italic> GroEL heat-shock gene</article-title>. <source>J Med Microbiol</source>. <year>2002</year>;<volume>51</volume>(<issue>1</issue>):<fpage>20</fpage>&#x2013;<lpage>26</lpage>. doi: <pub-id pub-id-type="doi">10.1099/0022-1317-51-1-20</pub-id>.<pub-id pub-id-type="pmid">11803949</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0141">
        <label>141</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Afshari</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Maleki</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Salouti</surname>
<given-names>M.</given-names></string-name></person-group>
<article-title>Immunological effects of two new nanovaccines against <italic toggle="yes">Brucella</italic> based on OPS and LPS antigens conjugated with PLGA nanoparticles</article-title>. <source>Eur Polym J</source>. <year>2020</year>;<volume>139</volume>:<fpage>110021</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.eurpolymj.2020.110021</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0142">
        <label>142</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hu</surname>
<given-names>XD</given-names></string-name>, <string-name><surname>Yu</surname>
<given-names>DH</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>ST</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>A combined DNA vaccine provides protective immunity against <italic toggle="yes">Mycobacterium bovis</italic> and <italic toggle="yes">Brucella abortus</italic> in cattle</article-title>. <source>DNA Cell Biol</source>. <year>2009</year>;<volume>28</volume>(<issue>4</issue>):<fpage>191</fpage>&#x2013;<lpage>199</lpage>. doi: <pub-id pub-id-type="doi">10.1089/dna.2008.0790</pub-id>.<pub-id pub-id-type="pmid">19364278</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0143">
        <label>143</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Zhao</surname>
<given-names>Z</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Evaluation of a DNA vaccine encoding <italic toggle="yes">Brucella</italic> BvrR in BALB/c mice</article-title>. <source>Mol Med Rep</source>. <year>2019</year>;<volume>19</volume>(<issue>2</issue>):<fpage>1302</fpage>&#x2013;<lpage>1308</lpage>. doi: <pub-id pub-id-type="doi">10.3892/mmr.2018.9735</pub-id>.<pub-id pub-id-type="pmid">30569140</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0144">
        <label>144</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jain</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Afley</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Dohre</surname>
<given-names>SK</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Evaluation of immunogenicity and protective efficacy of a plasmid DNA vaccine encoding ribosomal protein L9 of <italic toggle="yes">Brucella abortus</italic> in BALB/c mice</article-title>. <source>Vaccine</source>. <year>2014</year>;<volume>32</volume>(<issue>35</issue>):<fpage>4537</fpage>&#x2013;<lpage>4542</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.06.012</pub-id>.<pub-id pub-id-type="pmid">24950353</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0145">
        <label>145</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Velikovsky</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Cassataro</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Sanchez</surname>
<given-names>M</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Single-shot plasmid DNA intrasplenic immunization for the production of monoclonal antibodies. Persistent expression of DNA</article-title>. <source>J Immunol Methods</source>. <year>2000</year>;<volume>244</volume>(<issue>1&#x2013;2</issue>):<fpage>1</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0022-1759(00)00244-1</pub-id>.<pub-id pub-id-type="pmid">11033013</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0146">
        <label>146</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Al-Mariri</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Tibor</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lestrate</surname>
<given-names>P</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding <italic toggle="yes">Brucella abortus</italic> bacterioferritin or P39 antigen</article-title>. <source>Infect Immun</source>. <year>2002</year>;<volume>70</volume>(<issue>4</issue>):<fpage>1915</fpage>&#x2013;<lpage>1923</lpage>. doi: <pub-id pub-id-type="doi">10.1128/IAI.70.4.1915-1923.2002</pub-id>.<pub-id pub-id-type="pmid">11895955</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0147">
        <label>147</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Senevirathne</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hewawaduge</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>JH.</given-names></string-name></person-group>
<article-title>Attenuated <italic toggle="yes">Salmonella</italic> secreting <italic toggle="yes">Brucella</italic> protective antigens confer dual-faceted protection against brucellosis and salmonellosis in a mouse model</article-title>. <source>Vet Immunol Immunopathol</source>. <year>2019</year>;<volume>209</volume>:<fpage>31</fpage>&#x2013;<lpage>36</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vetimm.2019.02.001</pub-id>.<pub-id pub-id-type="pmid">30885303</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0148">
        <label>148</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bugybayeva</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Ryskeldinova</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Zinina</surname>
<given-names>N</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Development of human vectored brucellosis vaccine formulation: assessment of safety and protectiveness of influenza viral vectors expressing <italic toggle="yes">Brucella</italic> immunodominant proteins in mice and Guinea pigs</article-title>. <source>Biomed Res Int</source>. <year>2020</year>;<volume>2020</volume>:<fpage>1438928</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2020/1438928</pub-id>.<pub-id pub-id-type="pmid">33274194</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0149">
        <label>149</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mohammadi</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Golchin</surname>
<given-names>M.</given-names></string-name></person-group>
<article-title>High protection of mice against <italic toggle="yes">Brucella abortus</italic> by oral immunization with recombinant probiotic <italic toggle="yes">Lactobacillus casei</italic> vector vaccine, expressing the outer membrane protein OMP19 of <italic toggle="yes">Brucella</italic> species</article-title>. <source>Comp Immunol Microbiol Infect Dis</source>. <year>2020</year>;<volume>70</volume>:<fpage>101470</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cimid.2020.101470</pub-id>.<pub-id pub-id-type="pmid">32208191</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0150">
        <label>150</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lin</surname>
<given-names>GZ</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>YZ</given-names></string-name>, <string-name><surname>Cai</surname>
<given-names>KZ</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title><italic toggle="yes">Brucella abortus</italic> L7/L12 ve BCSP31 Proteinlerini Birlikte Eksprese Eden Rekombinant Adenoviruslar&#x131;n immunojenitesi</article-title>. <source>Kafkas Univ Vet Fak Derg</source>. <year>2018</year>;<volume>24</volume>(<issue>2</issue>):<fpage>211</fpage>&#x2013;<lpage>217</lpage>. doi: <pub-id pub-id-type="doi">10.9775/kvfd.2017.18644</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0151">
        <label>151</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bugybayeva</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Kydyrbayev</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Zinina</surname>
<given-names>N</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>A new candidate vaccine for human brucellosis based on influenza viral vectors: a preliminary investigation for the development of an immunization schedule in a Guinea pig model</article-title>. <source>Infect Dis Poverty</source>. <year>2021</year>;<volume>10</volume>(<issue>1</issue>):<fpage>13</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40249-021-00801-y</pub-id>.<pub-id pub-id-type="pmid">33593447</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0152">
        <label>152</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tabynov</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Sansyzbay</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Kydyrbayev</surname>
<given-names>Z</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Influenza viral vectors expressing the <italic toggle="yes">Brucella</italic> OMP16 or L7/L12 proteins as vaccines against <italic toggle="yes">B. abortus</italic> infection</article-title>. <source>Virol J</source>. <year>2014</year>;<volume>11</volume>(<issue>1</issue>):<fpage>69</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1743-422X-11-69</pub-id>.<pub-id pub-id-type="pmid">24716528</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0153">
        <label>153</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>S&#xE1;ez</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Fern&#xE1;ndez</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Rivera</surname>
<given-names>A</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Oral immunization of mice with recombinant <italic toggle="yes">Lactococcus lactis</italic> expressing Cu, Zn superoxide dismutase of <italic toggle="yes">Brucella abortus</italic> triggers protective immunity</article-title>. <source>Vaccine</source>. <year>2012</year>;<volume>30</volume>(<issue>7</issue>):<fpage>1283</fpage>&#x2013;<lpage>1290</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2011.12.088</pub-id>.<pub-id pub-id-type="pmid">22222868</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0154">
        <label>154</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cassataro</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Estein</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Pasquevich</surname>
<given-names>KA</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Vaccination with the recombinant <italic toggle="yes">Brucella</italic> outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against <italic toggle="yes">Brucella melitensis</italic> infection</article-title>. <source>Infect Immun</source>. <year>2005</year>;<volume>73</volume>(<issue>12</issue>):<fpage>8079</fpage>&#x2013;<lpage>8088</lpage>. doi: <pub-id pub-id-type="doi">10.1128/IAI.73.12.8079-8088.2005</pub-id>.<pub-id pub-id-type="pmid">16299302</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0155">
        <label>155</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>De la Rosa-Ramos</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Arellano-Reynoso</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Hern&#xE1;ndez-Badillo</surname>
<given-names>E</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Evaluation of the goat cellular immune response to rBtuB-Hia-FlgK peptides from <italic toggle="yes">Brucella melitensis</italic></article-title>. <source>Comp Immunol Microbiol Infect Dis</source>. <year>2023</year>;<volume>94</volume>:<fpage>101944</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cimid.2023.101944</pub-id>.<pub-id pub-id-type="pmid">36638645</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0156">
        <label>156</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nejad</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Krecek</surname>
<given-names>RC</given-names></string-name>, <string-name><surname>Khalaf</surname>
<given-names>OH</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Brucellosis in the Middle East: current situation and a pathway forward</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2020</year>;<volume>14</volume>(<issue>5</issue>):<fpage>e0008071</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pntd.0008071</pub-id>.<pub-id pub-id-type="pmid">32437346</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0157">
        <label>157</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Addis</surname>
<given-names>M.</given-names></string-name></person-group>
<article-title>Public health and economic importance of brucellosis: a review</article-title>. <source>Public Policy Admin Res</source>. <year>2015</year>;<volume>5</volume>(<issue>7</issue>):<fpage>2225</fpage>&#x2013;<lpage>2972</lpage>.</mixed-citation>
      </ref>
      <ref id="CIT0158">
        <label>158</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Islam</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Khatun</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Werre</surname>
<given-names>SR</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>A review of <italic toggle="yes">Brucella</italic> seroprevalence among humans and animals in Bangladesh with special emphasis on epidemiology, risk factors and control opportunities</article-title>. <source>Vet Microbiol</source>. <year>2013</year>;<volume>166</volume>(<issue>3&#x2013;4</issue>):<fpage>317</fpage>&#x2013;<lpage>326</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vetmic.2013.06.014</pub-id>.<pub-id pub-id-type="pmid">23867082</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0159">
        <label>159</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Alewy Almashhadany</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Zefenkey</surname>
<given-names>ZF</given-names></string-name>, <string-name><surname>Hassannejad</surname>
<given-names>S</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group> Milk borne brucellosis. In: Ibrahim SA, editor. Current issues and advances in the dairy industry. IntechOpen; <year>2023</year>. doi: <pub-id pub-id-type="doi">10.5772/intechopen.109124</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0160">
        <label>160</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Di Bari</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Venkateswaran</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Bruce</surname>
<given-names>M</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Methodological choices in brucellosis burden of disease assessments: a systematic review</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2022</year>;<volume>16</volume>(<issue>12</issue>):<fpage>e0010468</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pntd.0010468</pub-id>.<pub-id pub-id-type="pmid">36512611</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0161">
        <label>161</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Herrera</surname>
<given-names>JAR</given-names></string-name>, <string-name><surname>Thomsen</surname>
<given-names>ST</given-names></string-name>, <string-name><surname>Jakobsen</surname>
<given-names>LS</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>The burden of disease of three food-associated heavy metals in clusters in the Danish population&#x2013;towards targeted public health strategies</article-title>. <source>Food Chem Toxicol</source>. <year>2021</year>;<volume>150</volume>:<fpage>112072</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.fct.2021.112072</pub-id>.<pub-id pub-id-type="pmid">33610621</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0162">
        <label>162</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Golshani</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Buozari</surname>
<given-names>S.</given-names></string-name></person-group>
<article-title>A review of brucellosis in Iran: epidemiology, risk factors, diagnosis, control, and prevention</article-title>. <source>Iran Biomed J</source>. <year>2017</year>;<volume>21</volume>(<issue>6</issue>):<fpage>349</fpage>&#x2013;<lpage>359</lpage>. doi: <pub-id pub-id-type="doi">10.18869/acadpub.ibj.21.6.349</pub-id>.<pub-id pub-id-type="pmid">28766326</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0163">
        <label>163</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Franc</surname>
<given-names>KA</given-names></string-name>, <string-name><surname>Krecek</surname>
<given-names>RC</given-names></string-name>, <string-name><surname>H&#xE4;sler</surname>
<given-names>BN</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Brucellosis remains a neglected disease in the developing world: a call for interdisciplinary action</article-title>. <source>BMC Public Health</source>. <year>2018</year>;<volume>18</volume>(<issue>1</issue>):<fpage>125</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12889-017-5016-y</pub-id>.<pub-id pub-id-type="pmid">29325516</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0164">
        <label>164</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dowdle</surname>
<given-names>WR.</given-names></string-name></person-group>
<article-title>The principles of disease elimination and eradication</article-title>. <source>Bull World Health Org</source>. <year>1998</year>;<volume>76</volume>(<issue>Suppl. 2</issue>):<fpage>22</fpage>&#x2013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">10063669</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0165">
        <label>165</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Murray</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Cohen</surname>
<given-names>AL.</given-names></string-name></person-group>
<part-title>Infectious disease surveillance</part-title>. <source>Int Encycloped Public Health</source>. <year>2016</year>;<volume>2016</volume>:<fpage>222</fpage>&#x2013;<lpage>229</lpage>. doi: <pub-id pub-id-type="doi">10.1016/B978-0-12-803678-5.00517-8</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0166">
        <label>166</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Roth</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Zinsstag</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Orkhon</surname>
<given-names>D</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Human health benefits from livestock vaccination for brucellosis: case study</article-title>. <source>Bull World Health Organ</source>. <year>2003</year>;<volume>81</volume>(<issue>12</issue>):<fpage>867</fpage>&#x2013;<lpage>876</lpage>.<pub-id pub-id-type="pmid">14997239</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0167">
        <label>167</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dalrymple-Champneys</surname>
<given-names>W.</given-names></string-name></person-group>
<article-title>Undulant fever a neglected problem</article-title>. <source>The Lancet</source>. <year>1950</year>;<volume>255</volume>(<issue>6602</issue>):<fpage>429</fpage>&#x2013;<lpage>435</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(50)90361-8</pub-id>.</mixed-citation>
      </ref>
      <ref id="CIT0168">
        <label>168</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wyatt</surname>
<given-names>HV.</given-names></string-name></person-group>
<article-title>Brucellosis and Maltese goats in the Mediterranean</article-title>. <source>J Malt Hist</source>. <year>2009</year>;<volume>1</volume>(<issue>2</issue>):<fpage>4</fpage>.</mixed-citation>
      </ref>
      <ref id="CIT0169">
        <label>169</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Riedel</surname>
<given-names>S.</given-names></string-name></person-group>
<article-title>Biological warfare and bioterrorism: a historical review</article-title>. <source>Proc (Bayl Univ Med Cent)</source>. <year>2004</year>;<volume>17</volume>(<issue>4</issue>):<fpage>400</fpage>&#x2013;<lpage>406</lpage>. doi: <pub-id pub-id-type="doi">10.1080/08998280.2004.11928002</pub-id>.<pub-id pub-id-type="pmid">16200127</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0170">
        <label>170</label>
        <mixed-citation publication-type="webpage">Centers for Disease Control and Prevention. Risks from unpasteurized dairy products. Risk of exposure. Brucellosis. CDC; <year>2019</year>. Available from: <ext-link xlink:href="https://www.cdc.gov/brucellosis/exposure/unpasteurized-dairy-products.html" ext-link-type="uri">https://www.cdc.gov/brucellosis/exposure/unpasteurized-dairy-products.html</ext-link></mixed-citation>
      </ref>
      <ref id="CIT0171">
        <label>171</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yuan</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Zou</surname>
<given-names>H</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Emergency response to occupational brucellosis in a pharmaceutical manufacturing enterprise</article-title>. <source>J Occup Health</source>. <year>2018</year>;<volume>60</volume>(<issue>5</issue>):<fpage>404</fpage>&#x2013;<lpage>409</lpage>. doi: <pub-id pub-id-type="doi">10.1539/joh.2018-0089-CS</pub-id>.<pub-id pub-id-type="pmid">30068856</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0172">
        <label>172</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Elbehiry</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Aldubaib</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Marzouk</surname>
<given-names>E</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>The development of diagnostic and vaccine strategies for early detection and control of human brucellosis, particularly in endemic areas</article-title>. <source>Vaccines</source>. <year>2023</year>;<volume>11</volume>(<issue>3</issue>):<fpage>654</fpage>. doi: <pub-id pub-id-type="doi">10.3390/vaccines11030654</pub-id>.<pub-id pub-id-type="pmid">36992237</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0173">
        <label>173</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Micoli</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Bagnoli</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Rappuoli</surname>
<given-names>R</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>The role of vaccines in combatting antimicrobial resistance</article-title>. <source>Nat Rev Microbiol</source>. <year>2021</year>;<volume>19</volume>(<issue>5</issue>):<fpage>287</fpage>&#x2013;<lpage>302</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41579-020-00506-3</pub-id>.<pub-id pub-id-type="pmid">33542518</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0174">
        <label>174</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Behl</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Kaur</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Sehgal</surname>
<given-names>A</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Bioinformatics accelerates the major tetrad: a real boost for the pharmaceutical industry</article-title>. <source>Int J Mol Sci</source>. <year>2021</year>;<volume>22</volume>(<issue>12</issue>):<fpage>6184</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms22126184</pub-id>.<pub-id pub-id-type="pmid">34201152</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0175">
        <label>175</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>S</given-names></string-name>, <etal>et&#xA0;al.</etal></person-group>
<article-title>Search trends and prediction of human brucellosis using Baidu index data from 2011 to 2018 in China</article-title>. <source>Sci Rep</source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>5896</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-020-62517-7</pub-id>.<pub-id pub-id-type="pmid">32246053</pub-id>
</mixed-citation>
      </ref>
      <ref id="CIT0176">
        <label>176</label>
        <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Bank</collab></person-group>. World Bank approves $82 million for prevention of zoonotic, endemic diseases in India. World Bank; <year>2023</year> [cited 2023 Aug 23]. Available from: <ext-link xlink:href="https://www.worldbank.org/en/news/press-release/2023/05/10/world-bank-approves-82-million-for-prevention-of-zoonotic-endemic-diseases-in-india" ext-link-type="uri">https://www.worldbank.org/en/news/press-release/2023/05/10/world-bank-approves-82-million-for-prevention-of-zoonotic-endemic-diseases-in-india</ext-link></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>